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Abstract
The increasing occurrence of multi-drug-resistant bacteria poses a serious threat to modern
society. Therefore, novel types of anti-infective therapeutics are highly warranted. Antimi-
crobial peptides are a class of naturally occurring host-defense molecules that potentially
might be developed into such novel therapeutics. However, limited understanding of the
mechanisms underlying microbicidal activity of antimicrobial peptides has slowed down this
development.
A central step toward understanding the microbicidal mechanisms of action of antimi-
crobial peptides is to understand the mechanisms by which antimicrobial peptides interact
with phospholipid membranes. Motivated by that fact, the scope of this thesis is to study
these antimicrobial peptide-lipid membrane interactions. In particular, we attempt to study
these interactions with a quantitative approach. For that purpose, we consider the three
archetypal -helical antimicrobial peptides mastoparan X, melittin, and magainin 2 as model
peptides. These three peptides are investigated by three dierent experimental techniques.
The rst of these experimental techniques is analytical HPLC. We use this technique to
document an eect that might pose a signicant problem for quantitative studies of antimi-
crobial peptide-lipid membrane interactions; namely that antimicrobial peptides adsorb to
surfaces of glass and plastic. Specically, we demonstrate that under standard experimental
conditions, this eect is signicant for mastoparan X, melittin and magainin 2. Consequently,
we conclude that investigators should always take this adsorptive eect into account when
designing and interpreting their experiments on antimicrobial peptides.
The second experimental technique is uorescence correlation spectroscopy (FCS). We
optimize this technique so that it can be used to quantify antimicrobial peptide-induced leak-
age of uorescent markers from large unilamellar lipid vesicles in solution. For that purpose,
we derive the mathematical framework required to calculate leakage from the FCS data, and
we identify a number of experimental pitfalls that might lead to inaccurate conclusions, or
even completely wrong conclusions, when interpreting the FCS data. We show that, if all of
the pitfalls are avoided, then FCS is a technique with a large potential for quantitative studies
of antimicrobial peptide-induced leakage of uorescent markers from large unilamellar lipid
vesicles in solution. Particularly interesting is our nding that FCS might be used for study-
ing peptide-induced leakage of markers of dierent sizes, thereby providing a novel approach
for rapid sizing of transmembrane pores formed by antimicrobial peptides. We demonstrate
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the applicability of FCS by using the technique to study partial transient leakage induced
by mastoparan X, melittin, and magainin 2. The leakage data demonstrate that magainin
2 forms larger and/or more stable transmembrane pores in POPC/POPG (3:1) lipid bilayers
than do mastoparan X and melittin.
The third and nal technique is confocal imaging. Specically, we use this technique
to visualize uorescently-labeled surface-tethered large unilamellar lipid vesicles. We design
an experimental protocol that allows us to directly correlate antimicrobial peptide-induced
leakage of uorescent markers from these surface-tethered vesicles to antimicrobial peptide-
induced leakage of uorescent markers from lipid vesicles in solution. Thereby, we have
developed a direct and exible approach for quantitative evaluation of antimicrobial peptide-
induced leakage from large unilamellar lipid vesicles on the single-vesicle level, allowing us an
unprecedented level of insight into the leakage process. For example, the surface-tethered
lipid vesicles can be used to directly visualize how the single-vesicle leakage proles depend
on the marker size. We employ the surface-tethered vesicles to study partial transient leakage
induced by mastoparan X, melittin and magainin 2 from POPC/POPG (3:1) large unilamellar
lipid vesicles. The results show that on the single-vesicle level, all three peptides induce
heterogenous leakage in the sense that they induce complete emptying of some vesicles
and only partly emptying of other vesicles. This heterogenous leakage prole is observed
regardless of the size of the lumen dye.
Resume
Den stigende forekomst af antibiotika-resistente bakterier udgr en alvorlig trussel mod det
moderne samfund. Nye typer af antiinfektive lgemidler er derfor hjt eftertragtede. An-
timikrobielle peptider er en klasse af naturligt forekommende molekyler, der potential kan
udvikles til at blive en sadan ny type af lgemidler. Denne udvikling er dog indtil videre
blevet bremset af en begrnset viden om virkemaden af antimikrobielle peptider.
Et centralt skridt mod at forsta virkemaden af antimikrobielle peptider er at forsta de
mekanismer, hvormed antimikrobielle peptider vekselvirker med fosfolipidmembraner. Mo-
tiveret af denne kendsgerning er malet for nrvrende afhandling at studere disse vek-
selvirkninger. I srdeleshed er malet for afhandlingen at studere disse vekselvirkninger med
en kvantitativ indgangsvinkel. Til det formal anvender vi de tre -heliske antimikrobielle
peptider mastoparan X, melittin og magainin 2. Disse tre peptider studeres ved hjlp af tre
forskellige eksperimentelle teknikker.
Den frste eksperimentelle teknik er analytisk HPLC. Vi anvender denne teknik til at
dokumentere en eekt, der potentielt kan udgre et alvorligt problem for kvantitative studier
af vekselvirkningen mellem antimikrobielle peptider og lipidmembraner - nemlig at antimikro-
bielle peptider adsorberer til overader i glas- eller plastikbeholdere. Vi demonstrerer at denne
eekt er signikant for bade mastoparan X, melittin og magainin 2 ved almindeligt anvendte
eksperimentelle koncentrationer. Flgelig konkluderer vi at det er vigtigt at tage hjde for
denne eekt ved design og fortolkning af experimentelle studier af antimikrobielle peptider.
Den anden eksperimentelle teknik er uorescens korrelations spektroskopi (FCS). Vi opti-
merer denne teknik, sa den kan anvendes til kvantitative studier af peptid-induceret frigivelse
af uorescerende markrer fra store unilamellre lipidvesikler i oplsning. Til det formal
udleder vi den ndvendige matematik, og vi identicere et antal eksperimentelle faldgruber,
der kan fre til uprcise eller deciderede forkerte konklusioner ved fortolkningen af FCS data.
Vi viser, at hvis alle disse faldgruber undgas, er FCS en teknik med et stort potentiale for
kvantitative studier af peptid-induceret frigivelse af uorescerende markrer fra store unil-
amellre lipidvesikler. I denne forbindelse er det en srlig interessant observation at FCS kan
bruges til at studere frigivelse af markrer af forskellige strrelser. Derved kan FCS anvendes
til hurtige strrelsesbestemmelser af peptid-inducerede transmembranporer. Vi demonstrerer
anvendeligheden af FCS ved at benytte teknikken til at studere partiel transient frigivelse af
indholdet af lipidvesikler induceret af mastoparan X, melittin og magainin 2. Vores resultater
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demonstrerer at magainin 2 danner strre og/eller mere stabile porer i POPC/POPG (3:1)
lipidmembraner end mastoparan X og melittin.
Den tredje og sidste teknik er konfokal mikroskopi. Vi anvender denne teknik til at
visualisere uorescensmrkede store unilamellre lipidvesikler, der er immobiliserede til en
glasoverade. Vi designer en eksperimentel protokol, sa vi direkte kan korrelere peptid-
induceret frigivelse af uorescerende markrer fra de immobiliserede lipidvesikler til peptid-
induceret frigivelse af uorescerende markrer fra lipidvesikler i oplsning. Derved har vi
udviklet en direkte og eksibel metode til kvantitativ evaluering af peptid-induceret frigivelse
af uorescerende markrer fra store unilamellre lipidvesikler pa enkelt-vesikel niveau. Denne
metode giver os en hidtil uset indsigt i frigivelsesprocessen. For eksempel kan vi ved hjlp
af de immobiliserede vesikler studerer hvordan frigivelsesprocessen pa enkelt-vesikel niveau
afhnger af strrelsen af den uorescerende markr. Vi anvender de immobiliserede lipid-
vesikler til at studere partiel transient frigivelse induceret af mastoparan X, melittin og ma-
gainin 2 fra POPC/POPG (3:1) store unilamellre lipidvesikler. Resultaterne viser, at pa
enkelt-vesikel niveau inducerer alle tre peptider en heterogen frigivelsesprol i den forstand,
at de inducer fuldstndig tmning af nogle vesikler og kun delvis tmning af andre vesikler.
Denne heterogene frigivelsesprol observeres uanset strrelses af den indkapsulerede markr.
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CHAPTER 1
Introduction
1.1 Why study antimicrobial peptides?
The 20th century was a period that brought a series of revolutionary, technological break-
throughs to mankind. The discovery and development of antibiotics to ght infectious
diseases was one of these breakthroughs. Indeed, contemporary healthcare would not be
what it is today were it not for these wonder drugs.
However, ever since the introduction of the rst antibiotic agents, the problem of micro-
bial pathogen resistance to antibiotics has been well-known. Today, the problem of antibiotic
resistance has turned into a regular resistance crisis that poses a grave menace to modern
healthcare systems (1). To mitigate this emerging resistance crisis, novel alternatives to the
conventional antibiotics are needed (2). Unfortunately, in spite of this pressing demand for
novel antibiotics, only a few new antibiotic drugs have been approved for clinical use in recent
years (3). Furthermore, new antibiotic drug candidates in pipeline are scarce (4). This is
where antimicrobial peptides come into the picture.
Antimicrobial peptides are a class of host defense molecules that is ubiquitously present
in a variety of life forms across the evolutionary spectrum (5). Since one of their principal
biological roles is to protect their host organism by killing a broad spectrum of invading
microbial pathogens (6), antimicrobial peptides have also attracted considerable scientic
attention as candidates to become a novel class of antibiotics. As a matter of fact, an-
timicrobial peptides as anti-infective therapeutic candidates display several advantages over
conventional antibiotics. One important example of these advantages is the capability of an-
timicrobial peptides to kill microbes that are resistant to conventional antibiotics. Another
example is that antimicrobial peptides do not evoke resistance in pathogens to the same ex-
tent as conventional antibiotics, probably because the peptides act via multiple mechanisms
of action (7, 8).
As of today, a few antimicrobial peptides, such as polymyxin B and gramicidin S, have
successfully found their way into products on the pharmacy shelf, primarily for topical ap-
plications. Moreover, a number of antimicrobial peptides and peptidomimetics for mostly
topical applications are currently in preclinical or clinical trials (8, 9). However, in spite of
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these facts, a number of obstacles remain for the development of antimicrobial peptides into
eective protable drugs, especially in relation to drugs with systemic applications. These
obstacles include high manufacturing cost, unknown toxicity proles, and susceptibility to
proteolytic degradation (7). Yet another obstacle limiting the development of antimicrobial
peptides into successful cost-eective therapeutics is the lack of understanding of their mech-
anism of action (10). To be more specic, enhancing the understanding on the mechanisms
by which antimicrobial peptides kill microbes would greatly aid the rational design of novel
antimicrobial peptide-based drug formulations. Indeed, to overcome the above-mentioned
obstacles, there is still plenty of need to study antimicrobial peptides.
1.2 Thesis scope
There are two predominant hypotheses to explain the microbicidal mode of action of an-
timicrobial peptides. The rst predominant hypothesis suggests that antimicrobial peptides
kill microbes by disrupting the structural integrity of the microbial cytoplasmic membrane
(11). The second predominant hypothesis suggests that the peptides translocate across the
cytoplasmic membrane to target intracellular processes (12). Either way, the microbial cy-
toplasmic membrane is at the center of action. To understand the microbicidal mode of
action of antimicrobial peptides, it is, therefore, essential to understand their interactions
with phospholipid membranes (10). That takes us to the scope of this thesis; the scope
of this thesis is to quantitatively study the interactions between antimicrobial peptides and
phospholipid membranes. The fact that these interactions are studied quantitatively, and not
only qualitatively, should be emphasized. As opposed to qualitative information, quantita-
tive information will provide a direct basis for comparing the eect of dierent antimicrobial
peptides under varying experimental conditions. In addition, quantitative information will
essentially also allow the formulation of more detailed models to correlate the mode of mem-
brane interactions of antimicrobial peptides directly to the physicochemical characteristics of
the peptides.
1.3 Thesis outline
The thesis consists of one introductory chapter, three manuscripts in preparation, and a nal
concluding chapter. The introductory chapter, Chapter 2, reviews the state of the research
eld of antimicrobial peptides as of today. In particular, emphasis is put on reviewing the
current knowledge about antimicrobial peptide-lipid membrane interactions. Chapter 2 also
contains a more elaborate discussion about the thesis scope than provided in Section 1.2.
Chapters 3-5 contains each of the three manuscripts. The common denominator of these
three manuscripts is quantitative studies of antimicrobial peptide-lipid membrane interac-
tions. The lay-out of each of the manuscripts is adapted to t the lay-out of the thesis.
The nal concluding chapter, Chapter 6, summarizes the ndings of the thesis and briey
discusses future directions of research.
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1.4 Publications
The work conducted during this PhD study have resulted in three article manuscripts (con-
tained in Chapters 3-5) and two conference contributions.
1.4.1 Articles
1. K. Kristensen, J. R. Henriksen, and T. L. Andresen. Adsorption of cationic membrane-
active peptides to glass and plastic surfaces. Manuscript under preparation. To be
submitted.
2. K. Kristensen, J. R. Henriksen, and T. L. Andresen. Quantication of antimicro-
bial peptide-induced leakage from large unilamellar vesicles by FCS. Manuscript under
preparation. To be submitted.
3. K. Kristensen, N. Ehrlich, J. R. Henriksen, and T. L. Andresen. Single-vesicle analysis
of leakage induced by cationic membrane-active peptides. Manuscript under prepara-
tion. To be submitted.
1.4.2 Conference contributions
1. K. Kristensen, J. R. Henriksen, and T. L. Andresen. Quantitative studies of antimi-
crobial peptide pore formation in large unilamellar vesicles by uorescence correlation
spectroscopy (FCS). Platform presentation at Biophysical Society 57th Annual Meet-
ing, 2-6 February 2013, Philadelphia, PA, USA. Abstract published in Biophysical
Journal, 104(2; Suppl 1):21a, 2013.
2. K. Kristensen, N. Ehrlich, J. R. Henriksen, and T. L. Andresen. Quantitative single-
vesicle analysis of antimicrobial peptide-induced leakage. Poster presented at 9th
European Biophysics Congress, 13-17 July 2013, Lisbon, Portugal. Abstract published
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CHAPTER 2
Antimicrobial peptides
The research eld of antimicrobial peptides has been thriving for decades. Combined cross-
disciplinary eorts have provided valuable insight into the structure and function of these
peptides, but have also left the eld with a number of open questions. This chapter reviews
the state of the research eld as of today. In Sections 2.1-2.3, the functional and structural
properties of antimicrobial peptides are described. In Section 2.4, special emphasis is put on
interactions between antimicrobial peptides and phospholipid membranes, and a number of
popular interaction models are reviewed. Next, in Section 2.5, questions about antimicrobial
peptides that still remain to be answered are discussed. Subsequently, in Section 2.6, a
brief introduction is given to the three antimicrobial peptides that are studied in this thesis:
mastoparan X, melittin and magainin 2. At last, in Section 2.7, the chapter is concluded by
revisiting the thesis scope in the light of the information found in this chapter.
2.1 Functions in immunity
Antimicrobial peptides are a class of naturally occurring host defense molecules. To date,
more than 2000 peptides with antimicrobial activity have been identied in a broad range of
organisms across the biological world, including bacteria, fungi, plants, and animals (13, 14).
Antimicrobial peptides are also abundantly present in mammals where they, inter alia, are ex-
pressed in mast cells, monocytes, macrophages, neutrophils, epithelial cells, and keratinocytes
(8).
Antimicrobial peptides are thought to function as an important part of the innate immune
system, providing an eective protective machinery against infectious pathogens. Indeed, the
protective role of antimicrobial peptides has been implied in several studies on animal models.
For example, mice in which the gene encoding the antimicrobial peptide CRAMP was knocked
out were more susceptible to necrotic skin infection caused by the Gram-positive bacterium
Group A Streptococcus than were wild-type mice (15). In another example, transgenic mice
expressing the human Paneth cell antimicrobial peptide HD-5 were far more resistant to oral
challenge of the Gram-negative bacterium Salmonella typhimurium than were wild-type mice
(16). In fact, the transgenic mice expressing HD-5 completely recovered from oral doses that
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Figure 2.1: Non-comprehensive overview of the roles that antimicrobial peptides have been proposed
to play in innate immunity. Generally, antimicrobial peptides are thought to act through direct
microbicidal activities as well as immunomodulatory activities.
caused 100 % mortality in the wild-type mice, thus illustrating the protective capabilities of
HD-5.
Indications of the protective role of antimicrobial peptides, however, not only come from
observations in animal models, but also from observations in human patients. For instance,
patients with Kostmann disease, a severe congenital neutropenia, were devoid of the antimi-
crobial peptide LL-37, and this deciency correlated to the occurrence of frequent infections
and periodontal disease (17). The protective functions of antimicrobial peptides were also
implied by the increasing peptide expression levels in patients with inammatory conditions
such as cystic brosis, bronchiolitis, and psoriasis (8).
Many dierent suggestions as to the specic functions by which antimicrobial peptides
defend their host organism from invading microbial pathogens have been put forward. These
functions are generally divided into two categories: direct microbicidal functions and im-
munomodulatory functions (8), see Fig. 2.1.
2.1.1 Direct microbicidal functions
Direct killing of infectious microbial pathogens is thought to be one of the principal biological
functions of antimicrobial peptides (5). Indeed, there is plenty of evidence that antimicrobial
peptides are capable of directly killing a broad spectrum of Gram-positive and Gram-negative
bacteria, fungi, and viruses (6, 8).
The mechanisms by which antimicrobial peptides kill these microbes are still a topic for
debate (14). One predominant idea suggests that antimicrobial peptides act by disrupting
the structural integrity of the microbial cell membrane (11). Accordingly, the literature is rich
with in vitro examples showing that peptide action is associated with membrane disruption
and cell lysis. For example, bactericidal activity of the antimicrobial peptides magainin
2 and cecropin P1 against the Gram-negative bacterium Escherichia coli was coupled to
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cell lysis (18, 19). In another example, the human antimicrobial peptide LL-37, as well
as truncated peptide analogues, induced lateral separation of membrane components and
leakage of proteins and nucleotides from the cytoplasm when acting on the fungus Candida
albicans. In yet another illustrative example, the insect antimicrobial peptide defensin A
permeabilized the cytoplasmic membrane of the Gram-positive bacteriumMicrococcus luteus,
causing leakage of potassium ions (20).
There are, however, also in vitro indications that antimicrobial peptides might kill mi-
crobes without damaging the cell membrane itself (12). Thus, the antimicrobial peptide
buforin II rapidly killed Escherichia coli without lysing the cell membrane (18). Instead,
buforin II accumulated in the cytoplasm. Furthermore, buforin II was found to bind to DNA
and RNA, and it was hypothesized that this binding is important for the in vivo mechanism
of buforin II. PR-39, a peptide from the pig small intestine, did not kill Escherichia coli by
cell lysis either (19). Rather, data indicated that the peptide induced a halt in protein and
DNA synthesis, possibly due to PR-39-induced proteolytic activity. The fungal antimicrobial
peptide plectasin was involved in another interesting example of non-lytic peptide activity
(21). To be more specic, plectasin was shown to inhibit cell-wall biosynthesis in the Gram-
positive bacteria Bacillus subtilis and Staphylococcus simulans, rather than perforating the
cell membrane (21). Detailed experiments further indicated that the cell-wall precursor Lipid
II was the target of plectasin. Finally, in a last example of non-lytic peptide action, fungicidal
activity of the peptide histatin 5 against Candida albicans was suggested to be related to
non-lytic eux of ATP or generation of reactive oxygen species (22).
2.1.2 Immunomodulatory functions
In recent years, the idea that antimicrobial peptides exhibit other functions than just their
direct microbicidal functions has become increasingly widespread. More specically, it is now
clear that antimicrobial peptides can also modulate the immune response of their host or-
ganism. For instance, it is recognized that some antimicrobial peptides display chemotactic
activities. That is, some antimicrobial peptides can enhance pro-inammatory responses by
chemoattracting immune cells to sites of infection, either by direct chemoattraction or by
stimulation of chemokine release (8, 23). Also, in another example of immunomodulatory
activities, some antimicrobial peptides have been suggested to neutralize the eect of endo-
toxins by direct high-anity lipopolysaccharide binding or by stimulation of the expression
of anti-inammatory compounds (8, 23). In addition to these examples, antimicrobial pep-
tides have also been hypothesized to be involved in a plethora of other immunomodulatory
functions, including wound healing and angiogenesis (8, 23).
It has been even suggested that the immunomodulatory functions represent the principal
biological role of many antimicrobial peptides, as many peptides are found to be devoid of
direct microbicidal activities under physiological conditions. To more precisely describe their
complex involvement in immunity, it was, therefore, suggested that the peptides should be
termed "host defense peptides" instead of "antimicrobial peptides" (8). In this thesis, we
will however stick to the term "antimicrobial peptides".
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2.2 Structural categorization
Antimicrobial peptides are a diverse class of peptides with great variability in amino acid
sequence among individual peptides. However, despite this sequence variability, it is possible
to classify the peptides into a few groups based on their membrane-bound conformation.
The largest and most well-studied group of antimicrobial peptides is the -helical peptides
(14). These peptides are often in random coil conformation in aqueous solution and only
fold into helical conformation upon partitioning into phospholipid bilayers. Non-polar, polar
and charged amino acid residues are generally arranged in a characteristic pattern which
upon peptide folding creates an amphipathic helix. At low peptide-to-lipid ratios, this helix
typically reside at the bilayer interface with the long axis oriented parallel to the plane of
the bilayer (24), often with a small bend at the center of the peptide (25). Mastoparan X,
melittin and magainin 2, which are the three antimicrobial peptides to be investigated in this
thesis, are all prominent examples of the -helical antimicrobial peptides.
Another prominent example of the -helical antimicrobial peptides is the human an-
timicrobial peptide LL-37. Interestingly, one study on LL-37 indicated the importance of
helicity for peptide antimicrobial activity (26). In that study, dierent types and concen-
trations of ions was used to promote helix formation in LL-37, and a strong correlation
between the helicity of LL-37 and its antibacterial activity against both the Gram-negative
bacterium Escherichia coli and the Gram-positive bacterium Bacillus megaterium was estab-
lished. However, it should also be mentioned that there are also examples that show that
helicity is not always a requirement for antimicrobial peptide. Diastereomers of melittin thus
retained high antibacterial activity against both Gram-positive and Gram-negative bacteria
in spite of lacking the -helical secondary structure of native melittin (27).
-sheet antimicrobial peptides represent another large conformational group. In contrast
to the -helical peptides, the -sheet peptides are generally more rigid structures stabilized
by intermolecular disulde bonds (25). Therefore, these peptides are often both ordered in
aqueous solution and when partitioned into lipid bilayers. Like the -helical peptides, the
-sheet peptides are typically amphipathic in nature. Some of the most well-known examples
of -sheet antimicrobial peptides are the defensins and protegrins (14, 28).
A large number of antimicrobial peptides do not belong to the classical -helical or -
sheet categories. Instead, these peptides can sometimes be characterized by their enrichment
in one or more amino acid types. A well-known example of a peptide enriched in one type of
amino acid is the bovine neutrophil peptide indolicidin, in which the amino acid tryptophan
is strongly over-represented. The proline-arginine-rich peptides represent another example of
peptides enriched in certain amino acids (25, 28).
2.3 Physicochemical characteristics
A number of physicochemical characteristics pertaining to charge, hydrophobicity, and am-
phipathicity appear to be common for most antimicrobial peptides. Altering each of these
parameters for a given peptide might confer altered antimicrobial activities and selectivities
on that peptide.
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2.3.1 Charge
Most antimicrobial peptides carry a net positive charge between +2 to +9 (28). Especially,
the cationic amino acids lysine and arginine are highly abundant in antimicrobial peptides. In
contrast, the anionic amino acids aspartic acid and glutamic acid are generally scarce (14).
Several papers have report that the net peptide charge correlates to in vitro antimicrobial
activity. For example, one study considered a number of magainin 2 amide analogues in
which the net charge was varied while hydrophobicity, helicity and amphipathicity were kept
largely constant (29). For these magainin 2 amide analogues, increasing the net charge from
+3 to +5 lead to an increase in antibacterial activity against Escherichia coli and Bacillus
subtilis. A similar dependence on charge was also observed for a collection of synthetic
model peptides in which, as for the magainin 2 amide analogues, the net charge was varied
while hydrophobicity, helicity, and amphipathicity were kept constant (30). Thus, for these
synthetic model peptides, it was found that charge was a prerequisite for antimicrobial activity
toward a broad spectrum of Gram-positive and Gram-negative bacteria, and fungi, and for
peptides of charge +1 to +5, there were even indications that activity only depended on the
overall peptide cationicity and not on the specic positioning of charges along the amino
acid sequence per se. In yet another example on the importance of cationicity, a study on
a large number of C3a peptide analogues demonstrated that antibacterial activity against
Escherichia coli and Staphylococcus aureus and antifungal activity against Candida albicans
also correlated to net positive charge (31).
However, it should be noted that not all studies unambiguously show that antimicrobial
activity correlates directly to cationicity. For instance, adding four lysine residues to the
N-terminus of magainin 2 decreased the in vitro activity of the peptide against the bacteria
Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus (32).
It should also be noted that even though antimicrobial activity of a given peptide is often
increasing with increasing net charge, it can not unambiguously be said that the properties
of that particular peptide are improved when its net charge is increased. More specically,
increasing charge of a peptide will also often increase undesired host cell toxicity of that
peptide, typically gauged by the hemolytic activity of the peptide (29, 30). In other words,
increasing the charge will often not only change the antimicrobial activity of a given peptide
but also the selectivity of that peptide. Therefore, there is typically an optimum net charge
at which antimicrobial selectivity is maximal.
Finally, it should be mentioned that anionic antimicrobial peptides with a charge of -1 to
-7 do also exist (24). However, these anionic peptides are not as well-studied as the cationic
peptides and will not be discussed any further in this thesis.
2.3.2 Hydrophobicity
Antimicrobial peptides typically contain around 50 % hydrophobic amino acid residues (28).
These hydrophobic residues are thought to play an important role for the interaction of
antimicrobial peptides with cellular membranes, and, thereby, also for antimicrobial activity.
Accordingly, in many in vitro experiments, it has been found that hydrophobicity is an
important parameter for microbicidal activity of antimicrobial peptides. Equally important
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though, many experiments have also found hydrophobicity to be an important parameter for
hemolytic activity (24). As an example on the importance of hydrophobicity, four dierent
magainin 2 analogues in which hydrophobicity was varied while other physicochemical pa-
rameters were kept constant displayed increasing antibacterial activity against Escherichia
coli and to a lesser extent against Pseudomonas aeruginosa as a function of hydrophobicity,
but also increasing hemolytic activity as a function of hydrophobicity (33). Consequently, the
most hydrophobic magainin 2 analogues were still selective against Escherichia coli but not
against Pseudomonas aeruginosa. Similarly, analogues of the antimicrobial peptide V13KL
with systematic substitutions of alanine and leucine residues also displayed poor selectivity
against dierent Pseudomonas aeruginosa strains when peptide hydrophobicity was high,
although at an intermediate optimum hydrophobicity, antimicrobial selectivity was actually
maximized (34). Finally, the most hydrophobic analog of two template-based model peptides
with dierent hydrophobicities but identical charges and amphipathicities was found to be
more hemolytic and less selective toward Gram-positive and Gram-negative bacteria than the
less hydrophobic analog (35).
2.3.3 Amphipathicity
Amphipathicity measures the polarization of hydrophobic and hydrophilic amino acid residues
within a peptide. In the case of -helical peptides, amphipathicity is often quantied by
the hydrophobic moment. The hydrophobic moment is calculated as the vectorial sum of
individual amino acid hydrophobicity vectors, assuming an ideal -helix (24).
In the case of antimicrobial peptides, amphipathicity is thought to be an important pa-
rameter for their interaction with phospholipid bilayers. A general notion is that hydrophobic
peptide domains are buried in the acyl chain region and hydrophilic peptide domains interact
with polar and charged phospholipid head groups.
The importance of amphipathicity for microbicidal activity and selectivity has been
demonstrated in several in vitro experimental investigations. As in the case of the afore-
mentioned investigations on charge and hydrophobicity, also amphipathicity has been found
to impact both antimicrobial activity and host cell toxicity. For instance, the importance
of amphipathicity was demonstrated in a study in which a scrambled non-amphipathic syn-
thetic model peptide displayed poorer antimicrobial activity but similar hemolytic activity
when compared to an amphipathic analog with the same amino acid residue composition
(30). In another example, three template-based model peptides, in which the hydrophobic
moment was varied while charge and hydrophobicity were kept constant, exhibited increasing
antibacterial activity against a large number of Gram-positive and Gram-negative bacteria
as a function hydrophobic moment (35). However, these peptides also displayed strongly
increasing hemolytic activity as a function of increasing hydrophobic moment, rendering an-
tibacterial selectivity of the most amphipathic model peptides inferior. Accordingly, natural
antimicrobial peptides often exhibit an imperfect amphipathic structure (31), and it has been
suggested that these imperfect structures might have been chosen by evolution as structures
that yields maximal antimicrobial activity and minimal host cell toxicity.
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2.4 Popular themes in antimicrobial peptide-lipid membrane
interactions
The interactions between antimicrobial peptides and cellular lipid membranes are a topic of
uttermost importance. No matter whether a given antimicrobial peptide acts by disrupting
the microbial cell membrane or by crossing the membrane to do intracellular damage, it is
certainly clear that understanding the antimicrobial peptide-cell membrane interactions is
crucial for the overall understanding of peptide activity.
To date, an enormous number of studies on antimicrobial peptide-lipid membrane inter-
actions have been published. These studies are often carried out using synthetic minimal
model membranes and various biophysical techniques. Based on these studies, a number of
prevailing ideas and models have arisen.
2.4.1 Specic interactions with microbial cell membranes
The cell architecture diers fundamentally between host cells and microbial cells. The lit-
erature on antimicrobial peptides often considers these dierences to be the reason for the
capability of antimicrobial peptides to specically target infectious microbial pathogens and
not the cells of their host organism (28, 36). In particular, the literature on antimicrobial
peptides often considers the dierences in cell membrane architecture between infectious bac-
terial cells and mammalian host cells to explain antimicrobial peptide selectivity. An overview
of the molecular factors that are thought to contribute to bacterial versus mammalian cell
selectivity of antimicrobial peptides is given in Fig. 2.2.
One of the major dierences between the cell membrane architectures of bacterial and
mammalian membranes is pertaining to charge. To be more specic, bacterial cell en-
velopes are generally strongly anionic (14). Thus, the lipid A core of lipopolysaccharides
on the outer cell membrane of Gram-negative bacteria and teichoic and teichuronic acids
on the cell wall of Gram-positive bacteria are negatively charged. Furthermore, bacterial
cytoplasmic membranes are generally enriched in the anionic lipids phosphatidylglycerol and
cardiolipin. In contrast, mammalian host cell membranes consist primarily of zwitterionic
and neutral components, especially in the exoplasmic leaet. That is, exoplasmic leaets of
mammalian membranes are generally enriched in the zwitterionic phospholipids phosphatidyl-
choline, phosphatidylethanolamine, and sphingomyelin. Mammalian cell membranes do also
contain anionic phospholipids, but they are primarily sequestered in the cytoplasmic leaet.
Thus, antimicrobial peptides, which, as mentioned in Section 2.3.1, generally are cationic,
are thought to be electrostatically attracted to bacterial cell envelopes but not to mammalian
cell membranes (37, 38).
Charge is not the only proposed modulator of peptide selectivity. For example, as opposed
to bacterial membranes, mammalian membranes contain a signicant amount of cholesterol
(28). Cholesterol alters the packing of lipid membranes, and might, thereby, confer increased
resistance on mammalian cells to antimicrobial peptides by preventing the peptides to bind to
the mammalian membranes (39{41). The potential protective role of cholesterol is underlined
by the fact that the presence of cholesterol in erythrocyte membranes decreases the hemolytic
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Figure 2.2: Sketch of molecular determinants that have been suggested to promote antimicrobial
peptide selectivity to bacterial cell envelopes (left) over mammalian cell membranes (right). Negative
charges on the bacterial cell envelopes, e.g., introduced by anionic phospholipids and lipopolysaccha-
ride, are thought to attract cationic antimicrobial peptides through electrostatic interactions. Other
factors, such as cholesterol and membrane potential, might further direct antimicrobial peptide ac-
tivity.
potency of some antimicrobial peptides, (42). Similar to cholesterol, sphingomyelin is also
present in mammalian membranes but not in bacterial membranes. It has been shown
that sphingomyelin, together with cholesterol, prevents membrane association of the human
antimicrobial peptide LL-37 to synthetic membranes, thereby implying that sphingomyelin
might further direct the action of antimicrobial peptides toward bacteria (39).
The transmembrane potential represents another parameter that diers between bacterial
cells and mammalian cells. Thus, for bacterial cells in logarithmic growth, the transmembrane
potential is -130 to -150 mV, whereas for mammalian cells, the transmembrane potential is
-90 to -110 mV (28). This dierence might promote activity of antimicrobial peptides in
bacterial cells relative to mammalian cell, for example by electrophoretically driving peptide
translocation across the cell membrane (42).
It is noteworthy that none of the aforementioned determinants for antimicrobial peptide
selectivity are related to any specic molecular targets. Accordingly, even though a few
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examples of such specic molecular targets for antimicrobial peptides have been identied
(28), the typical notion is that antimicrobial peptides interact with microbial membranes in
an unspecic manner and, therefore, that antimicrobial peptide selectivity is determined by
general cell surface characteristics, such as those mentioned before. This notion is corrob-
orated by the fact that diastereomers of antimicrobial peptides often retain antimicrobial
activity, indicating that antimicrobial peptides do not interact specically with any molecular
receptors on the microbial cell surface (27).
2.4.2 The concept of a threshold concentration
The concept of a threshold concentration is another recurring theme in the literature on
antimicrobial peptides. The idea of the concept is that peptides only become active when
their membrane-bound concentration increases above a certain threshold. Thus, at low
membrane-bound concentrations, peptides typically reside in a planar orientation at the
lipid head group level (24), but when the membrane-bound concentration increases above a
certain threshold, peptides are thought to be activated (43), for example by inserting into the
membrane to form transmembrane pores or by solubilizing the membrane in a detergent-like
manner (44).
Typically, threshold concentrations for antimicrobial action in lipid membranes are hy-
pothesized to be in the range of 0.05 to 0.1 peptide-to-lipid molar ratios (43). Since the
cross-sectional area of an average antimicrobial peptide containing 20-30 amino acid residues
is much larger than the cross-sectional area of a phospholipid, peptides cover one-fth or even
more of the bilayer surface area at these typical threshold concentrations. In other words,
typical threshold concentrations represent extremely high membrane-bound concentrations
of antimicrobial peptides (43).
2.4.3 Formation of transmembrane pores
It is well-known that antimicrobial peptides can permeabilize lipid bilayers; that is, they can
form holes or defects in the bilayers, allowing transmembrane passage of polar solutes that
can not cross the unperturbed bilayer (11). For example, as mentioned in Section 2.1.1,
microbicidal peptide action is often associated with permeabilization of cellular membranes,
entailing leakage of ions or macromolecules. However, there are also ample examples from
synthetic model membranes that antimicrobial peptides can induce membrane permeabiliza-
tion. In fact, most of the structural information on antimicrobial peptide-induced membrane
permeabilization has roots in studies on such synthetic model membranes.
For instance, valuable insights into antimicrobial peptide-induced membrane permeabi-
lization have been gained from experiments on synthetic lipid unilamellar vesicles. In typical
experiments with such vesicles, an aliquot of a peptide solution is transferred to a solution of
lipid vesicles, and leakage of an encapsulated marker from the vesicle lumen is subsequently
gauged. A hallmark feature of these vesicle experiments is that peptide-induced membrane
permeabilization is only transient; following an initial rapid burst of leakage within the rst
few minutes after peptide addition, leakage slows down or ceases altogether before all vesicle
contents have been released (45{48). A hypothesis that is often suggested to explain this
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transience in leakage is that peptides initially only bind to the outer membrane leaet entail-
ing an asymmetric strain of the membrane. In the process of relieving this asymmetric strain,
membrane permeabilization occurs. However, once the peptides are equilibrated across the
membrane, the propensity for membrane permeabilization is signicantly reduced (45, 49).
In agreement with this hypothesis, it has been observed that peptide-induced membrane
permeabilization in lipid vesicles is coupled to translocation of peptides across lipid bilayers
(50).
A number of other noteworthy observations on antimicrobial peptide-induced membrane
permeabilization also come from work done on lipid unilamellar vesicles. For example, mem-
brane permeabilization has been found to be directly coupled to lipid ip-op (51). Further-
more, leakage kinetics have implied that antimicrobial peptides might self-assemble as part
of the membrane permeabilization process (52). Finally, in experiments on peptide-induced
leakage of markers from individual giant lipid vesicles, it has been observed that initiation of
leakage from individual lipid vesicles occurs at a probabilistic point in time and membrane-
bound peptide concentration (47, 48, 53{55). This latter observation implies that nucleation
defects in the bilayers are required for peptides to initiate membrane permeabilization (53).
Valuable structural insights into antimicrobial peptide-induced membrane permeabiliza-
tion also come from experiments conducted on oriented lipid multibilayers. Thus, neu-
tron in-plane scattering experiments on oriented multibilayers have revealed that when the
membrane-bound peptide concentration is above a certain threshold, water-lled transmem-
brane pores are formed (56, 57), in agreement with the ideas of a threshold concentration
introduced in Section 2.4.2. Interestingly, oriented circular dichroism experiments on ori-
ented multibilayers have also demonstrated that membrane-bound peptides change orienta-
tion when their concentration is above that threshold concentration (58, 59). For -helical
peptides, this corresponds to a change in orientation from their long-axis being parallel to
the plane of the membrane surface to their long axis being perpendicular to the plane of the
membrane surface. In other words, from these experiments, it seems that the formation of
transmembrane pores in oriented multibilayers is directly coupled to peptide insertion into
the bilayers (59).
Experiments conducted on oriented lipid multibilayers have also revealed another impor-
tant feature of antimicrobial peptide-lipid membrane interactions. Thus, X-ray diraction
experiments on oriented multibilayers have shown that peptides, at membrane-bound con-
centrations below the threshold concentration, entail pronounced stretching and thinning of
the bilayers (60), see Fig. 2.3. This bilayer stretching and thinning is thought to occur
as a result of peptide preferential embedment in the lipid head group region. That is, the
peptides are thought to embed in the head group region and create an empty void in the acyl
chain region to be lled by the acyl chains of the adjacent lipids. In order for the bilayer to
adapt to this new situation, local stretching and thinning of the bilayer around the surface-
associated peptides are required. This stretching and thinning of the membrane is thought
to be important for creation of energy-favorable transmembrane pores in the oriented multi-
bilayers; when peptides stretch the membrane area, they will create an internal membrane
tension. When this tension is suciently high, above a certain threshold, the formation of
transmembrane pores is energetically favored (53, 55, 61). It has been suggested that this
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Figure 2.3: Sketch of peptide-induced membrane stretching and thinning. Peptides (schematically
drawn as red rectangles) preferentially partition into the lipid head group region creating a gap in the
acyl chain region. Acyl chains of adjacent lipids ll this gap causing local membrane stretching and
thinning.
internal membrane tension is equivalent to an externally applied membrane tension (61, 62).
Some attempts have been made to bridge the experimental observations from oriented
lipid multibilayers to the observations from lipid vesicles. In one example, it was suggested
that threshold concentrations for pore formation in oriented multibilayers can be directly cor-
related to threshold concentrations for peptide-induced membrane permeabilization in giant
lipid vesicles simply by observing the peptide-induced bilayer stretching (53, 55). Further-
more, it has been hypothesized that the cooperative formation of transmembrane equilibrium
pores observed in oriented lipid multibilayers is also detectable in lipid vesicles by calorimetric
techniques (44, 63, 64).
To understand the molecular details of the experimental observations in lipid vesicles
and oriented lipid multibilayers, a plethora of dierent models have been proposed. Two
prominent examples of these models, namely the toroidal pore model and the barrel-stave
model, involve the formation of explicit water-lled transmembrane pores.
The toroidal pore model
The most inuential model to explain the mechanisms underlying antimicrobial peptide pore
formation is the toroidal pore model (14). This model is supported by substantial evidence
from oriented lipid multibilayers (65{68) and from computer simulations (69, 70). In the
toroidal pore model, the two leaets of a lipid bilayer are connected through a torus-like pore
of high local membrane curvature, see Fig. 2.4. The peptides are inserted into the lipid
head group region in the toroidal pore in a tilted or perpendicular orientation to stabilize
the pore (70, 71), for example, by functioning as llers in the highly curved head group
region (59). Due to the high local membrane curvature of toroidal pores, it has been
suggested that bilayers consisting of positive curvature-inducing lipids are much more prone
to forming toroidal pores than bilayers consisting of negative curvature-inducing lipids (72).
In recent years, this idea has however been challenged in several papers (59, 73), suggesting
other factors rather than spontaneous curvature, for example, pertaining to lipid head group
hydration, to be the real cause of experimental dierences between bilayers.
It has been proposed that antimicrobial peptides promote toroidal pore formation by
reducing the line tension of the pore edge. That is, antimicrobial peptides preferentially
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Figure 2.4: Sketch of the toroidal pore model. Peptides (schematically drawn as red rectangles)
alter the local curvature of phospholipid bilayers causing formation of toroidal pores lined by peptides
and lipids.
associate to the rims of the toroidal pores and stabilize the pores by reducing the line tension
(74, 75), similar to the way that also detergents reduce the line tension of pore edges (76).
From a physicochemical point of view, antimicrobial peptide pore formation might thus
be thought of as a process in which the peptides induce pore formation by simultaneously
increasing membrane tension and decreasing pore edge line tension (61).
The barrel-stave pore model
The barrel-stave model represents another model that is quite often cited in the literature.
However, in reality, barrel-stave pores are only thought to occur for a few peptides, with
alamethicin being the most well-studied example (14, 77, 78). Even so, for completeness,
the model is recapitulated in the following lines.
In the barrel-stave model, the peptides insert perpendicularly into the lipid bilayers to
line a water-lled pore in a barrel-like manner, see Fig. 2.5. The hydrophilic domains of the
peptides preferentially face the pore lumen whereas hydrophobic domains face the bilayer to
interact with the hydrophobic acyl chains (14, 79). In this way, a characteristic ngerprint
of the barre-stave model is that the orientation of lipid molecules in the bilayer is largely
undisturbed (68, 80). This is in contrast to the toroidal pore model in which the local lipid
orientation in the vicinity of pores deviates from a lamellar bilayer structure; compare Fig.
2.4 to Fig. 2.5.
Figure 2.5: Sketch of the barrel stave pore model. Peptides (schematically drawn as red rectangles)
line the pore lumen. The hydrophilic peptide domains face the pore lumen, whereas the hydrophobic
domains face the hydrophobic acyl chains.
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Figure 2.6: Sketch of the sinking raft model. Peptides (schematically drawn as red rectangles)
aggregate, in this sketch into a dimer, and sink into the bilayer with their hydrophobic domains facing
the acyl chains and their hydrophilic forming an inner cavity.
2.4.4 Non-pore models
Besides the above-mentioned pore models, a number of alternative models have also been
suggested, inter alia, to explain how peptide-induced membrane disruption and permeabi-
lization might occur without the formation of explicit water-lled transmembrane pores.
The sinking raft model
Based on a detailed quantitative analysis of vesicle leakage induced by the peptide -lysin,
the sinking raft model was proposed (81). In the sinking raft model, peptides initially
associate to the outer membrane leaet, creating an asymmetric strain across the bilayer.
This process promotes the insertion of small peptide aggregates into the bilayer. Via these
small aggregates, peptides translocate across bilayers with their hydrophobic domains facing
the lipid acyl chains. In this process, the hydrophilic peptide domains will form an inner cavity
through which polar solutes can be transported across the bilayer. Thereby, membrane
permeabilization and peptide translocation occur simultaneously, and also lipid ip-op is
expected to occur concomitantly. However, upon peptide equilibration across the lipid bilayer,
peptide translocation, and thus also membrane permeabilization and lipid ip-op, cease
(82, 83), in agreement with the observation that peptide-induced leakage from lipid vesicles
is a transient process. The sinking raft model is sketched in Fig. 2.6.
One consequence of the sinking raft model is that peptides do not insert perpendicularly
into lipid membranes but rather in a planar orientation. This idea matches the observation
that -helical antimicrobial peptides at low peptide-to-lipid ratios are quite often experimen-
tally found in an orientation with their long axis parallel to the bilayers (82). However, even
though this observation might support the sinking raft model, it does not directly dismiss
the aforementioned toroidal pore model. Thus, it has also been suggested that antimicro-
bial peptides might associate to toroidal pores while being in a nearly planar orientation, so
that tilted or perpendicular peptide insertion is not per se a requirement for toroidal pore
formation (68, 71).
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Figure 2.7: Sketch of the interfacial activity model. Imperfect amphipathic peptides (schematically
drawn as red rectangles) disrupt the vertical segregation of polar and nonpolar phospholipid moi-
eties. This disruption is associated with peptide and lipid translocation. At high amounts of peptide
asymmetrically bound to the bilayer leaets, transbilayer transport of other polar solutes may also
occur.
The interfacial activity model
The interfacial activity model was recently suggested to address the fact that membrane-
permeabilizing activity of antimicrobial peptides do not depend on the specic amino acid
sequence or peptide structure but rather on the general physicochemical properties of the
peptide (84, 85). In addition, the model also addresses the fact that leakage rates across an-
timicrobial peptide-permeabilized bilayers are often too slow to be explained by the formation
of long-lived water-lled transmembrane pores (45).
In the interfacial activity model, the antimicrobial peptides are hypothesized to disrupt
the vertical organization of lipid bilayers as a result of imperfect amphipathic peptide struc-
ture, see Fig. 2.7. Accordingly, naturally occurring antimicrobial peptides often comprise
such imperfect amphipathic structures, in which hydrophobic domains are interrupted by po-
lar or charged amino acid residues. When these imperfect amphipathic peptides insert into
lipid bilayers, their hydrophobic domains will naturally insert into the hydrophobic acyl chain
core of the bilayer. However, the polar or charged residues adjacent to these hydrophobic
domains will preferentially interact with the lipid head groups, promoting the incursion of
the lipid head groups deeper into the membrane and, thereby, disruption of vertical bilayer
polar-nonpolar segregation. At low concentrations of membrane-bound peptides, the inter-
facial activity of antimicrobial peptides is thought to lead to concomitant peptide and lipid
translocation across the lipid bilayer. At high concentrations of asymmetrically bound pep-
tides, polar solutes may be transported across the lipid bilayer concurrently with peptide and
lipid translocation until equilibrium is reached. Thus, the interfacial activity model also pro-
vides a possible explanation to the transience of peptide-induced leakage from lipid vesicles
(45).
The carpet model
In the carpet model, antimicrobial peptides cover the lipid bilayers in a carpet-like manner
(86), see Fig. 2.8. The hydrophilic domains of the peptides interact with the lipid head
groups, whereas the hydrophobic domains are oriented towards the acyl chain core of the
bilayers. For -helical antimicrobial peptides, this corresponds to the orientation in which
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Figure 2.8: Sketch of the carpet model. Peptides (schematically drawn as red rectangles) cover the
bilayer like a carpet. At high peptide concentrations, this leads to disruption of lipid packing and
disintegration in a detergent-like manner.
their long axis is parallel to the plane of the bilayer. Above a certain threshold concentration,
the peptide carpet will entail a global bilayer destabilization thereby leading to a detergent-like
disintegration of the bilayer (27, 87). One consequence of the carpet model is that peptide
activity does not require any specic peptide structure, explaining why so many dierent
peptides of diverse amino acid sequence and secondary structure display antimicrobial activity
(88).
It is worth noting that the carpet model is thought to be compatible with the toroidal pore
model (88). Thus, prior to membrane solubilization, the formation of toroidal pores in the
membrane might occur. Accordingly, it was observed by calorimetry and electron microscopy
that the antimicrobial peptide mastoparan X formed transmembrane pores at low peptide
concentrations and globular and worm-like micelles at high peptide concentrations (44).
The lipid clustering model
The lipid clustering model is another proposed scheme for antimicrobial peptide-lipid mem-
brane interactions. In the lipid clustering model, antimicrobial peptides, which, as mentioned
in Sections 2.3.1 and 2.4.1, are cationic, will preferentially interact with anionic phospholipids,
see Fig. 2.9. In membranes composed of mixtures of zwitterionic and anionic phospholipids,
this preferential interaction will lead to the formation of lateral domains enriched in peptides
and anionic lipids (89{92). Even in membranes composed solely of anionic phospholipids, lat-
eral segregation might occur (93). Such peptide action might disrupt natural lateral domains
existing in microbial membranes, thereby, for example, hampering the function of transmem-
brane proteins associated to these lateral domains (94). Additionally, peptide-induced lipid
clustering might also introduce more boundary eects in the bilayers, facilitating peptide
translocation and membrane permeabilization (95, 96).
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Figure 2.9: Sketch of the lipid clustering model. Peptides (schematically drawn as red rectangles)
preferentially interact with anionic phospholipids, thereby causing lateral segregation of anionic phos-
pholipids (drawn with blue head groups) from zwitterionic phospholipids (drawn with white head
groups). Clustering of some anionic phospholipids from other anionic phospholipids has also been
observed.
2.4.5 A unifying model: phase diagrams and molecular shapes
It has been suggested that many of the aforementioned models represent specic domains
in a peptide-lipid phase diagram (97). According to this idea, many of the above models do
not contradict each other, but rather they represent dierent domains in the phase diagram.
For example, the formation of toroidal pores might occur in one specic peptide-to-lipid
ratio domain in the phase diagram, whereas carpet-induced disintegration of the bilayers
into micelles might occur in another specic peptide-to-lipid ratio domain. In that way,
the actions of antimicrobial peptides on lipid bilayers are equivalent to the actions of other
amphiphiles, such as detergents or phospholipids (98).
An important parameter for these phase diagrams is the molecular shapes of peptides
and lipids (99). Thus, certain molecular shapes are ascribed to peptides and lipids, see
Fig. 2.10; these molecular shapes then determine the peptide-lipid supramolecular assembly
structure, and, thereby, the position of the individual domains in the phase diagrams. For
example, phosphatidylcholine is described as a cylinder and form lamellar bilayer structures.
In contrast, phosphatidylethanolamine is described as an inverted truncated cone due to its
small head group, and, as a result, this lipid tend to aggregate into structures with negative
curvature, such as the inverse hexagonal phase. As another example, lysolipids are described
as a cone; therefore, they tend to aggregate into structures with positive curvature, such as
micelles (98). In continuation of these ideas, antimicrobial peptides, which, as illustrated in
Fig. 2.3, typically assume a planar orientation in the lipid head group region, are thought
to be similar to a truncated cone, thereby inducing positive curvature strain (98). As a
result of this positive curvature strain, antimicrobial peptides might, for instance, promote
the formation of toroidal pores (72). According to these ideas, peptide-induced toroidal
pore formation would, therefore, be promoted in bilayers with positive-curvature-inducing
phospholipids. However, as also mentioned before, it should again be mentioned that the
idea of molecular shape to explain the propensity of antimicrobial peptides to induce toroidal
pores has been challenged in recent years (59, 73).
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Figure 2.10: Examples of lipids and peptides with dierent molecular shapes. The molecular shape of
lipids and peptides are thought to determine the structure of their resulting supramolecular assembly.
2.5 What questions remain unanswered about antimicrobial
peptide activity?
From the above sections, it is clear that much is known about antimicrobial peptides. How-
ever, even so, a number of questions about antimicrobial peptides still remain to be answered.
2.5.1 Structure-activity relationship
One topic that still remains unclear, in spite of years of intense research eorts, is the rela-
tionship between the physicochemical structure and the microbicidal activity of antimicrobial
peptides. While it is clear that physicochemical parameters such as charge, hydrophobic-
ity, and amphipathicity all aect antimicrobial activity and selectivity, it is also clear that
peptide optimization is not just a simple linear process in which each of these parameters
independently can be optimized. Rather, antimicrobial activity and selectivity depend on an
intricate interplay between many parameters (100). Thus, even subtle changes in the amino
acid sequence of a given peptide might confer great changes on the properties of that peptide
(84, 85, 101). In addition, peptide microbicidal activity also depends on the properties of
the microbial membrane, including the lipid composition (102). This further complicates the
understanding of the factors contributing to antimicrobial peptide activity.
However, advanced computational methods might hold future promise to reveal these
delicate structure-activity relationships of antimicrobial peptides. For example, computa-
tional methods in conjunction with high-throughput activity data have been used to identify
molecular descriptors that correlate to antimicrobial activity and, thereby, design novel syn-
thetic antimicrobial peptides with high potency (103). Also, molecular dynamics simulations
might provide insight into the molecular mechanisms of antimicrobial peptide action; indeed,
there are already examples of synthetic antimicrobial peptides being designed on the basis
of molecular dynamics simulations (104).
2.5.2 Antimicrobial peptide-lipid membrane interactions
As mentioned previously, it is evident that antimicrobial peptides must interact with the cell
membrane to kill a given cell; as a result, antimicrobial peptide-lipid membrane interactions
22 Antimicrobial peptides
have been studied extensively. However, a number of open questions still remain about these
interactions (10).
A central question to be answered is related to the actual role of the microbial cell
membrane in antimicrobial peptide action (10). To be more specic, it is not known how
interactions between antimicrobial peptides and microbial cell membranes lead to cell death.
As mentioned before in Section 2.1.1, there are indications that lethal action of antimicrobial
peptides is related to membrane disruption, but there are also indications that lethal action
of antimicrobial peptides is related to translocation across the cell membrane to inhibit
vital intracellular metabolic processes. As these two routes to cell death are not mutually
exclusive, it is unclear whether cell killing always proceeds via one or the other of these routes,
or whether peptides follows both routes simultaneously. Certainly, rational optimization of
antimicrobial peptides for anti-infective therapeutic purposes would be a lot easier if it was
known for which route exactly that the peptides were optimized.
Another central question on antimicrobial peptide-lipid membrane interactions is related
to the mechanisms of peptide-induced membrane permeabilization. Even though much is
known about antimicrobial peptide-induced membrane permeabilization and many models
have been proposed, the molecular details underlying this membrane permeabilization is
still unraveled. For instance, the reasons that permeabilization of model membranes in
lipid vesicles is a transient phenomenon remain elusive (10). It seems that some sort of
structural reorganization in the membrane brings leakage to a halt, possibly due to complete
peptide equilibration across the lipid membrane, but the details of this process is not entirely
understood. As an extension of this question, it is also still an open question how exactly
that peptide and lipid translocation across the bilayer is coupled with permeabilization of
membranes in lipid vesicles.
Another important question about peptide-induced membrane permeabilization is per-
taining to the correlation between the transient permeabilization that have been identied in
lipid vesicles and the equilibrium pores that have been identied in oriented lipid multibilayers.
Even though elegant experimental designs have been applied to study permeabilization un-
der equilibrium conditions in free-standing lipid bilayers (46, 105, 106), no direct correlation
between permeabilization in lipid vesicles and pore formation in oriented multibilayers has so
far been established. Without such a correlation, the structural insights gained from experi-
ments on oriented multibilayers are not easily transferrable to the free-standing membranes
in lipid vesicles and, thereby, also not easily transferable to cellular membranes1.
Yet another pivotal question is about whether all of the many models that have been
suggested to explain antimicrobial peptide-lipid membrane interactions represent distinct
mechanisms, or whether many of them are manifestations of one single grand mechanism
(10). As mentioned in Section 2.4.5, it was suggested that many of the individual models
could be unied into a single model by considering phase diagrams and molecular shapes of
phospholipids and peptides, but a denite validation of this approach is still lacking.
Finally, it would of course be highly desirable if the mode of interaction of antimicrobial
peptides with phospholipid bilayers could be understood and predicted based on the physic-
1Considerations on the correlation between transient permeabilization in lipid vesicles and equilibrium pores
in oriented multibilayers represent personal views of the author of this thesis.
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Peptide Sequence Charge Hydrophobic One-letter
name length (pH 7.4) residues sequence
Mastoparan X 14 +4 43 % INWKGIAAMAKKLL-NH2
Melittin 26 +6 31 % GIGAVLKVLTTGLPALISW-
IKRKRQQ-NH2
Magainin 2 23 +3 30 % GIGKFLHSAKKFGKAFVG-
EIMNS
Table 2.1: Summary of the amino acid sequence characteristics of the three antimicrobial peptides
studied in this thesis. To estimate the net peptide charge at pH 7.4, it was assumed that lysines and
arginines are completely protonated and that histidines are completely deprotonated. Furthermore,
estimates of the net charge also took into account that mastoparan X and melittin each gain an extra
charge due to C-terminal amidation. To calculate the percentage of hydrophobic residues, the Wimley-
White interfacial hydrophobicity scale was considered (114). Thus, a given residue was dened to
be hydrophobic if it according to the Wimley-White interfacial hydrophobicity scale preferentially
partitions into the lipid bilayer interface. According to this denition, tryptophan, phenylalanine,
tyrosine, leucine, isoleucine, cysteine, and methionine are dened as hydrophobic.
ochemical characteristics of the peptides, for example, through quantication of molecular
shapes (45). However, models to explain antimicrobial peptide-lipid membrane interac-
tions are generally qualitative, and data aiming at quantitative correlations between peptide
physicochemical properties and behavior in lipid bilayers is scarce. In a series of noteworthy
papers, antimicrobial peptide free energies of binding and insertion in lipid bilayers were at-
tempted correlated to peptide behavior in membranes (107{109) but no certain conclusions
were reached. However, it is clear that successful completion of such attempts to quanti-
tatively correlate peptide physicochemical characteristics to their behavior in lipid bilayers
would represent a great scientic advance in the understanding of antimicrobial peptide-lipid
membrane interactions (10).
2.6 Antimicrobial peptides studied in this thesis
In this thesis, three representative peptides with antimicrobial activity are studied (110{112):
mastoparan X, melittin, and magainin 2. Each of these peptides originate from natural
sources; mastoparan X was isolated from the venom of the hornet Vespa xanthoptera (113),
melittin was isolated from the venom of the honeybee Apis mellifera (27), and magainin 2
was isolated from the skin of the frog Xenopus laevis (52). The amino acid sequences of
these three peptides are archetypal to that of antimicrobial peptides; the sequences are short
and enriched in cationic and hydrophobic residues. A summary of the amino acid sequence
characteristics of mastoparan X, melittin and magainin 2 is given in Table 2.1.
In addition to their archetypal amino acid sequences, mastoparan X, melittin, and mag-
ainin 2 are also characterized by a number of other typical structural and functional features
of antimicrobial peptides. Thus, similar to many other antimicrobial peptides, all three pep-
tides are often reported to be in random coil or partially folded states in aqueous solution
(111, 113, 115{117), albeit high peptide concentration, high ionic strength, and high pH
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Figure 2.11: Helical wheel projection of the three antimicrobial peptides studied in this thesis:
mastoparan X, melittin and magainin 2. Cationic residues are red, anionic residues are blue, hy-
drophobic residues are white, and the remaining residues are grey. Hydrophobic residues are dened
as residues that according to the Wimley-White interfacial hydrophobicity scale preferentially partition
into the bilayer interface (114). Histidine is assumed to be deprotonated at pH 7.4 and is, therefore,
not represented as a cationic residue.
might induce peptide structuring and/or aggregation (111, 112, 118, 119). Upon associa-
tion to lipid bilayers, all three peptides fold into -helical structures (111, 117, 120{123): for
mastoparan X, it has been suggested that residues Trp3-Leu14 form a stable helix, whereas
Ile1-Asn2 are unstructured (120, 121); for melittin, it has been suggested that about 20 amino
acid residues take part in a stable helix and that the cationic residues at the C-terminal are
unstructured (111); and for magainin 2, it has been suggested that at least residues Ile2-Ile20
take part in a stable helix (112, 117). The helical wheel projections, shown in Fig. 2.11,
predict that hydrophobic residues in these helical structures tend to cluster on one side of the
helix and polar and charged residues tend to cluster on the opposite side, thereby creating
an amphipathic structure as is also commonly observed in many other antimicrobial peptides
(28). However, it should be noted that the helical wheel projections, drawn in Fig. 2.11, are
primarily meant for illustrative purposes; they do not provide a completely accurate represen-
tation of the actual membrane-bound structure. For instance, the Ile1 residue in mastoparan
X is not necessarily located at the hydrophilic face as it has been predicted to not take part
in the helical segment of the peptide (120, 121). Likewise, the C-terminal cationic resides
in melittin are probably not distributed as predicted by the helical wheel projection as they
also have been predicted not to take part in the helical segment of the peptide (111). Even
so, in spite of these limitations of the helical wheel projection, it should still be clear that
mastoparan X, melittin, and magainin 2 to some extent all fold into amphipathic structures
upon association to phospholipid membranes.
The amphipathic features of mastoparan X, melittin, and magainin 2 allow them to
interact with phospholipid bilayers in a manner similar to other antimicrobial peptides. Due
to their amphipathic nature, they are thus often found in a planar orientation with their
long axis parallel to the plane of the bilayer (111, 117, 122, 124). In this orientation, their
hydrophobic faces are turning towards the acyl chain core of the bilayers, whereas their
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hydrophilic faces are turning towards the lipid head groups of the bilayers, just as the typical
orientation of many other -helical antimicrobial peptides. However, there are certainly also
examples that the all three peptides might insert perpendicularly into oriented multibilayers
or lipid bicelles, and it has been hypothesized that this perpendicular insertion is coupled to
the formation of transmembrane toroidal pores (56, 59, 66, 124). For all three peptides, it is
not clear whether they generally are monomeric (111, 125, 126) or aggregated (64, 122, 127)
when partitioned into phospholipid membranes.
The three peptides also display other archetypal features of antimicrobial peptides. Thus,
in agreement with their net cationic charge, their partition coecient is typically higher for
partitioning into anionic phospholipid vesicles than for partitioning into zwitterionic phospho-
lipid vesicles (110, 112, 128, 129). Furthermore, they have all been found to induce partial
transient leakage from lipid vesicles (50, 52, 55, 56, 66, 128, 130{133). However, whereas
mastoparan X and magainin 2 have been found to lyse anionic lipid vesicles more eec-
tively than zwitterionic lipid vesicles (51, 112, 128), melittin has interestingly been found to
lyse zwitterionic lipid vesicles more eectively than anionic lipid vesicles (42, 111), possibly
because anionic lipid head groups immobilize melittin at the head group region (134).
2.7 Thesis scope revisited
In Section 1.2, it was stated that the thesis scope is to quantitatively study interactions be-
tween antimicrobial peptides and phospholipid membranes. To elaborate on that statement,
a brief introduction to each of the manuscripts in Chapters 3, 4, and 5 is now given.
The manuscript in Chapter 3 is concerned with the adsorption of mastoparan X, melittin,
and magainin 2 to solid surfaces of glass and plastic. This adsorption is examined by ana-
lytical HPLC. In that way, the manuscript is not per se concerned with quantitative studies
of antimicrobial peptide-lipid membranes interactions. Rather, the manuscript is concerned
with an eect that might have immense experimental implications for anyone who wants to
perform quantitative studies of antimicrobial peptide-lipid membranes interactions. Thus,
these adsorptive interactions might lead to poor control of the actual experimental concen-
tration of peptides. Without accurate control of the experimental peptide concentration, it
is impossible to conduct any quantitative studies on antimicrobial peptide-lipid membranes
interactions.
The manuscript in Chapter 4 is concerned with using uorescence correlation spec-
troscopy (FCS) as a method for quantitative studies of antimicrobial peptide-induced leakage
of uorescent markers from lipid vesicles. The goal of the manuscript is rst and foremost to
develop the technique for the purpose of quantifying leakage from lipid vesicles in solution;
that is, the goal of the manuscript is not to apply the technique for any systematic investi-
gations of antimicrobial peptide-induced membrane permeabilization; only mastoparan X is
considered to show the applicability of FCS.
The manuscript in Chapter 5 is concerned with using uorescently-labeled surface-tethered
vesicles to quantitatively study antimicrobial peptide-induced leakage of uorescent mark-
ers on the single-vesicle level. Specically, confocal imaging of surface-tethered vesicles are
combined with FCS to quantitatively study leakage induced by mastoparan X, melittin, and
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magainin 2. In other words, the scope of the manuscript is both to introduce a novel ap-
proach for quantitative studies of antimicrobial peptide-induced leakage on the single-vesicle
level and to use this approach, together with FCS, to quantitatively study leakage induced
by mastoparan X, melittin, and magainin 2
It should be mentioned that in the rst and third manuscript, the peptides are called
"cationic membrane-active peptides" instead of "antimicrobial peptides"; this is due to the
fact that the angles of the three manuscripts dier slightly. However, the reader of this thesis
should keep in mind that the term "cationic membrane-active peptides" is basically just a
synonym for the antimicrobial peptides that were discussed in the present chapter.
It should also be mentioned that the three manuscripts do not contain any discussion
about how their contents might specically be used to answer some of the questions posed
in Section 2.5.2. However, for completeness, Chapter 6 contains a brief discussion about
the future perspectives of the work presented in the three manuscripts, and, thereby, also
a discussion about how the work presented in the manuscripts might be used for answering
some of the questions posed in Section 2.5.2.
Finally, a comment should be made concerning the choice of synthetic lipid vesicles
used in this thesis. Thus, it should be mentioned that several type of lipid vesicles with
dierent sizes prepared by dierent methods are used in the literature to study antimicrobial
peptide-phospholipid membrane interactions: Small unilamellar vesicles (SUVs) with a typical
diameter of approximately 30 nm, prepared by ultrasonic irradiation (132); large unilamellar
vesicles (LUVs) with a typical diameter of approximately 100 nm, prepared by extrusion
(51, 110); and giant unilamellar vesicles (GUVs) with a typical diameter of approximately
5-100 m, prepared by electroformation or spontaneous swelling (47, 135, 136). In terms
of experimental design, both possibilities and limitations are associated with each type of
lipid vesicles, and it can not be said that one type of lipid vesicle is better than the other.
That being said, the work presented in this thesis is based on LUVs as they provide a
model membrane system with multiple desirable attributes. In particular, solutions of LUVs
represent a collection of size-homogenous vesicles with low membrane curvature. In addition,
the lipid concentration of these solutions can, within a broad concentration range, be ne-
tuned to the exact needs of a given experiment. In the following chapters, the usefulness of
these attributes will be clearly demonstrated.
CHAPTER 3
Adsorption of antimicrobial peptides
to glass and plastic surfaces
The following chapter contains a manuscript in preparation. The manuscript is entitled
"Adsorption of cationic membrane-active peptides to glass and plastic surfaces".
3.1 Abstract
Cationic membrane-active peptides have been studied for years in the hope of developing
them into novel types of therapeutics. In this article, we report on an eect that might
have immense experimental implications for investigators who wish to study these peptides,
namely, that the peptides adsorb to solid surfaces of glass and plastic. Specically, we used
analytical HPLC to systematically study the inuence of parameters like surface-to-volume
ratio and ionic strength on the adsorption of the three -helical cationic membrane-active
peptides mastoparan X, melittin, and magainin 2 to the walls of disposable plastic and glass
containers. The results show that at typical experimental concentrations, 90 % or more of
the peptides might be lost due to rapid surface adsorption. Consequently, we conclude that
investigators should keep these adsorptive eects in mind when designing and interpreting
experiments on cationic membrane-active peptides.
3.2 Introduction
Cationic membrane-active peptides with antimicrobial (5, 14) and/or cell-penetrating prop-
erties (137, 138) have been studied intensely for years with the goal of developing these
peptides into new types of therapeutics; for example, cationic membrane-active peptides
have been suggested to hold promise for becoming a novel class of antibiotics (8). In the
endeavor of studying and understanding these cationic membrane-active peptides, numerous
advanced experimental and theoretical methods have been employed, resulting in a wealth
of informative scientic articles. In these many articles, however, a quite important piece of
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information is often put in a side note; cationic membrane-active peptides adsorb to solid
surfaces, such as surfaces of glass or plastic. In spite of its immense experimental implica-
tions, this eect is seldom considered in its own right, except in a small handful of papers
that clearly demonstrate the seriousness of this issue (139{143).
The goal of the present article is, therefore, to provide a systematic investigation of the
adsorption of cationic membrane-active peptides to solid surfaces. Specically, the goal is
to systematically investigate the adsorption of the three -helical cationic membrane-active
peptides mastoparan X, melittin, and magainin 2 to the walls of disposable glass and plastic
containers. Each of these three peptides have previously been extensively studied, especially,
to reveal the mechanisms by which they interact with phospholipid bilayers (50, 52, 110{
112, 128{132). For the purpose of studying the surface adsorption of these three peptides, we
used analytical HPLC. Our results clearly show that interactions between cationic membrane-
active peptides and solid surfaces of glass and plastic is an eect that should not be taken
lightly upon by experimental investigators.
3.3 Materials and methods
3.3.1 Materials
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-sn-glyce-
ro-3-[phospho-rac-(1-glycerol)], sodium salt (POPG) were purchased from Avanti Polar Lipids
(Alabaster, AL, USA). N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES)
and the corresponding sodium salt (HEPES-Na), acetonitrile (MeCN), triuoroacetic acid
(TFA), and NaCl were purchased from Sigma-Aldrich (Brndby, Denmark). Melittin was
purchased from Peptide 2.0 (Chantilly, VA, USA), and mastoparan X and magainin 2 were
purchased from GL Biochem (Shanghai, China). Mastoparan X was further puried by
semi-preparative HPLC (Waters semi-preparative HPLC equipped with a Waters 600 pump
& controller and a Waters 2489 UV/vis detector, Waters, Milford, MA, USA). The pu-
rity of all three peptides was checked by analytical HPLC (Shimadzu LC-2010C analytical
HPLC equipped with a UV/vis detector, Shimadzu, Kyoto, Japan, or Gilson analytical HPLC
equipped with a Gilson 321 HPLC pump and a Gilson 155 UV/vis detector, Gilson, Mid-
dleton, MI, USA) and the identity of the peptides was conrmed by MALDI-TOF (Bruker
Reex IV MALDI-TOF spectrometer, Bruker, Billerica, MA, USA).
Glass vials (borosilicate glass sample vials, 2 mL, diameter 12 mm) were purchased from
Brown Chromatography Supplies (VWR - Bie & Berntsen, Herlev, Denmark), plastic tubes
(polypropylene Safe-Lock tubes, 2 mL, inner diameter 9.2 mm) and LoBind tubes (Protein
LoBind tubes, 2 mL, inner diameter 9.2 mm) were purchased from Eppendorf (VWR - Bie
& Berntsen). Quartz glass cuvette (Suprasil, inner dimensions 4  10 mm) was purchased
from Hellma (Mullheim, Germany). PTFE-coated magnetic stirring bar was purchased from
VWR (VWR - Bie & Berntsen).
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3.3.2 LUV preparation and characterization
POPC/POPG (3:1) solutions were prepared in chloroform/methanol (9:1). The organic
solvent was removed under a gentle stream of nitrogen. The samples were subsequently
kept in vacuum overnight to remove the residual solvent. The lipid lms were hydrated in
10 mM HEPES, 100 mM NaCl, pH 7.4 buer with vigorous vortexing every 5 min for a
period of 30 min. The hydrated lipid suspensions were then subject to 5 freeze-thaw cycles
by alternately placing the sample vials in an isopropanol/dry ice bath and a warm water
bath. Next, the lipid suspensions were extruded 21 times through a 100 nm polycarbonate
lter (Whatman, Maidstone, UK) using a mini-extruder (Avanti Polar Lipids) to form LUVs.
The size of the LUVs was checked by dynamic light scattering (ZetaPALS, Brookhaven
Instruments, Holtsville, NY, USA). Phosphorous concentrations of the LUV solutions were
determined using the method of Rouser et al. (144), albeit with slightly modied reagent
concentrations.
3.3.3 Peptide stock solutions
Peptide stock solutions were prepared in 10 mM HEPES, 100 mM NaCl, pH 7.4 buer. To
prevent loss of peptides due to adsorption to tube walls and/or pipette tips, the peptide stock
solutions were handled in LoBind tubes at a high concentration of at least 100 M. To deter-
mine the concentration of peptide stock solutions, the extinction coecients of peptides at
220 nm were calculated to be 40100 cm 1M 1 for mastoparan X, 46700 cm 1M 1 for melit-
tin, and 23900 cm 1M 1 for magainin 2 by correlating the peptide concentrations determined
by an Antek 8060 chemiluminescent nitrogen detector (PAC, Houston, TX, USA) to the ab-
sorbance of the same peptide samples, determined by a NanoDrop 2000c spectrophotometer
(NanoDrop Products, Wilmington, DE, USA). Given these extinction coecients, peptide
concentrations of stock solutions were then always determined by recording the absorbance
at 220 nm using the NanoDrop 2000c spectrophotometer.
3.3.4 Preparation of samples for analytical HPLC
The general procedure for preparation of samples for analytical HPLC, to be described in
detail in the following lines, was that peptide solutions were incubated in glass or plastic con-
tainers before they were transferred to HPLC autosampler vials containing inserts (conical
inserts, borosilicate glass, 300 L, diameter 6 mm, Brown Chromatography Supplies, Mikro-
lab Aarhus, Hjbjerg, Denmark). After transfer of solutions to the inserts, POPC/POPG
(3:1) LUVs were added to the inserts to prevent surface adsorption of peptides to the walls
of the inserts. The solutions in the inserts were then subject to HPLC analysis to quantify
the amount of peptide in the inserts and, thereby, also the amount of peptide that had been
lost to surface adsorption in the glass and plastic containers in which the peptide solutions
had been incubated before they were transferred to the inserts.
In the following, all samples were prepared in 10 mM HEPES, 100 mM NaCl, pH 7.4
buer, except where otherwise noted.
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Concentration standard curves
Peptide solutions of varying concentrations were prepared directly in the inserts in the au-
tosampler vials. Specically, varying volumes of 100 M peptide stock solutions were added
to varying volumes of buer in the inserts to a nal solution volume of 200 L. After peptide
addition, the autosampler vials were vortexed for a few seconds. Next, 50 L of 5 mM
POPC/POPG (3:1) LUV was added to each of the inserts to a nal LUV concentration of
1 mM and a nal volume of 250 L. The autosampler vials were again vortexed for a few
seconds. Finally, the samples in the inserts were subject to HPLC analysis.
Peptide loss in glass and plastic containers
Peptide solutions of 1, 2, 5, 10, or 20 M were prepared by adding varying volumes of
100 M peptide stock solutions to varying volumes of buer in glass vials, plastic tubes, or
LoBind tubes to a nal solution volume of 220 L. After peptide addition, solutions were
vortexed for a few seconds and then incubated for 1 h. Next, 200 L of each solution was
transferred by pipette to the inserts in the autosampler vials. The autosampler vials were
then vortexed for a few seconds. Subsequently, 50 L of 5 mM POPC/POPG (3:1) LUV
was added to each of the inserts to a nal LUV concentration of 1 mM and a nal volume
of 250 L. Autosampler vials were again vortexed for a few seconds. Subsequently, samples
in the inserts were subject to HPLC analysis.
Loss in peptide solutions of larger volumes were also considered. Specically, 2 mL
solutions of 2 M peptide were prepared in glass vials, plastic tubes, LoBind tubes, or quartz
glass cuvettes by adding 40 L of 100 M peptide stock solutions to 1960 L buer. The
solutions in the glass vials, plastic tubes, and LoBind tubes were then vortexed for a few
seconds and incubated for 1 h before 200 L of each solution was transferred by pipette to the
inserts in the autosampler vials. The solutions in the quartz glass cuvettes were constantly
stirred for 1 h by a magnetic bar before 200 L of each solution was transferred by pipette
to the inserts in the autosampler vials. For all samples, upon transfer to the inserts, the
protocol was then identical to that described before; the autosampler vials were vortexed for
a few seconds, 50 L of 5 mM POPC/POPG (3:1) LUV was added to each of the inserts
to a nal LUV concentration of 1 mM, the autosampler vials were again vortexed for a few
seconds, and, nally, samples in the vial inserts were subject to HPLC analysis.
Peptide loss during successive transfers between containers
Peptide solutions in four identical containers (glass vials, plastic tubes, or LoBind tubes)
were prepared by adding 12:5 L of 100 M peptide stock solution to 237:5 L buer in
each of the containers to a nal peptide concentration of 5 M and a nal solution volume
of 250 L. Following peptide addition, each of four the containers were vortexed for a few
seconds. The solution in the rst container was then incubated for 1 h before 200 L of
the solution was transferred by pipette to an insert in an autosampler vial. The solution in
the second container was transferred by pipette into an empty container of the same kind.
This new container was then vortexed for a few seconds. After 1 h incubation, 200 L of
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the solution in this new container was transferred by pipette to an insert in an autosampler
vial. The solution in the third container was successively transferred by pipette into two
empty containers of the same kind. After each transfer step, the solution was vortexed for
a few seconds. Upon transfer to the last empty container, the solution was incubated for 1
h before 200 L of the solution was transferred by pipette to an insert in an autosampler
vial. The solution in the fourth container was successively transferred by pipette into three
empty containers of the same kind. After each transfer step, the solution was vortexed for
a few seconds. Upon transfer to the last empty container, the solution was incubated for 1
h before 200 L of the solution was transferred by pipette to an insert in an autosampler
vial. Once in the inserts in the autosampler vials, each of the four solutions were treated
as described before; the autosampler vials were vortexed for a few seconds, 50 L of 5 mM
POPC/POPG (3:1) LUV was added to each of the inserts to a nal LUV concentration of 1
mM, the autosampler vials were again vortexed for a few seconds, and, at last, the samples
in the inserts were subject to HPLC analysis.
Peptide loss as a function of NaCl concentration
Peptide solutions of 2 M were prepared in glass vials, plastic tubes, or LoBind tubes.
The solutions were prepared by adding 4:4 L of 100 M peptide stock solution (in 10 mM
HEPES, 100 mM NaCl, pH 7.4 buer) to 215:6 L buer (10 mM HEPES, pH 7.4 with either
0 mM NaCl or 150 mM NaCl) to a nal volume of 220 L and nal NaCl concentrations of 2
mM or 149 mM, respectively. In that way, solutions with dierent NaCl concentrations were
prepared. The rest of the protocol was then identical to that described before; solutions were
vortexed for a few seconds, incubated for 1 h before 200 L of each solution was transferred
by pipette to inserts in autosampler vials. Then, the autosampler vials were vortexed for a
few seconds, 50 L of 5 mM POPC/POPG (3:1) LUV (in 10 mM HEPES, 100 mM NaCl,
pH 7.4 buer) was added to each of the inserts to a nal LUV concentration of 1 mM, the
autosampler vials were again vortexed for a few seconds, and, nally, samples in the inserts
were subject to HPLC analysis.
To conrm that peptide concentrations could still be quantied by the HPLC method
upon changing the NaCl concentration, we prepared 2 M peptide solutions directly in the
inserts in the autosampler vials by adding 4 L of 100 M peptide stock solution (in 10 mM
HEPES, 100 mM NaCl, pH 7.4 buer) to 196 L buer (10 mM HEPES, pH 7.4 with either
0 mM NaCl or 150 mM NaCl) to a nal volume of 200 L. Autosampler vials were vortexed
for a few seconds. Next, 50 L of 5 mM POPC/POPG (3:1) LUV (in 10 mM HEPES, 100
mM NaCl, pH 7.4 buer) was added to each of the inserts to a nal LUV concentration of 1
mM. The autosampler vials were again vortexed for a few seconds, and, at last, the contents
of the vial inserts were subject to HPLC analysis.
Surface pre-saturation and LUV-induced desorption
Peptide solutions of 2 M were prepared in glass vials, plastic tubes, or LoBind tubes by
adding 4:4 L of 100 M peptide stock solution to 215:6 L buer to a nal volume of
220 L. The solutions were vortexed for a few seconds and then incubated for 1 h. Following
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this incubation time, 200 L of each solution was aspirated into a pipette tip and discarded.
Next, 196 L buer and then 4 L of 100 M peptide stock solution were added to the
each of the containers to a nal volume of 220 L (20 L had remained in the containers
after discarding 200 L). The solutions were vortexed for a few seconds and incubated for
1 h. Subsequently, the solutions were treated in the same manner as described before;
200 L of each of the solutions were transferred by pipette to inserts in autosampler vials,
the autosampler vials were vortexed for a few seconds, 50 L of 5 mM POPC/POPG (3:1)
LUV was added to each of the inserts to a nal LUV concentration of 1 mM, the autosampler
vials were again vortexed for a few seconds, and, at last, the samples in the inserts were
subject to HPLC analysis.
In connection with these pre-saturation experiments, we also investigated the eect of
POPC/POPG (3:1) LUVs to entail desorption of peptides from the walls of the glass vials,
plastic tubes, and LoBind tubes. Specically, we considered the eect of POPC/POPG (3:1)
LUVs to induce desorption in both containers that had not been pre-saturated with peptide
and containers that had been pre-saturated with peptide. In the experiments with non-
saturated containers, peptide solutions were prepared in glass vials, plastic tubes, or LoBind
tubes by adding 4:4 L of 100 M peptide stock solution to 205:6 L buer. Solutions were
vortexed for a few seconds and then 10 L of 22 mM POPC/POPG (3:1) LUV was added to
each of the solutions to a nal peptide concentration of 2 M, a nal LUV concentration of
1 mM, and a nal volume of 220 L. Solutions were again vortexed for a few seconds, and
then incubated for 1 h. Next, 200 L of each of the solutions were transferred by pipette to
the inserts in the autosampler vials. The autosampler vials were vortexed for a few seconds
and 50 L of 1 mM POPC/POPG (3:1) LUV was added to each of the inserts to a nal
LUV concentration of 1 mM. The autosampler vials were again vortexed and the samples in
the inserts were subject to HPLC analysis.
In the experiments with pre-saturated containers, peptide solutions were prepared in glass
vials, plastic tubes, or LoBind tubes by adding 4:4 L of 100 M peptide stock solution to
215:6 L buer to a nal peptide concentration of 2 M and a nal volume of 220 L.
Solutions were vortexed for a few seconds and, subsequently, incubated for 1 h. After
this incubation time, 200 L of each of the solutions was aspirated into a pipette tip and
discarded. Next, 186 L buer and then 4 L of 100 M peptide stock solutions were added
to each container. The solutions were vortexed for a few seconds and then 10 L of 22 mM
POPC/POPG (3:1) LUV was added to each of the solutions to a nal peptide concentration
of 2 M, a nal LUV concentration of 1 mM, and a nal volume of 220 L. The containers
were again vortexed and incubated for 1 h. Then the samples were treated in a manner
identical to before; 200 L of each of the solutions were transferred by pipette to inserts in
autosampler vials, the autosampler vials were vortexed for a few seconds, 50 L of 1 mM
POPC/POPG (3:1) LUV was added to the inserts to a nal LUV concentration of 1 mM, the
autosampler vials were again vortexed, and, nally, the samples in the inserts were subject
to HPLC analysis.
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Adsorption and desorption kinetics
To investigate the adsorption kinetics of peptides, we considered only mastoparan X. Specif-
ically, a number of samples with 2 M mastoparan X were prepared by adding 4:4 L of
100 M mastoparan X stock solution to 215:6 L buer in glass vials, plastic tubes, or
LoBind tubes to a nal volume of 220 L. The solutions were vortexed for a few seconds and
then incubated for 10 s, 1 h, or 24 h. After these incubation times, solutions were handled
as also described before; 200 L of the solutions were transferred by pipette to inserts in
autosampler vials, the autosampler vials were vortexed for a few seconds, 50 L of 5 mM
POPC/POPG (3:1) LUV was added to each of the inserts to a nal LUV concentration of 1
mM, the autosampler vials were again vortexed, and, nally, the samples in the inserts were
subject to HPLC.
3.3.5 Analytical HPLC measurements
Analytical HPLC was performed on a Shimadzu LC-2010C integrated HPLC system equipped
with a UV/vis detector (Shimadzu, Kyoto, Japan). For samples of mastoparan X together
with 1 mM POPC/POPG (3:1) LUV, 80 L was loaded onto the system. For samples of
melittin or magainin 2 together with 1 mM POPC/POPG (3:1) LUV, 50 L was loaded onto
the system. We found that when larger volumes were injected, peptide peak areas were no
longer linear to peptide concentrations. The ow rate of the system was 1 mL/min. Mobile
phases were (A) water with 5 % MeCN and 0:1 % TFA and (B) MeCN with 0:1 % TFA.
Gradients were linear from 85 % A to 0 % A over 12 min. Peptides and lipids were separated
on a XTerra RP8 (5 m, 4:6  150 mm) column (Waters). UV absorbances were recorded
at 220 nm. Peptide peak areas were determined by using the LC Postrun Analysis software.
3.4 Results
3.4.1 Concentration standard curves
To conrm that the HPLC method is applicable to quantify peptide concentrations, we
prepared a number of 200 L concentration standard solutions of varying mastoparan X,
melittin, or magainin 2 concentrations directly in inserts in HPLC autosampler vials. To
each of these standard solutions, 50 L of 5 mM POPC/POPG (3:1) LUV solution was
added to a nal LUV concentration of 1 mM to prevent adsorption of peptides to the walls
of the inserts. Samples were then subject to HPLC analysis. Fig. 3.1 shows a typical HPLC
chromatogram of a 200 L standard solution of 5 M mastoparan X to which 50 L of 5
mM POPC/POPG (3:1) LUV solution had been added. The peptide peak and the lipid peak
are clearly separated. For melittin and magainin 2, we also found that the peptide and lipid
peaks were well separated in chromatograms (examples not shown). Fig. 3.2, A, C, and E,
shows the peptide peak area as a function of the mastoparan X, melittin, and magainin 2
concentration of the 200 L standard solutions, respectively. (That is, the concentrations
in Fig. 3.2 are the concentration of the standard solutions before 50 L LUV solutions were
added). A linear correlation between the peptide peak area and the peptide concentration was
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Figure 3.1: Example of HPLC chromatogram for a sample in which 200 L of 5 M mastoparan X
had been mixed with 50 L of 5 mM POPC/POPG (3:1) LUV directly in inserts in HPLC autosampler
vials. The peptide peak and the lipid peak was found to be clearly separated.
observed for all three peptides, albeit at concentrations  200 nM, signicant uncertainties
in the peak area was observed for mastoparan X and magainin 2, see Fig. 3.2, A and E,
respectively. Nevertheless, the linear standard curves lead to the conclusion that HPLC
is suitable to quantify peptide concentrations across the entire investigated concentration
range.
In order to further assess the accuracy of the HPLC method to quantify peptide concen-
trations, the percentage of recovered peptide was calculated by the equation
Recovered peptide = 100 Peak area
Slope Concentration (3.1)
using the peak areas, the slopes and the concentrations from Fig. 3.2, A, C, and E. In order
for HPLC to be applicable for accurately quantifying the peptide concentration across the
entire concentration range, the percentage of recovered peptide should be close to 100 % for
all of the concentration standard solutions. Fig. 3.2, B, D, and F, conrms that this is indeed
the case for all three peptides, underlining the conclusion from Fig. 3.2, A, C, and E, that
the HPLC method is an accurate method for quantifying peptide concentrations across the
entire investigated concentration range. However, it should be noted that Fig. 3.2, B and
F, also underlines the conclusion from Fig. 3.2, A, and E, that measurements of mastoparan
X and magainin 2 concentration  200 nM are subject to large relative uncertainties.
In the following, we present the results of a number of experiments in which peptide
solutions were incubated in dierent types of sample containers before 200 L of the solutions
were transferred by pipette to inserts in HPLC autosampler vials together with 50 L of 5 mM
POPC/POPG (3:1) LUV for HPLC analysis. The acquired peptide peak areas are always
recalculated to percentages of recovered peptide using Eq. 3.1. In this recalculation, we
always use the slopes from the standard curves in Fig. 3.2, A, C, and E. If the percentages
of recovered peptides are found to be < 100 %, that must mean that some peptide have
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Figure 3.2: Peptide concentration standard curves. Samples were prepared by mixing 200 L peptide
standard solutions of varying peptide concentration with 50 L of 5 mM POPC/POPG (3:1) LUV
directly in inserts in HPLC autosampler vials. The concentrations in the gure are the concentrations
of the 200 L peptide standard solutions. (A, C, E ) Peak area vs concentration of mastoparan
X, melittin, and magainin 2 standard solutions, respectively. The straight lines are the best least
squares ts to the data. (B, D, F ) Percentage of recovered peptide, as calculated from Eq. 3.1,
vs concentration of mastoparan X, melittin, and magainin 2 standard solutions. In all panels, the
data are the average of three separate experiments. The error bars show the standard deviations.
The error bars are not shown when they are smaller than the symbols. The data demonstrate that
the HPLC method is applicable to quantify the peptide concentration across the entire investigated
concentration range.
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Figure 3.3: Loss of mastoparan X (A), melittin (B), and magainin 2 (C ) in 220 L peptide solutions
incubated in glass vials, or plastic or LoBind tubes as a function of the peptide concentration. In
all panels, the data are the average of two separate experiments. The error bars show the standard
deviations. The error bars are not shown when they are smaller than the symbols. The data demon-
strate that all three peptides tend to adsorb to glass and plastic surfaces, especially at low peptide
concentration where only 10   20 % of the expected peptide contents are recovered. In contrast,
peptides do not absorb to LoBind tubes to the same extent.
been lost in the experimental process; either because peptides adsorb onto the walls of the
samples containers, or because peptides adsorb on pipette tips during the transfer from
solutions from the sample containers to the inserts. The latter explanation was ruled out by
a control experiment, see Fig. 3.9 in the Supporting material. Thereby, the loss of peptide
reported in the following experiments is ascribed to adsorption of peptide onto the walls of
the disposable glass and plastic containers.
3.4.2 Peptide loss in glass and plastic containers
To study the adsorption of mastoparan X, melittin, and magainin 2 to the walls of disposable
glass and plastic containers, we prepared a number of 220 L peptide solutions of 1, 2, 5, 10,
or 20 M peptide in glass vials or plastic tubes. For comparison, we also prepared a number
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Figure 3.4: Loss of mastoparan X, melittin, and magainin 2 in 2 mL, 2 M peptide solutions
incubated in glass vials, plastic tubes, LoBind tubes, or quartz glass cuvettes. The data are the average
of two separate experiments. The error bars show the standard deviations. The data demonstrate that
peptide surface-adsorption is not just a phenomenon that occurs at high container surface-to-solution
volume ratios.
of 220 L peptide solutions of 1, 2, 5, 10, or 20 M peptide in LoBind tubes, designed to
reduce the surface adsorption of proteins and peptides. After a few seconds of vortexing and
1 h incubation, 200 L of each of the solutions was transferred to inserts in the autosampler
vials together with 50 L of 5 mM POPC/POPG (3:1) LUV and subject to HPLC analysis.
Fig. 3.3 shows the percentage of peptide thus recovered from the 220 L peptide solutions
as a function of the peptide concentration. A number of common observation were done for
all three peptides. First, for 1 M peptide solutions incubated in glass vials or plastic tubes,
only 10  20 % of the peptides were recovered, meaning that most of the peptide adsorbed
to the walls of these containers at this concentration. Second, for peptide solutions in glass
vials or plastic tubes, an increasing percentage of peptide was recovered as a function of the
peptide concentration, indicating that the walls became saturated with peptide. Third, for
peptide solutions incubated in LoBind tubes, peptides were not lost to the same extent as
in the glass vials and plastic tubes, albeit loss of peptide did in some cases still occur, see,
for example, melittin at 1 M in Fig. 3.3 B.
To investigate whether surface adsorption also occurred at lower container surface-to-
solution volume ratios, at which the surfaces would more easily be saturated with peptides,
we prepared a number of 2 mL, 2 M mastoparan X, melittin, or magainin 2 solutions in glass
vials, plastic tubes, and LoBind tubes. In addition, in these experiments, we also prepared 2
mL, 2 M mastoparan X, melittin, or magainin 2 solutions in quartz glass cuvettes. After
a few seconds of vortexing and 1 h incubation, 200 L of each solution was transferred to
inserts in the autosampler vials together with 50 L of 5 mM POPC/POPG (3:1) LUV, and
the samples were analyzed by HPLC. Fig. 3.4 shows the percentage of peptide recovered
from the 2 mL solutions. The data in the gure shows that reducing the container surface-
to-solution volume ratio entails an increase in the percentage of recovered peptide (compare
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Figure 3.5: Loss of mastoparan X (A), melittin (B), and magainin 2 (C ) during successive transfers
of 250 L, 5 M peptide solutions between glass vials, plastic tubes, and LoBind tubes. In all panels,
the data are the average of two separate experiments. The error bars show the standard deviations.
The error bars are not shown when they are smaller than the symbols. The data highlights the strong
interaction between peptides and the walls of glass vials and plastic tubes; after four transfer steps
in glass vials or plastic tubes, all three peptides were below the detection limit of the HPLC method.
Fig. 3.3 to 3.4), albeit the data also shows that surface adsorption of mastoparan X, melittin,
and magainin 2 is a phenomenon that not only occurs at high container surface-to-solution
volume ratios. An interesting observation from Fig. 3.4 is that mastoparan X, melittin, and
magainin 2 adsorb rather eectively to quartz glass cuvettes; the percentage of recovered
peptide in the quartz glass cuvettes was generally  50 % for all peptides. Another peculiar
observation from Fig. 3.4 is that peptides, within the experimental uncertainty, adsorb to
the same extent to the walls of LoBind tubes on the one hand and to the walls of glass vials
and plastic tubes on the other hand. This is in marked contrast to the observations in Fig.
3.3, in which peptides were found to adsorb much more eectively to glass vials and plastic
tubes than to LoBind tubes.
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3.4.3 Peptide loss during successive transfers between containers
We also investigated the eect of successively transferring 250 L, 5 M mastoparan X,
melittin, and magainin 2 solutions between glass vials, plastic tubes, and LoBind tubes;
specically, peptides were transferred between 1 to 4 containers with vortexing of solutions
between each transfer step. After 1 h incubation in the last container, 200 L of each of
the solutions was transferred to inserts in the autosampler vials together with 50 L of 5
mM POPC/POPG (3:1) LUV, and the samples were subject to HPLC analysis. Fig. 3.5
shows the percentage of recovered peptide as a function of the number of transfer steps.
The data conrms the observations from Figs. 3.3 and 3.4; peptides adsorb to the walls of
the containers. In particular, the data in Fig. 3.5 highlights the strong interaction between
peptides and the walls of glass vials and plastic tubes; in no cases after four transfer steps
were any peptide recovered in neither the glass vials nor the plastic tubes.
3.4.4 Peptide loss as a function of NaCl concentration
Up until now, presented experiments were carried out in 10 mM HEPES, 100 mM NaCl,
pH 7.4 buer. To investigate whether the NaCl concentration impacted the adsorption
process of mastoparan X, melittin, and magainin 2, we prepared a number of 220 L, 2 M
peptide solutions in glass vials, plastic tubes, or LoBind tubes using buers of varying NaCl
concentrations. Specically, the solutions were prepared in 10 mM HEPES, pH 7.4 with
2 mM NaCl, 100 mM NaCl, or 149 mM NaCl. After a few seconds of vortexing and 1
h incubation in the containers, 200 L of each of the solutions was transferred to inserts
in the autosampler vials together with 50 L of 5 mM POPC/POPG (3:1) LUV, and the
samples were subject to HPLC. In addition, samples with 200 L, 2 M mastoparan X,
melittin, or magainin 2 solutions with dierent NaCl concentration were prepared directly in
the inserts, similar to the way that also the solutions for the concentration standard curves
in Fig. 3.2 were prepared directly in inserts. Fig. 3.6 A shows that in the samples mixed
directly in the inserts, approximately 100 % peptide is recovered for all peptides, independent
on the NaCl concentration, demonstrating that the applicability of the HPLC method is not
dependent upon the NaCl concentration of the solutions. Fig. 3.6, B, C, and D, shows
that the percentage of recovered mastoparan X, melittin, or magainin 2 as a function of
NaCl concentration. We found that, within the experimental uncertainty, the percentage of
surface-adsorbed peptide was not inuenced by the concentration of NaCl.
3.4.5 Surface pre-saturation and LUV-induced desorption
We investigated the eect of pre-saturating containers with peptide. More specically, glass
vials, plastic tubes, and LoBind tubes were pre-saturated with 220 L, 2 M peptide solution
before fresh 220 L, 2 M peptide solutions were transferred to each of the containers.
After a few seconds of vortexing and 1 h incubation, 200 L of each of the solutions were
transferred to inserts in autosampler vials together with 50 L of 5 mM POPC/POPG (3:1)
LUV. Solutions were then subject to HPLC analysis. Fig. 3.7 shows the eect of pre-
saturation on the peptide content in the dierent containers; pre-treating glass vials and
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Figure 3.6: Percentage of recovered peptide as a function of NaCl concentration for 220 L, 2 M
mastoparan X (B), melittin (C ), and magainin 2 (D) solutions in glass vials, plastic vials, or LoBind
tubes. (A) The percentage of recovered peptide in control solutions prepared directly in the inserts
of the autosampler vials. The data are the average of two separate experiments, expect in (A) in
which three experiments were averaged. The error bars show the standard deviations. Within the
experimental uncertainties of the HPLC method, the NaCl concentration was not found to impact
the surface adsorption of any of the three peptides.
plastic tubes with peptide solutions does entail a small increase in the peptide content, but
the percentages of recovered peptide are generally still well below 100 %.
In connection with these experiments on the eect of pre-saturation of containers with
peptide solutions, we also investigated the eect of LUVs to entail desorption of peptide
from the walls of glass vials, plastic tubes, and LoBind tubes; both containers that had not
been pre-saturated with peptide solution and containers that had been pre-saturated with
220 L, 2 M peptide solution were considered. To both the non-saturated and in the pre-
saturated containers, 210 L, 2:1 M peptide solutions were added and, following vortexing,
10 L of 22 mM POPC/POPG (3:1) LUV was added to a nal peptide concentration of
2 M and a nal LUV concentration of 1 mM. After 1 h incubation, samples were then
transferred to inserts in the autosampler vials together with 50 L of 1 mM POPC/POPG
(3:1) LUV for HPLC analysis. Fig. 3.7 shows the capability of LUVs to entail desorption
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Figure 3.7: Eect of pre-saturation of glass vials, plastic tubes, and LoBind tubes with peptide
solutions, and the capability of 1 mM POPC/POPG (3:1) LUV to induce desorption in non-saturated
and pre-saturated containers. (A) Mastoparan X. (B) Melittin. (C ) Magainin 2. N/S: 220 L, 2 M
peptide solutions in vials that were not pre-saturated. N/S+LUV: 10 L of 22 mM POPC/POPG
(3:1) LUV was added to 210 L, 2:1 M peptide solutions in vials that were not pre-saturated. S:
220 L, 2 M peptide solutions in vials that had been pre-saturated. S+LUV: 10 L of 22 mM
POPC/POPG (3:1) LUV was added to 210 L, 2:1 M peptide solutions in vials that had been pre-
saturated. The data are the average of two separate experiments. The error bars show the standard
deviations. The N/S-samples together with S-samples demonstrate that pre-saturation of surfaces
with peptide does not necessarily ensure complete recovery of peptide. The N/S+LUV-samples
demonstrate that LUVs induce partly desorption of peptide from the walls of the glass and plastic
containers. The S+LUV-samples demonstrate that LUVs also induce desorption from pre-saturated
samples, and in many cases, more than 100 % peptide was recovered.
from both non-saturated and pre-saturated containers. For the non-saturated containers,
LUV induced some desorption, especially from the glass vials and plastic tubes. However,
in many cases, LUVs were not found to induce complete desorption. For the pre-saturated
containers, LUVs were also found to induce desorption, and in many cases, more than 100 %
peptide was recovered. A peculiarly observation from Fig. 3.7 C is that for magainin 2 in
LoBind tubes, the percentage of recovered peptide was lowest for samples in which LUVs
were added to pre-saturated tubes; no good explanation to this observation was found.
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Figure 3.8: Kinetics of mastoparan X adsorption and desorption in glass vials, plastic tubes, and
LoBind tubes. (A) Kinetics of adsorption in 2 M, 220 L mastoparan X solutions. (B) Kinetics
of adsorption in 2 M, 220 L mastoparan X solutions with 1 mM POPC/POPG (3:1) LUV. (C )
Kinetics of desorption in 2 M, 220 L mastoparan X solutions induced by 1 mM POPC/POPG
(3:1) LUV. The data are the average of two separate experiments. The error bars show the standard
deviations. Generally, adsorption and desorption are fast processes that takes place within a few
seconds. The data indicate that mastoparan X adsorption to glass surfaces is partly irreversible.
3.4.6 Adsorption and desorption kinetics
We studied the kinetics of mastoparan X adsorption onto the walls of the glass vials, plastic
tubes, and LoBind tubes. To do that, volumes of mastoparan X stock solutions were added to
volumes buer in glass vials, plastic tubes, and LoBind tubes to a nal concentration of 2 M
mastoparan X and a nal volume of 220 L. After a few seconds of vortexing, the solutions
were incubated for 10 s, 1 h, or 24 h and, thereafter, 200 L of each solution was transferred
to the inserts in the autosampler vials together with 50 L of 5 mM POPC/POPG (3:1)
LUV for analysis by HPLC. Fig. 3.8 A shows the recovered percentage of mastoparan X for
the three dierent incubation times. Within the experimental uncertainty, the percentage of
recovered peptide is independent on incubation time, showing that adsorption of mastoparan
X to surfaces of glass and plastic is a fast process that occurs during the vortexing within
the rst few seconds after peptide addition to the solutions.
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We also studied the adsorption kinetics of mastoparan X in the presence of 1 mM
POPC/POPG (3:1) LUV in glass vials, plastic tubes, and LoBind tubes. In order to do
that, volumes of mastoparan X stock solutions were added to volumes of LUV solutions in
glass vials, plastic tubes, and LoBind tubes to a nal concentration of 2 M mastoparan
X, a nal LUV concentration of 1 mM, and a nal volume of 220 L. After a few seconds
of vortexing, the solutions were incubated for 10 s, 1 h, or 24 h and, thereafter, 200 L
of each solution was transferred to inserts in the autosampler vials together with 50 L of
1 mM POPC/POPG (3:1) LUV and, subsequently, analyzed by HPLC. Fig. 3.8 B shows
the percentage of recovered peptide as a function of the incubation time. For all incubation
times in all sample containers, the presence of 1 mM POPC/POPG (3:1) LUV prevented
surface adsorption of mastoparan X, meaning that mastoparan X partitioned rapidly onto
the LUVs.
Finally, we also studied the desorption kinetics of mastoparan X. In order to do that,
we prepared solutions with 210 L, 2:1 M mastoparan X in glass vials, plastic tubes, and
LoBind tubes. After vortexing, 10 L of 22 mM POPC/POPG (3:1) LUV was added to each
of these solutions. After vortexing, the solutions were incubated for 10 s, 1 h, or 24 h, and,
thereafter, 200 L of each solution was transferred to inserts in the autosampler vials together
with 50 L of 1 mM POPC/POPG (3:1) LUV for analysis by HPLC. Fig. 3.8 C shows the
percentage of recovered peptide as a function of the incubation time. The percentage of
recovered peptide was found to be independent on the incubation time; thereby, similarly
to the adsorption process, we found that the desorption process was a fast process that
happened during the vortexing within the rst few seconds after LUV addition. In the case
of the glass vials, as also shown in Fig. 3.7 A, the LUVs did not induce complete desorption
of mastoparan X. In additional experiments, we found that vortexing for longer periods did
not induce additional desorption from the glass surfaces (data not shown).
3.5 Discussion
In this article, we conrm previous studies demonstrating the applicability of analytical HPLC
to study surface adsorption of peptides (145), and we conrm previous observations that pro-
teins and peptides in general (146, 147) and cationic membrane-active peptides in specic
(139{142) adsorb to dierent types of solid surfaces. Specically, we considered the three
archetypal -helical cationic membrane-active peptides mastoparan X, melittin, and maga-
inin 2, which previously have been suggested to adsorb to solid surfaces of glass and plastic
(130, 148, 149). In this article, we conrm that all three peptides readily adsorb to negatively
charged surfaces (borosilicate and quartz glass) as well as hydrophobic surfaces (polypropy-
lene), see Figs. 3.3 to 3.5. Importantly, we show that this surface adsorption is signicant at
commonly chosen experimental peptide concentrations. That is, at peptide concentrations of
1 to 2 M, 90 % percent or even more of the peptides might be adsorbed to the walls of the
glass and plastic containers, see Fig. 3.3. It is needless to say that ignoring this phenomenon
might lead to inaccurate experimental conclusions, for example, in in vitro assays evaluating
the antimicrobial and hemolytic potencies of cationic membrane-active peptides.
Our experiments also revealed a few other details about the adsorption of mastoparan
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X, melittin, and magainin 2 to surfaces of glass and plastic. For example, our experiments
revealed that the adsorption is not dependent on the NaCl concentration of the buer, at
least within the experimental uncertainty of the HPLC method, see Fig. 3.6. Not even for
negative glass surfaces where interactions are electrostatically driven (141) did we notice
a signicant screening eect of NaCl. This is in contrast to previous observations on the
cationic peptide salmon calcitonin, for which it was found that the ionic strength aected
the adsorption of the peptide to both surfaces of borosilicate glass and polypropylene (141).
Using mastoparan X as a model peptide, our experiments also revealed that the adsorption
process is a fast process, see Fig. 3.8; during vortexing of the solutions in the glass or plastic
containers, mastoparan X adsorbed to the walls of the containers within a few seconds. In
addition, experiments on mastoparan X show that also desorption from glass and plastic
surfaces induced by LUVs is a rapid process occurring within a few seconds during vortexing.
However, the fact LUVs did not always induce complete desorption of neither mastoparan X
from glass surfaces (Figs. 3.7 and 3.8) nor of melittin and magainin 2 from both glass and
plastic surfaces (Fig. 3.7), not even during longer periods of vortexing (data not shown),
could indicate that part of the peptides were irreversibly bound: However, further experiments
are required to conrm or dismiss that notion.
In order to reduce the problem of surface adsorption of cationic membrane-active pep-
tides, several strategies have previously been pursued. One strategy has been to modify the
surfaces. For example, adsorbing the cationic polymer poly(ethylenimine) to the walls of
quartz glass cuvettes was found to eectively prevent the surface adsorption of the peptide
penetratin (139). Another strategy has been to pre-saturate the surfaces with peptide. How-
ever, due to the, at least partly, reversible nature of the adsorption process, this strategy
might in some cases be dangerous. Thus, as demonstrated in Fig. 3.7, in experiments where
volumes of LUV solutions are added to glass or plastic containers with peptide solutions,
the walls of the containers might provide a reservoir of peptides that, upon addition of
LUVs, desorb from the walls and instead partition onto the LUVs. These peptide reservoirs
will persist even after pre-saturation of container walls with peptide solution; thus, the pre-
saturation strategy will not always be an eective strategy for controlling the experimental
peptide concentration.
Our results lead to a few other recommendations on how to alleviate the problem of
surface adsorption of cationic membrane-active peptides. The rst recommendation comes
from the observation that relatively more peptide adsorbs to surfaces of glass and plastic
at low peptide concentrations, see Fig. 3.3. This observation leads to the recommendation
that peptide concentrations should be kept as high as possible during handling. The second
observation comes from the observation that some sample tubes lead to more surface ad-
sorption than other sample tubes. To be more specic, we observe that surface adsorption
of peptides is more dominant in sample tubes consisting of borosilicate or polypropylene
than in the commercially available LoBind tubes, see Figs. 3.3 to 3.5. These observations
lead to the recommendation that also the choice of sample containers should be subject to
careful considerations. Finally, the most important recommendation following from our data
is that experimental investigators at all times should be aware of the critical impact that the
adsorptive interactions can have on the outcome of their experiments.
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Figure 3.9: Adsorption loss during pipetting of 200 L of 1 M mastoparan X (A), melittin (B), or
magainin 2 (C ) solutions. Solutions were subject to 1-4 pipetting manipulations. The data are the
average of two separate experiments. The error bars show the standard deviations. The error bars
are not shown when they are smaller than the symbols. Only a small loss, if any, is observed during
pipetting.
3.6 Supporting material
3.6.1 Adsorption on pipette tips
Method
Four identical peptide solutions of 1 M were prepared in LoBind tubes by adding 2:2 L
of 100 M peptide stock solution to 217:8 L buer to a nal volume of 220 L. The
solutions were vortexed for a few seconds and then incubated for 1 h. After this incubation
time, 200 L of each of the solutions were aspirated into a pipette tip and allowed to adsorb
to the pipette tip for  5 s before being deposited back into the same tube from which
they were aspirated. This manipulation was repeated 1-4 times using new pipette tips for
each manipulation. After the last manipulation, solutions were not deposited back into the
LoBind tubes but instead into the inserts in the HPLC autosampler vials. The autosampler
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vials were then vortexed for a few seconds. Subsequently, 50 L of 5 mM POPC/POPG
(3:1) LUV was added to each of the inserts to a nal LUV concentration of 1 mM and a
nal volume of 250 L. Autosampler vials were again vortexed, and, subsequently, samples
in the inserts were subject to HPLC analysis.
Results
Fig. 3.9 shows that the percentage of recovered peptide does not change much as a function
of the number of pipetting manipulations. Thus, we conclude that aspiration of 200 L,
1 M peptide solutions into the pipette tips does not entail a dramatic loss of peptide due to
adsorption on the pipette tips. Thereby, the loss of peptide presented in the main document
must be due to the adsorption of peptide to the walls of the glass vials, plastic tubes, LoBind
tubes, and quartz glass cuvettes.
CHAPTER 4
Quantication of antimicrobial peptide-
induced leakage by FCS
The following chapter contains a manuscript in preparation. The manuscript is entitled
"Quantication of antimicrobial peptide-induced leakage from large unilamellar vesicles by
FCS".
4.1 Abstract
The mechanisms by which antimicrobial peptides permeabilize lipid bilayers have been subject
to extensive scientic interest for years. In this article, we evaluate the potential of the tech-
nique uorescence correlation spectroscopy (FCS) to study these membrane-permeabilizing
activities. Specically, we derive the mathematical framework needed for using FCS to study
peptide-induced leakage from large unilamellar vesicles, and we highlight a number of exper-
imental artifacts that might compromise the accuracy of the FCS-determined leakage values.
We show that if all of these pitfalls are avoided, then FCS can be used to quantify leakage
of uorescent markers from the lumen of the lipid vesicles, including leakage of uorescent
markers of dierent sizes. To demonstrate the applicability of FCS to study antimicrobial
peptide-induced leakage, we consider the antimicrobial peptide mastoparan X, and we show
that the peptide forms transmembrane pores to induce size-dependent leakage of markers
from POPC/POPG (3:1) vesicles.
4.2 Introduction
Antimicrobial peptides with broad-spectrum microbicidal activity have been identied in
organisms across the entire evolutionary spectrum, including bacteria, fungi, plants, shes,
amphibians, birds, and mammals (5, 14). Due to the natural capabilities of these peptides to
kill a wide range of infectious pathogens, including multi-drug resistant bacteria, they have
attracted signicant scientic attention as candidates to become a novel class of anti-infective
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therapeutics (8). However, despite this attention, the mechanisms by which antimicrobial
peptides kill pathogenic microbes are still not fully elucidated.
As a group, antimicrobial peptides represent a large variety of dierent primary amino
acid sequences. Despite this diversity, antimicrobial peptides are, however, still described by
a number of common characteristics. More specically, antimicrobial peptides are typically
small and enriched in cationic and hydrophobic amino acid residues. Furthermore, antimi-
crobial peptides typically form amphipathic secondary structures that allow dierent modes
of interaction with cellular membranes (28). The central role of these peptide-membrane
interactions are emphasized by the fact that antimicrobial peptides always interact with the
cell membrane to kill a given cell; either the antimicrobial peptides disrupt the structural
integrity of the cell membrane, or they translocate across the cell membrane to target an
intracellular metabolic process, such as DNA, RNA, or protein synthesis (12). Accordingly, it
is widely believed that a detailed understanding of these antimicrobial peptide-cell membrane
interactions is key to unraveling the mechanisms of antimicrobial peptide activity (10).
In order to study these peptide-membrane interactions, synthetic lipid vesicles are often
used as minimal models of cellular membranes. In particular, size-homogenous unilamellar
lipid vesicles with a diameter of 100 nm, commonly termed large unilamellar vesicles (LUVs),
are often employed. Typically, these LUVs are incubated with antimicrobial peptides to in-
duce leakage of entrapped uorescent markers from the LUVs. Leakage is then commonly
observed as an increase in emission intensity as a result of uorescence dequenching (52, 150);
that is, the uorescent molecules are initially entrapped at high self-quenching concentrations
or together with a quencher, but upon leakage, their local concentration decreases entailing
a dramatic increase in uorescent emission intensity. This approach has yielded valuable
insights into the mechanisms underlying antimicrobial peptide-induced membrane permeabi-
lization, for example, revealing that peptide-induced leakage from lipid vesicles is a transient
process in which leakage, following an initial rapid burst over the course of a few minutes,
slows down or ceases altogether before all LUVs are empty of uorescent markers (45). In
addition to the dequenching-based detection approach, other elaborate schemes have also
been employed to detect leakage from LUVs, for example, to study leakage of uorescent
markers of dierent sizes, thereby providing information on the size of transmembrane pores
formed by antimicrobial peptide (151, 152).
Another spectroscopic technique that has been used to study antimicrobial peptide-
induced leakage from LUVs is uorescence correlation spectroscopy (FCS) (153{155). In
FCS, uctuations in emission intensity from uorescent molecules diusing across a small
excitation volume are statistically analyzed via an autocorrelation function to yield informa-
tion about concentrations, diusion properties, triplet state kinetics, and other things of the
uorescent molecules (156, 157). Thus, FCS can be used to detect leakage of uorescent
molecules from LUVs as the diusion coecient of entrapped uorescent molecules dier
from that of released uorescent molecules; entrapped uorescent molecules are restricted to
diuse together with the LUVs, thereby having the same diusion coecient as the LUVs,
whereas released uorescent molecules diuse freely with a much higher diusion coecient
than the LUVs and thereby the entrapped uorescent molecules. In addition, by labeling
the lipid membranes of the LUVs with a lipid-anchored uorescent probe, FCS can also be
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used to evaluate the release mechanism (158). If leakage is due to formation of transmem-
brane pores, the LUVs will remain intact, and the diusion coecient of the lipid-anchored
uorophores will not change during leakage. In contrast, if leakage is due to membrane
solubilization, the diusion coecient of the lipid-anchored uorophores will decrease as the
uorophores are incorporated into mixed peptide-lipid micelles. The diusion time of the
lipid-anchored uorophores will also reveal if vesicle aggregation and/or fusion occurs during
leakage as that would entail an increase in the diusion coecient of the lipid-anchored
uorophores.
In this article, we evaluate the requirements for using FCS to quantify antimicrobial
peptide-induced leakage from LUVs. In particular, we derive the necessary mathematical
framework to quantify leakage, and we highlight the experimental pitfalls. We show that, if
all of these pitfalls are avoided, FCS can be used to accurately quantify leakage of uorescent
markers from LUVs, including leakage of uorescent markers of dierent sizes.
To demonstrate the potential of FCS as a method to study antimicrobial peptide-induced
leakage, we consider the natural peptide mastoparan X (MPX), isolated from the venom of
the hornet Vespa xanthoptera (159). MPX displays many archetypal features of antimicrobial
peptides, including a short sequence of 14 amino acid residues, a strong net charge of +4 and
an amphipathic -helical secondary membrane-bound structure (120, 121). It has previously
been shown that MPX entails leakage of contents from LUVs, including size-dependent
leakage of entrapped markers (51, 128, 130, 160, 161). Here, we conrm these observations
as we show that MPX-induced leakage from POPC/POPG (3:1) LUVs is due to the formation
of transmembrane pores and that the size of these pores leads to size-selective leakage of
uorescent probes ranging in size from  500 Da to  10 kDa. Thereby, we show that FCS
as a method to study antimicrobial peptide-induced leakage from LUVs display a number of
advantages over other existing methods to study leakage.
4.3 Theory
Upon transfer of leakage-inducing antimicrobial peptides to a solution of LUVs entrapping
uorescent molecules, a certain fraction of the initially entrapped uorescent molecules will
leak out of the LUVs. This fraction L must be given by the equation
L =
Cf   Cf0
Cf100   Cf0 (4.1)
where Cf0 is the concentration of unentrapped uorescent molecules before peptide addition,
Cf is the concentration of unentrapped uorescent molecules after peptide addition, and
Cf100 is the concentration of unentrapped uorescent molecules at complete leakage. In the
following section, we derive an analytical expression relating leakage L, as dened in Eq. 4.1,
to the output parameters of FCS. This derivation begins with the fundamental equations of
FCS.
For a single species of uorescent molecules diusing freely into and out of a three-
dimensional Gaussian excitation volume, the autocorrelation function, G(), with triplet
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state contribution is given by (156, 162)
G() =
1
N
g() =
1
N

1 +
T
1  T e
 =T

1 +

D
 1
1 +

S2D
  1
2
(4.2)
where  is the lag time, N is the average number of uorescent molecules in the excitation
volume, T is the fraction of uorescent molecules in the triplet state, T is the characteristic
triplet state lifetime, S is the ratio of the radial to axial dimensions of the excitation volume,
and D is the characteristic translational diusion time of the uorescent molecules. In case
there are multiple diusing species of uorescent molecules, the autocorrelation function is
a weighted sum of the autocorrelation functions of the individual species (156, 162):
G() =
nX
i=1
B2iN
2
i Gi()
, 
nX
i=1
BiNi
!2
=
nX
i=1
B2iNigi()
, 
nX
i=1
BiNi
!2
=
nX
i=1
Aigi() (4.3)
where Bi is the brightness (photon count rate per molecule) of the molecules of the ith
species, Ni is the mean number of molecules of the ith species in the excitation volume, and
Ai is the amplitude of the ith species. The sum in the denominator corresponds to the total
photon count rate of the system, Btot:
nX
i=1
BiNi = Btot: (4.4)
For leaky LUVs in solution, there are two distinct diusing species: LUVs entrapping
uorescent molecules (index v) and unentrapped uorescent molecules (index f). The auto-
correlation function must then be given by
G() =
B2f Nfgf() +B
2
vNvgv()
B2tot
= Afgf() +Avgv(): (4.5)
The mean number of unentrapped molecules in the excitation volume Nf must be linearly
proportional to the concentration of the unentrapped molecules Cf through the relation
Cf = Nf= (NAVe) where NA is Avogadro's number and Ve is the eective excitation
volume (163). Consequently, Eq. 4.1 can be rewritten to contain Nf -values instead of
Cf -values:
L =
Nf  Nf0
Nf100  Nf0 : (4.6)
According to Eq. 4.5, Nf is related to Af by the equation
Af =
B2f Nf
B2tot
: (4.7)
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The total photon count rate Btot in the denominator of this equation is a function of leakage,
L:
Btot = Bf (Nf100  Nf0)L+ kBf (Nf100  Nf0) (1  L) +BfNf0 +Bb (4.8)
where Bb is an uncorrelated background contribution, Bf is the brightness of unentrapped
molecules, and k is the brightness ratio between entrapped and unentrapped molecules,
dened by k = Be=Bf where Be is the brightness of entrapped molecules. Setting Nf0 = 0
in Eq. 4.8, we then get that
Btot = BfNf100L+ kBfNf100(1  L) +Bb: (4.9)
By inserting Eqs. 4.7 and 4.9 into Eq. 4.6, a quadratic equation in L is nally obtained:
L =
Af (BfNf100L+ kBfNf100(1  L) +Bb)2  Af0 (kBfNf100 +Bb)2
Af100 (BfNf100 +Bb)
2  Af0 (kBfNf100 +Bb)2
: (4.10)
The details on how to experimentally determine each of the parameters in Eq. 4.10 in
order to calculate L are given in the Materials and Methods section. However, before pro-
ceeding to this section, a number of comments should be made regarding the derivation of
Eq. 4.10. Firstly, in the above derivation, it was implicitly assumed that all unentrapped u-
orescent molecules have the same brightness. However, this assumption might not always be
true. For example, in the case of uorescently-labeled dextrans, individual dextran molecules
are labeled with variable numbers of uorophores. However, as long as the probability of a
given dextran molecule being released is not dependent on the number of uorescent-labels
on that dextran molecule, then the above theoretical framework is still applicable, albeit with
the modication that Nf and Bf only represent apparent values for the unentrapped dextran
molecules. Additional mathematical derivations to gain a more elaborate understanding on
the interpretation of such apparent N and B-values are presented in the Supporting material.
Secondly, even though they are not included in the Eq. 4.10, the Nv and Bv-parameters
also deserve some attention. In the limit where the mean number of entrapped uores-
cent molecules per LUV is much smaller than 1, i.e., in the limit where the number of
LUVs with more than 1 uorescent molecule entrapped is negligibly small, then Nv and
Bv represent the B and N -values of the entrapped uorescent molecules, i.e., in this limit
Nv = (Nf100  Nf0) (1   L) and Bv = kBf . In the opposite limit where the concentration
of encapsulated uorescent molecules is so high that the relative variations in the number of
entrapped uorescent molecules among LUVs is very small, then Nv and Bv correspond to
the mean number of LUVs in the excitation volume and the average brightness of the LUVs,
respectively, i.e., Nv = NLUV where NLUV is the mean number of LUVs in the excitation
volume, and Bv = kBf ~B where ~B is the mean number of uorescent molecules entrapped
per LUV. However, in order for this limit to apply, it is required that all LUVs have the same
lumen volume and that the encapsulation process itself does not entail variations in the num-
bers of entrapped uorescent molecules among individual LUVs; therefore, it is questionable
whether this limit is at all experimentally feasible. For any experimental system in between
the two limiting cases, the interpretation of the apparent Nv and Bv-values is not trivial and
requires specic information about the brightness distribution of the LUVs.
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Thirdly, dierent assumptions about Nf0 were made in Eqs. 4.6, and 4.9. Thus, in Eq.
4.6, Nf0 was included, leading to the inclusion of Af0 in Eq. 4.10. The inclusion of this
Af0-value in Eq. 4.10 is important, even in cases where all unentrapped uorescent molecules
are completely removed from the LUVs during the preparation process. Thus, when Eq. 4.5
is tted to autocorrelation curves recorded in sample only containing LUVs, then an articial
non-zero value of Af is often obtained, typically of a few percent of the entire amplitude of
the autocorrelation curve. Thus, removing Af0 from Eq. 4.10 would bias the calculated L-
values toward higher values, and especially small values of L would be subject to signicant
bias. In contrast, omitting Nf0 in Eq. 4.9 does not lead to the same bias of the calculated
values of leakage, provided that unentrapped uorescent molecules are eciently removed
from the LUVs during the preparation process.
Fourthly, when setting Af0 = 0, k = 1, and Bb = 0 kHz in Eq. 4.10, an expression
completely analogous to previously derived expressions to determine the LUV-bound fractions
of uorescently-labeled proteins by FCS is obtained (162, 164). However, in the present study,
this simplied expression will not be used as (i) setting Af0 = 0 will bias calculated values
of L toward higher values as mentioned above, (ii) k 6= 1 in our experimental system, and
(iii) Bb is included to calculate L as precise as possible.
Finally, as Btot is a direct output parameter of any FCS experiment, Nf , Nf0, and
Nf100 can all be estimated from individual experiments, using Eq. 4.7, provided that Bf is
determined in a control experiment. In that way, the Nf -values can be directly inserted into
Eq. 4.6 to calculate leakage, L. This approach would denitely be simpler than solving the
quadratic equation in Eq. 4.10. However, in our experience, due to variations in Btot between
individual experiments, this approach would entail large uncertainties in the determination of
L. In contrast, Eq. 4.10 provides a more robust and accurate approach to calculate leakage.
In particular, the brightness ratio parameter k can be determined by averaging multiple
experiments. In that way, Eq. 4.10 is based on more precise estimates of the relative changes
of Btot-values as a function of leakage, L, than what is attainable by actually recording Btot
in each individual experiment.
4.4 Materials and methods
4.4.1 Materials
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)], sodium salt (POPG), and 1-palmitoyl-2-[11-(dipyrromethenebo-
ron diuoride)undecanoyl]-sn-glycero-3-phosphocholine (TopFluor PC) were purchased from
Avanti Polar Lipids (Alabaster, AL, USA). 4-(1,1,3,3-tetramethylbutyl)phenyl-polyethylene
glycol (Triton X-100), N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES) and
the corresponding sodium salt (HEPES-Na), and NaCl were purchased from Sigma-Aldrich
(Brndby, Denmark). Rhodamine 6G chloride (Rh6G), Alexa Fluor 488 hydrazide, sodium
salt (Alexa488), Alexa Fluor 488 dextran, 3000 MW, anionic (Alexa488-3kMW), and Alexa
Fluor 488 dextran, 10000 MW, anionic, xable (Alexa488-10kMW) were purchased from Life
Technologies (Nrum, Denmark). Mastoparan X (MPX) was purchased from GL Biochem
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(Shanghai, China) and further puried by semi-preparative HPLC (Waters semi-preparative
HPLC equipped with a Waters 600 pump & controller and a Waters 2489 UV/vis detector,
Waters, Milford, MA, USA). The purity of the puried peptide was assessed to be > 99 %
by analytical HPLC (Gilson analytical HPLC equipped with a Gilson 321 HPLC pump and
a Gilson 155 UV/vis detector, Gilson, Middleton, MI, USA). Furthermore, the peptide iden-
tity was conrmed by MALDI-TOF (Bruker Reex IV MALDI-TOF spectrometer, Bruker,
Billerica, MA, USA).
4.4.2 Sample preparation
LUV preparation and characterization
Lipid solutions were prepared in chloroform/methanol (9:1). The organic solvent was removed
under a gentle stream of nitrogen. The samples were subsequently kept in vacuum overnight
to remove the residual solvent. The lipid lms were hydrated in HEPES buer (10 mM
HEPES, 100 mM NaCl, pH 7.4) with vigorous vortexing every 5 min for a period of 30
min. The hydrated lipid suspensions were then subject to 5 freeze-thaw cycles by alternately
placing the sample vials in an isopropanol/dry ice bath and a warm water bath. Next, the
lipid suspensions were extruded 21 times through a 100 nm polycarbonate lter (Whatman,
Maidstone, UK) using a mini-extruder (Avanti Polar Lipids) to form LUVs. The size of
the LUVs was checked by dynamic light scattering (ZetaPALS, Brookhaven Instruments,
Holtsville, NY, USA). Phosphorous concentrations of the LUV solutions were determined
using the method of Rouser et al. (144), albeit with slightly modied reagent concentrations.
To prepare LUVs labeled with TopFluor PC, POPC/POPG (3:1) with 0.1 mol% TopFluor
PC was dissolved in the initial chloroform/methanol (9:1) solution. The rest of the prepara-
tion protocol was then completely identical to the above protocol for preparation of unlabeled
LUVs.
To prepare LUVs entrapping uorescent molecules, the HEPES buer used to hydrate
the POPC/POPG (3:1) lipid lms was prepared with 4 or 30 M Alexa488, 5 M Alexa488-
3kMW, or 2.5 M Alexa488-10kMW. Concentrations of these uorescent molecules were
determined from the absorbance, recorded by a NanoDrop 2000c spectrophotometer (Nan-
oDrop Products, Wilmington, DE, USA), assuming that (i) the extinction coecient of
Alexa488 at maximum absorption at ca. 495 nm is 71000 cm 1M 1 and (ii) that the degree
of labeling of Alexa488-3kMW and Alexa488-10kMW is 1 and 2, respectively, as stated by
the manufacturer. The rest of the preparation protocol was again completely identical to
the above protocol for unlabeled LUVs, except that before the determination of phospho-
rous concentrations, LUV solutions were run on a size exclusion chromatography column
(Sepharose CL-4B, GE Healthcare, VWR - Bie & Berntsen, Herlev, Denmark) to remove the
unentrapped uorescent molecules from the LUV solution.
MPX stock solutions
MPX stock solutions were prepared in HEPES buer. To prevent loss of MPX due to adsorp-
tion to vial surfaces, MPX stock solutions were generally handled in Protein LoBind tubes
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(Eppendorf, VWR - Bie & Berntsen) and at high concentrations of at least 100 M. To cal-
culate the concentration of MPX stock solutions, the extinction coecient of MPX at 220
nm was calculated to be 40100 cm 1M 1 by correlating the MPX concentration determined
by an Antek 8060 chemiluminescent nitrogen detector (PAC, Houston, TX, USA) to the
absorbance of the same MPX sample, determined by a NanoDrop 2000c spectrophotometer.
Given this extinction coecient, MPX concentrations of stock solutions were then always
determined by recording the absorbance at 220 nm using the NanoDrop 2000c spectropho-
tometer.
4.4.3 FCS experiments
Experimental setup
FCS measurements were performed using a DCS-120 confocal scanning FLIM system (Becker
& Hickl, Berlin, Germany) connected to a Zeiss Axio Observer Z1 inverted microscope
equipped with a C-Apochromat 40x/1.2 W Corr UV-VIS-IR water immersion objective (Carl
Zeiss, Jena, Germany). The excitation source for the system was a 473 nm picosecond diode
laser (BDL-473-SMC, Becker & Hickl) operated at a pulse repetition rate of 50 MHz. The
incident excitation power at the objective rear aperture was measured by a PM100D optical
power meter (Thorlabs, Goteborg, Sweden). After passing through a 485 nm long-pass lter
(HQ485LP, Becker & Hickl) and a confocal pinhole, the uorescence emission was detected
with a HPM-100-40 hybrid detector connected to a SPC-150 module (Becker & Hickl).
Lifetime-gating was used to partially suppress background noise. SPCM software (Becker
& Hickl) was used to calculate the experimental autocorrelation curves. The curves were
subsequently exported to be tted by MATLAB (The MathWorks, Natick, MA). All samples
were measured in uncoated -slide 8 wells (ibidi, DFA Instruments, Glostrup, Denmark) by
positioning the laser focus  50 m above the top of the cover glass. The acquisition time for
all experiments was 300 s. By calibration with Alexa488, the eective excitation volume was
determined to be 1.0 fL (163). From the same calibration experiments, the S-parameter was
determined to be 7.4 by weighted least squares tting of the experimental autocorrelation
curves to the single-component autocorrelation function given in Eq. 4.2 (165). The S-
parameter was always xed to this value when tting all other experimental autocorrelation
curves. Except for the experiments determining the S-parameter, all autocorrelation curves
in this article were analyzed using unweighted least squares tting. Autocorrelation curves
dominated by single bright events were discarded in the data analysis.
Protocol to determine leakage from FCS data
Values of T and T were determined in separate experiments; these values were then kept
xed when tting the autocorrelation curves from the leakage experiments. For a given
leakage experiment, a number of samples with unknown values of leakage, L, were prepared.
In addition, two samples with 0% and 100% leakage, respectively, were also prepared. The
vesicle diusion time Dv was obtained by tting Eq. 4.2 to the autocorrelation curve of the
sample with 0% leakage. The diusion time of free molecules Df was obtained by tting Eq.
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4.2 to the autocorrelation curve of the sample with 100 % leakage. From this t, we also
obtained a average number of molecules in the excitation volume, Nm100. Correcting Nm100
for an uncorrelated background contribution yields the true average number of molecules in
the excitation volume, Nf100 (163, 166):
Nf100 =
Nm100 (B100  Bb)2
B2100
(4.11)
where B100 is the photon count rate of the sample with 100 % leakage. The uncorrelated
background count rate Bb was determined by a measurement in buer. In principle, Eq.
4.11 is only valid for molecules with negligible triplet contribution, but since we already know
T and since this value of T is generally small, below 0.05, the equation is also valid to t our
autocorrelation data. Complete leakage of initially entrapped molecules from the LUVs was
conrmed by comparing Df with a control experiment on free molecules in solution. Given
Nf100, the brightness of unentrapped molecules Bf was then obtained by
Bf =
B100  Bb
Nf100
: (4.12)
Next, keeping Dv and Df xed, Eq. 4.5 was tted to all autocorrelation curves of the given
leakage experiment to obtain the Af -values required in Eq. 4.10. In particular, Af0 and Af100
were obtained from the samples with 0% leakage to 100 % leakage, respectively, and Af was
obtained from the samples with unknown leakage, L. Finally, in order to solve Eq. 4.10, the
ratio between the brightness of entrapped to unentrapped molecules k was determined using
the equation
k =
B0  Bb
B100  Bb (4.13)
where B0 is recorded from samples with 0 % leakage. Across all individual experiments
studying leakage of a given type of uorescent molecule at a given excitation power, the
same value of k, as determined by averaging six individual experiments, was used to solve
Eq. 4.10. Thus, for an excitation power of 10.9 W, we found that k = 0:85 for Alexa488,
k = 0:96 for Alexa488-3kMW, and k = 0:95 for Alexa488-10kMW. In addition, for an
excitation power of 43.2 W, we found that k = 0:59 for Alexa488. Given the parameters
determined via the above protocol, Eq. 4.10 was then solved using Maple (Maplesoft,
Waterloo, Ontario, Canada) to determine the unknown values of L.
Test experiments
We prepared a series of samples in which variable percentages (0 % to 100 %) of Alexa488,
Alexa488-3kMW, or Alexa488-10kMW were entrapped in POPC/POPG (3:1) LUVs. These
samples were prepared by mixing variable volumes of (i) a stock sample with 1 mM POPC/PO-
PG (3:1) LUVs entrapping 4 M Alexa488, 5 M Alexa488-3kMW, or 2:5 M Alexa488-
10kMW with (ii) a stock sample with free Alexa488, Alexa488-3kMW, or Alexa488-10kMW
in buer. The molar concentrations of the stock samples with free Alexa488, Alexa488-
3kMW, or Alexa488-10kMW were identical to those of samples in which 0:1 % Triton X-
100 had induced complete release from 1 mM POPC/POPG (3:1) LUVs entrapping 4 M
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Alexa488, 5 M Alexa488-3kMW, or 2:5 M Alexa488-10kMW, respectively. The mixed
samples were vigorously vortexed before being transferred to the -slide 8 wells for examina-
tion by FCS. Experiments were conducted with an excitation power of 10.9 W. Percentages
of unentrapped molecules were calculated using Eq. 4.10.
Experimental artifacts
To investigate the eect of the number of uorescent molecules per LUVs, samples with
variable percentages of entrapped Alexa488 were, again, prepared. However, in these sam-
ples, Alexa488 was entrapped in LUVs at a local concentration of 30 M instead of the
concentration of 4 M used in the above test experiments. FCS experiments were then
conducted with an excitation power of 10.9 W.
To investigate the eect of the brightness ratio parameter k, we reused the samples of the
test experiments in which LUVs entrapping 4 M Alexa488 were mixed with free Alexa488.
However, FCS experiments were conducted with an excitation power of 43.2 W instead of
the excitation power of 10.9 W used in the test experiments.
To investigate interactions of Alexa488, Alexa488-3kMW, Alexa488-10kMW, and Rh6G
with POPC/POPG (3:1) LUVs, we prepared samples with 40 nM of Alexa488, Alexa488-
3kMW, Alexa488-10kMW or Rh6G in (i) buer, (ii) 1 mM unlabeled POPC/POPG LUVs
(3:1) or (iii) 1 mM unlabeled POPC/POPG (3:1) LUVs with 50 M MPX. All samples were
mixed in Protein LoBind tubes, and vigorously vortexed for a few seconds before transfer to
the -slide 8 wells for examination by FCS. Experiments were conducted with an excitation
power of 10.9 W.
Interaction of MPX with LUVs
To investigate MPX-induced leakage from POPC/POPG (3:1) LUVs, variable volumes of
MPX stock solutions were transferred to Protein LoBind tubes containing POPC/POPG
(3:1) LUVs entrapping 4 M Alexa488, 5 M Alexa488-3kMW, or 2.5 M Alexa488-10kMW.
The nal LUV concentrations of these samples were always 1 mM. Immediately after addition
of MPX, each sample was vigorously vortexed for a few seconds and subsequently incubated
at room temperature. After 1 hour incubation, the samples were transferred to the -slide 8
wells for examination by FCS. Experiments were conducted with an excitation power of 10.9
W. Leakage values were calculated using Eq. 4.10.
To investigate whether MPX-induced leakage is due to membrane solubilization, MPX
stock solutions were transferred to Protein LoBind tubes containing POPC/POPG (3:1)
LUVs labeled with TopFluor PC. The nal LUV concentrations of these samples were always
1 mM. After vigorous vortexing, the samples were incubated for 1 h before transfer to the
-slide 8 wells for examination by FCS. The excitation power of these experiments was 2.6
W.
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Figure 4.1: Calculated percentage of unentrapped uorescent molecules, L, vs actual percentage
of unentrapped uorescent molecules, Lreal, for samples with variable percentages of uorescent
molecules entrapped in POPC/POPG (3:1) LUVs. (A) Samples of free Alexa488 and POPC/POPG
(3:1) LUVs entrapping 4 M Alexa488. (B) Samples of free Alexa488-3kMW and POPC/POPG (3:1)
LUVs entrapping 5 M Alexa488-3kMW. (C ) Samples of free Alexa488-10kMW and POPC/POPG
(3:1) LUVs entrapping 2:5 M Alexa488-10kMW. In all panels, the data are the average of three
separate experiments. The error bars show the standard deviations. The L-values at Lreal = 0 %
and Lreal = 100 % are, by denition, always set to 0 % and 100 %, respectively. The data conrms
that FCS can be used to accurately quantify leakage of uorescent molecules of dierent sizes from
LUVs.
4.5 Results and discussion
4.5.1 Test experiments
The simple experimental situation of only one type of diusing species is considered in Figs.
4.7 and 4.8 in the Supporting material. From these experiments, we found that the typical
diusion times are  46 s,  110 s,  220 s, and  4800 s for Alexa488, Alexa488-
3kMW, Alexa488-10kMW, and POPC/POPG (3:1) LUVs, respectively, corresponding to
hydrodynamic radii of  0:5 nm,  1:3 nm,  2:6 nm, and  56 nm, respectively.
Next, we prepared a series of samples in which one percentage (between 0 % to 100 %)
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of Alexa488, Alexa488-3kMW, or Alexa488-10kMW were entrapped in POPC/POPG (3:1)
LUVs and the remaining percentage of Alexa488, Alexa488-3kMW, or Alexa488-10kMW,
respectively, was free in solution. In these samples, the local concentrations inside the LUVs
were 4 M for Alexa488, 5 M for Alexa488-3kMW, or 2:5 M for Alexa488-10kMW. In
the samples with 100 % of the molecules being entrapped, the lipid concentrations were
1 mM. In that way, these series of samples mimicked a perfect all-or-none leakage process
from 1 mM POPC/POPG (3:1) LUVs entrapping 4 M Alexa488, 5 M Alexa488-3kMW,
or 2:5 M Alexa488-10kMW. Fig. 4.9 in the Supporting material shows some examples of
autocorrelation curves obtained from these samples. Fig. 4.1 shows the calculated percent-
ages of unentrapped uorescent molecules, L, as obtained by solving Eq. 4.10, vs the actual
percentages of unentrapped uorescent molecules, Lreal. The good agreement between the
calculated and actual values conrm that FCS is indeed applicable to accurately calculate the
percentage of unentrapped uorescent molecules and thereby also applicable for quantitative
studies on leakage from LUVs.
4.5.2 Experimental pitfalls
In order for FCS to correctly quantify leakage from LUVs, a number of experimental pitfalls
should be avoided. In the following sections, we highlight three of the most prominent
examples of such pitfalls.
Number of uorescent molecules per LUV, ~B
In a multicomponent autocorrelation function, written in a generalized form in Eq. 4.3,
the amplitude of the ith component, Ai, scales with the square of the brightness of that
component B2i . Consequently, molecules with very high brightness will dominate such mul-
ticomponent autocorrelation functions. In cases where uorophore concentrations inside the
LUVs are high, this eect might signicantly compromise the capability of FCS to quantify
leakage from LUVs (158). In order to understand this eect in detail, we prepared two series
of samples in which variable percentages of Alexa488 were entrapped inside POPC/POPG
(3:1) LUVs at local concentrations of 4 M or 30 M, respectively. Autocorrelation curves
recorded from these samples were tted using Eq. 4.5 with xed values of Df and Dv. Fig.
4.2 shows fractional amplitudes of unentrapped Alexa488, ff = Af=(Af+Av), as determined
from the data tting vs the percentage of unentrapped Alexa488, L. From Fig. 4.2, it is
clear that the fractional amplitude, ff , is generally less sensitive to changes in L in the case
of 30 M Alexa488 inside the vesicles than in the case of 4 M Alexa488 inside the vesicles,
especially at low values of L; thus, when using LUVs entrapping 30 M Alexa488 inside the
LUVs, it will be more dicult to distinguish low values of leakage, L, than when using LUVs
entrapping 4 M Alexa488.
To further elucidate the impact of the number of molecules per LUV on the capability of
FCS to calculate leakage, we also included four theoretical curves in Fig. 4.2. These curves
were calculated using the equation
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Figure 4.2: Fractional amplitude of unentrapped uorescent molecules in the autocorrelation func-
tion, ff = Af=(Af + Av), vs the percentage of unentrapped molecules, L, for dierent numbers of
uorescent molecules per LUV, ~B. Data points are recorded from samples in which variable per-
centages of Alexa488 molecules are entrapped in POPC/POPG (3:1) LUVs at local concentrations
of 4 M or 30 M, corresponding 2.39 or 9.60 Alexa488 molecules per apparent LUV, respectively.
The data are the average of three separate experiments. The error bars show the standard deviations.
The error bars are not shown if they are smaller than the symbols. Lines are theoretically calculated
using Eq. 4.14 by assuming that the apparent number of uorescent molecules per LUV is 1, 2.39,
9.60 and 30, respectively. The results demonstrate that in order to calculate leakage from LUVs, the
concentration uorescent molecules inside the LUVs should be kept as low as possible.
ff =
Af
Af +Av
=
L
L+ k2 ~B (1  L) (4.14)
where ~B = Nf100=Nv0 is the apparent number of uorescent molecules per LUV and Nv0
is the apparent number of LUVs recorded in a sample with 0 % leakage. The derivation of
Eq. 4.14 is given in the Supporting material. To calculate the four theoretical curves, we
assumed that k = 0:85 and ~B = 1; 2:39; 9:60; or 30, respectively. The value of k = 0:85
was used because it corresponds to the experimental value of k. Likewise, the values of
~B = 2:39 and ~B = 9:60 were used because they correspond to the apparent values of ~B for
POPC/POPG (3:1) LUVs containing 4 M or 30 M Alexa488, respectively. Accordingly,
the theoretical curves for ~B = 2:39 and ~B = 9:60 should agree with the experimental data
points. Indeed, Fig. 4.2 demonstrate a very good agreement between the experimental
results and the theoretical curves, conrming the validity of Eq. 4.14.
Thus, the theoretical curves supplement the experimental data, and thereby they can be
used to further emphasize the problematic consequences of encapsulating high numbers of
uorescent molecules per LUV. More specically, for the theoretical curve calculated using
~B = 30, we nd that ff < 0:02 for L < 30 %. This mean that the value of ff for L < 30 %
is essentially indistinguishable from the articial non-zero value of ff that is usually obtained
from samples only containing LUVs and no free uorophores. Thus, in a system where
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~B = 30, it would be impossible to use FCS to study leakage when L < 30 %. Along these
lines, it can then be concluded that the concentration of uorescent molecules inside the
LUVs should, in principle, be kept as low as possible to obtain maximal sensitivity of Af to
leakage. On the other hand, a lower limit to the number of uorescent molecules per LUV
is dictated by the fact that a certain experimental photon count rate signicantly above the
background level is also required. Accordingly, optimal experimental designs to accurately
calculate leakage by FCS should balance the requirement for low numbers of uorescent
molecules per LUV and high photon count rates.
Brightness ratio between entrapped and unentrapped molecules, k
In order for the number of uorescent molecules per LUV to be kept low, a high photon
count rate per molecule is required. One way to increase the photon count rate per molecule
is to increase the intensity of the excitation source. However, as shown in Fig. 4.3 in
the Supporting material, increasing the excitation intensity might signicantly aect the
ratio between the brightness of entrapped and unentrapped uorescent molecules k. To
understand the eect of k, we considered a number of samples with variable percentages
of Alexa488 entrapped in POPC/POPG (3:1) LUVs. The local concentration of Alexa488
inside the LUVs was 4 M. Two dierent laser intensities, corresponding to k = 0:59 and
k = 0:85, respectively, were employed to conduct FCS on the samples. Autocorrelation
curves were tted using Eq. 4.5 with xed values of Df and Dv. Fig. 4.3 shows Af vs the
percentage of unentrapped molecules, L. For both laser intensities, we observed that Af is
a monotonic function of L, albeit for k = 0:59, we observe that Af levels o at high values
of L, indicating that for this value of k, it might be dicult to precisely calculate leakage at
high values of leakage.
To gain further insight into the eect of k, we also plotted four theoretical curves for
k = 0:40; 0:59; 0:85; or 1:00, respectively, using the equation
Af =
B2f Nf100L
(LNf100Bf + (1  L)Nf100kBf +Bb)2
: (4.15)
This equation is derived by inserting Eq. 4.9 into Eq. 4.7 and assuming that Nf = Nf100L.
The theoretical curves for k = 0:40 and k = 0:59 are based on the Bf , Bb and Nf100-values
from the experiments in which k = 0:59, whereas the theoretical curves for k = 0:85 and
k = 1:00 are based on the Bf , Bb and Nf100-values from the experiments in which k = 0:85.
Fig. 4.3 shows that a very good agreement between the experimental results and theoretical
curves is achieved, conrming the validity of Eq. 4.15. Thus, we can use the theoretical
curves to further understand the eect of k. In particular, we observe that Af will become
a completely linear function of L when k = 1. However, for k = 0:40, we observe that Af
will display a single maximum at L  68 %. That is, Af will not be a monotonic function
of L for low values of k, and it will, therefore, be impossible to use Eq. 4.10 to calculate
leakage in this case. Thus, from both the experimental data and the theoretical curves, we
can conclude that the value of k should be kept close to 1 in order for Eq. 4.10 to be used
to calculate leakage. Please note that as k is dependent on the excitation intensity, it is not
sucient to determine k from experiments with a conventional uorometer.
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Figure 4.3: The amplitude of the unentrapped molecules, Af , vs the percentage of unentrapped
molecules, L, for dierent brightness ratios between entrapped and unentrapped uorescent molecules,
k. Data points were recorded from samples in which variable percentages of Alexa488 molecules were
entrapped in POPC/POPG (3:1) LUVs at a local concentration of 4 M. To record the data points,
two dierent excitation powers were employed, corresponding to k = 0:59 and k = 0:85, respectively.
The data are the average of three separate experiments. The error bars show the standard deviations.
The error bars are not shown if they are smaller than the symbols. Theoretical curves were calculated
using Eq. 4.15 and assuming that k = 0:40; 0:59; 0:85; or 1:00. Both the experimental data and the
theoretical lines demonstrate that k should be kept close to 1 in order for Eq. 4.10 to be applicable
for calculating leakage.
Interaction of uorescent molecules with LUVs
Another important part of the experimental design is the choice of uorescent molecules
to be entrapped inside the LUVs. In the present article, we used the hydrophilic anionic
dye Alexa488, unconjugated or conjugated to dextran molecules, However, another popular
choice of dye for leakage studies by FCS is the cationic dye Rh6G. To investigate the suitability
of each of these dyes for leakage experiments by FCS, we prepared a series of samples in
which 40 nM Alexa488, Alexa488-3kMW, Alexa488-10kMW, or Rh6G was mixed with (i)
buer, (ii) 1 mM unlabeled POPC/POPG (3:1) LUV, or (iii) 1 mM POPC/POPG (3:1)
LUV and 50 M MPX. Fig. 4.4 shows the fractional amplitude of the unbound molecules,
ff = Af=(Af + Av), for each of these samples as obtained by tting the data with Eq.
4.5 with Df xed at diusion times recorded in buer and Dv xed at 4800 s, a typical
diusion time for LUVs. For Alexa488, Alexa488-3kMW, and Alexa488-10kMW, ff was
always found to be close to 1, indicating that none of these uorescent molecules bound to
the POPC/POPG (3:1) LUVs. In contrast, when Rh6G was mixed with 1 mM POPC/POPG
(3:1) LUV, then ff  0:14, indicating that a large fraction of the cationic Rh6G molecules
bound to the anionic LUV surfaces. Interestingly, if MPX was present together with the
LUVs, then ff increased to  0:48. Thus, binding of MPX to the LUVs will entail unbinding
of Rh6G, probably due to charge neutralization of the lipid membrane. Such peptide-induced
unbinding of Rh6G from the LUVs might easily be mistaken for peptide-induced leakage from
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Figure 4.4: Fractional amplitude of the free molecules, ff = Af=(Af + Av), for samples with
40 nM Alexa488, Alexa488-3kMW, Alexa488-10kMW, or Rh6G in (i) buer, (ii) 1 mM unlabeled
POPC/POPG (3:1) LUV, or (iii) 1 mM POPC/POPG (3:1) LUV and 50 M MPX. The data are
the average of three separate experiments. Error bars show the standard deviations. The data shows
that Alexa488, Alexa488-3kMW, and Alexa488-10kMW do not interact with the LUVs. In contrast,
Rh6G clearly interacts with the LUVs. Upon addition of MPX, a signicant fraction of the membrane-
bound Rh6G molecules dissociates from the membrane. This peptide-induced unbinding might easily
be confused with peptide-induced leakage from LUVs.
the LUVs. Therefore, great caution should be taken when using Rh6G as the uorescent
marker in leakage experiments.
4.5.3 Leakage induced by MPX
In order to demonstrate the potential of our FCS-based protocol to study antimicrobial
peptide-induced leakage, we considered the peptide MPX. Fig. 4.5 shows MPX-induced
leakage, L, vs the peptide-to-lipid ratio, [P]/[L] ratio as determined by FCS after 1 h incu-
bation of variable concentrations of MPX with 1 mM POPC/POPG (3:1) LUVs entrapping
4 M Alexa488, 5 M Alexa488-3kMW, or 2:5 M Alexa488-10kMW. It is clear that MPX-
induced leakage from POPC/POPG (3:1) LUVs is dependent on the size of the entrapped
uorescent molecules; for example, Alexa488 (570 Da) was completely released at [P]/[L]
= 0.025, whereas only  55 % and  24 % of Alexa488-3kMW and Alexa488-10kMW,
respectively, were released at the same [P]/[L] ratio. However, at higher [P]/[L] ratios,
Alexa488-3kMW and Alexa488-10kMW were also completely released. Such size-dependent
leakage have also previously been reported for MPX (51). Fig. 4.11 in the Supporting ma-
terial shows leakage at selected [P]/[L] ratios recorded after 10 min, 20 min, 1 h, and  18
h incubation of MPX with LUVs. These data conrm that leakage of all three uorescent
markers is a transient process, in which a rapid burst of leakage within the rst few minutes
is followed by a dramatic slowing down or complete cessation of marker eux. Such biphasic
leakage kinetics have also previously been reported for MPX (128, 130) as well as for many
other antimicrobial peptides (45). In that way, the leakage values recorded from samples
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Figure 4.5: MPX-induced leakage, L, vs [P]/[L] ratio. Leakage was calculated after 1 h incubation
of MPX together with 1 mM POPC/POPG (3:1) LUVs entrapping 4 M Alexa488, 5 M Alexa488-
3kMW, or 2:5 M Alexa488-10kMW. The data are the average of three separate experiments. The
error bars show the standard deviations. The leakage values at the lowest and highest peptide-to-
lipid ratios correspond to no leakage and complete leakage, respectively, and, therefore, they are, by
denition, always set to 0 % and 100 %, respectively. Trendlines are added to guide the line. Smaller
uorescent probes were more eectively released than larger uorescent probes.
incubated for 1 h are, by and large, representative of the leakage occurring within the rst
few minutes after addition of peptide to the LUVs.
To investigate whether MPX-induced leakage is due to the formation of transmembrane
pores, we incubated MPX together with 1 mM of POPC/POPG (3:1) LUVs labeled with
0:1 % TopFluor PC. Experimental autocorrelation data was tted with the single-component
autocorrelation function (Eq. 4.2) to obtain the apparent mean number of LUVs in the
excitation volume, Napp, and the LUV diusion time, D. Fig. 4.6 shows the obtained
values of Napp and D vs the [P]/[L] ratio. From the gure, it is clear that both Napp and
D are largely unaected by MPX. This observation strongly implies that the LUVs remain
intact and therefore release of entrapped markers is due to the formation of transmembrane
pores and not due to membrane solubilization. This is in accordance with previously published
data that shows that MPX only solubilizes POPC/POPG (3:1) LUVs at higher [P]/[L] ratios
than what we consider in this article (44).
In the Theory section, we pointed out that Eq. 4.10 is fully applicable to study leakage of
uorescently-labeled dextrans as long as the probability of a given dextran molecule being re-
leased is not dependent on the number of uorescent labels bound to that dextran molecule.
A control experiment, based on equilibrium dialysis, is presented in Fig. 4.12 in the Sup-
porting material to demonstrate that this is a reasonable assumption for Alexa488-labeled
dextrans. From the release proles of the Alexa488 and the Alexa488-labeled dextrans in Fig,
4.5, we can then get an estimate of the pore size. Thus, at low [P]/[L] ratios, Alexa488, with a
hydrodynamic radius of  0:5 nm, was more eectively released than were Alexa488-3kMW,
with a hydrodynamic radius of  1:3 nm, and Alexa488-10kMW, with a hydrodynamic radius
64 Quantication of antimicrobial peptide-induced leakage by FCS
0 0.02 0.04 0.060
2
4
6
8
10
[P]/[L]
N a
pp
0 0.02 0.04 0.060
2
4
6
8
τ D
 
[m
s]
[P]/[L]
A B
Figure 4.6: Interaction of MPX with TopFluor PC-labeled LUVs.(A) The apparent mean number of
LUVs in the excitation volume, Napp, vs [P]/[L] ratio. (B) the LUV diusion time, D, vs the [P]/[L]
ratio. Data was recorded after 1 h incubation of MPX with 1 mM LUVs. The data are the average
of three separate experiments. The error bars show the standard deviations. Error bars are not shown
when they are smaller than the symbols. The fact that Napp and D are largely independent on the
[P]/[L] ratio indicate that leakage is due to the formation of transmembrane pores and not due to
membrane solubilization.
of  2:6 nm. This observation suggests that the typical pore radius at low [P]/[L] ratios is
between  0:5 nm and  2:6 nm. At higher [P]/[L] ratios, the Alexa488-labeled dextrans
were completely released, suggesting that the pore radius at higher [P]/[L] ratio increases to
above  2:6 nm. However, please note that the pore radii estimated from the hydrodynamic
radii of the dextran molecules should be regarded with caution. Thus, the dextran molecules
are not perfect spheres with a well-dened radius. Rather, dextran molecules are modeled
as prolate ellipsoids with a short axis and a long axis, complicating attempts to relate their
hydrodynamic radius to pore sizes (167). In addition, it has been suggested that the dextran
molecules might pass through the peptide-induced pores by reptation, further complicating
the interpretation of dextran leakage data (151). Therefore, other types of uorescently-
labeled macromolecules might represent more appropriate choices for accurately estimating
the size of transmembrane pores. Nevertheless, in this article, we chose to use dextrans as
that is also the common choice in most other articles in the literature.
Under all circumstances, it is clear that FCS can be used to rapidly determine peptide-
induced leakage of probes of dierent sizes. Therefore, FCS can be used as a medium-
throughput technique to answer questions that, as of today, are unanswered about antimi-
crobial peptides. For example, FCS can be used to compare the pore size for dierent
peptides, providing information about the dependence of the pore size on the amino acid
residue sequence. Another interesting question that FCS could address pertains to the de-
pendence of the pore size on the lipid composition. For instance, for the bee venom peptide
melittin, size-dependent leakage was observed from POPC LUVs, whereas size-independent
leakage was observed from POPG LUVs (151, 168). This observation strongly implies that
the size of the pores formed by melittin is dependent on the lipid composition. FCS could
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be used as a method to expand on these observations by probing pore size of melittin, and
other antimicrobial peptides, in many dierent lipid compositions.
Another interesting attribute of FCS is, as demonstrated by the results in Fig. 4.6, that it
reveals whether leakage is due to the formation of transmembrane pores or due to detergent-
like solubilization of the lipid membrane. This information could, for example, be used to
understand whether the above-mentioned size-independent leakage, as observed for melittin
in POPG LUVs, is indeed due the formation of large transmembrane pores or, in reality, just
due to peptide-induced solubilization of the LUVs.
Yet another advantageous feature of FCS is that it only requires very low concentrations
of uorescent molecules inside the LUVs. More specically, in a typical FCS leakage experi-
ment, only a few uorescent molecules are encapsulated in each vesicle. Consequently, when
studying leakage by FCS, investigators are free to systematically vary the osmolarity and
ionic strengths of the buers inside and outside the vesicles. In contrast, the experimental
designs in the conventional quenching-based leakage experiments are restricted by the fact
that uorophore concentrations inside the LUVs have to be in the millimolar range to obtain
self-quenching (52, 150).
Finally, an important advantage of FCS is that calculation of leakage is independent on
the leakage mode of the uorescent molecules. More specically, as there are no contributions
from Av in Eq. 4.10, calculation of leakage by FCS is independent on whether leakage
proceeds by a graded process, in which all vesicles release part of their contents, or an all-or-
none process, in which part of the vesicles release all of their contents and part of the vesicles
release no contents. This is a great advantage of FCS as compared to the conventional
quenching-based leakage assays, in which the self-quenching factor of entrapped uorescent
molecules is highly dependent on the nature of the leakage process (52, 150).
4.6 Concluding remarks
In this work, we considered FCS as a technique to study antimicrobial peptide-induced leak-
age from large unilamellar vesicles (LUVs). To this endeavor, we derived the necessary
theoretical framework, and we highlighted the experimental pitfalls that might lead to inac-
curate and/or false conclusions. To avoid these pitfalls, we showed that (i) the number of
uorescent molecules per LUV should be low, (ii) the brightness ratio between entrapped and
unentrapped molecules should be close to 1, and (iii) control experiments should ensure that
the uorescent probe does not interact with the LUVs. FCS was then used to investigate
leakage induced by the antimicrobial peptide mastoparan X (MPX). From the leakage data of
MPX, we concluded that FCS displays a number of advantages when compared to other ex-
isting methods to study leakage: (i) FCS provides a fast method for sizing of transmembrane
pores, whereas this is often more laborious with other existing methods; (ii) FCS requires
a much lower concentration of entrapped uorescent molecules per LUV than does other
existing methods, allowing investigators to more freely vary the experimental conditions; (iii)
FCS reveals whether leakage is due to the formation of transmembrane pores or membrane
solubilization; and (iv) calculation of leakage by FCS is independent on whether the leakage
process is an all-or-none process or a graded process, whereas calculation of leakage by the
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conventional quenching-based methods requires that the leakage process is taken explicitly
into account.
4.7 Supporting material
4.7.1 Additional theory
Interpretation of apparent B and N -values
Consider a solution with multiple diusing species. If this solution contains a subset of
particles (index r) with variable values of B but constant values of T, T , and D, then the
multicomponent autocorrelation function in Eq. 4.3 can be written as
G() =
mP
j=1
B2rjNrjgr() +
nP
i=1
B2iNigi()  
mP
j=1
BrjNrj
!
+

nP
i=1
BiNi
!2 (4.16)
where Nrj is the average number of particles within the subset with brightness Brj . The
total number of particles within the subset, Nr, is related to Nrj by
Nrj = pjNr (4.17)
where pj is the probability for a given particle within the subset to have brightness Brj . By
denition:
mX
i=j
pj = 1: (4.18)
Using Eqs. 4.17 and 4.18, then Eq. 4.16 can be rewritten to
G() =
Nr
mP
j=1
pjB
2
rjgr() +
nP
i=1
B2iNigi()  
Nr
mP
j=1
pjBrj
!
+

nP
i=1
BiNi
!2
=


B2r

Nrgr() +
nP
i=1
B2iNigi()
hBriNr +
nP
i=1
BiNi
2 (4.19)
where hBri is the mean brightness of the particles within the subset and


B2r

is the mean
square brightness of the particles within the subset. If we want to represent the particles
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within the subset by apparent B and N -values, then we would write Eq. 4.16 on the form
G() =
B2raNragr() +
nP
i=1
B2iNigi()
BraNra +

nP
i=1
BiNi
2 (4.20)
where Bra is the apparent brightness value for the particles within the subset and Nra is
the apparent average number of particles in the excitation volume within the subset. By
comparing Eqs. 4.19 and 4.20, it follows that
Nra =
hBri2
hB2r i
Nr (4.21)
and that
Bra =


B2r

hBri : (4.22)
Thus, the apparent particle number, Nra, is linearly proportional to the real particle number,
Nr, and Bra is a constant number that depends on the brightness distribution of the particles
within the subset.
Derivation of Eq. 4.14
To derive Eq. 4.14 from the main document, we use that
Af =
B2f Nf
B2tot
(4.23)
and
Av =
B2vNv
B2tot
: (4.24)
Then we get that the fractional amplitude, ff , is given by
ff =
Af
Af +Av
=
B2f Nf
B2f Nf +B
2
vNv
: (4.25)
Assuming that Nf0 = 0, then the apparent number of molecules per LUV, ~B,is be given by
~B =
Nf100
Nv0
=
Bv
kBf
; (4.26)
and the values of Nf and Nv are given by
Nf = LNf100 (4.27)
Nv = (1  L)Nv0: (4.28)
Note that Eq. 4.28 is only valid for a situation of perfect all-or-none leakage, which fortu-
nately is exactly the type of process that we mimick in our experiments. Finally, by inserting
Eqs. 4.26, 4.27, and 4.28 into Eq. 4.25 we retrieve Eq. 4.14 from the article:
ff =
Af
Af +Av
=
L
L+ k2 ~B (1  L) : (4.29)
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4.7.2 Concentration standard curves
Method
A number of samples with varying concentrations of Alexa488, Alexa488-3kMW, or Alexa488-
10kMW in HEPES buer solution were prepared. The samples were transferred to the -slide
8 wells for examination by FCS. Experiments were conducted with an excitation power of
10.9 W, expect for samples with concentrations above 100 nM, in which the excitation
power had to be reduced to avoid overloading the detector. Recorded autocorrelation curves
were tted using Eq. 4.2. Additionally, we also prepared a number of samples with varying
concentrations of POPC/POPG (3:1) LUVs either labeled with 0:1 % TopFluor PC or loaded
with 4 M Alexa488, 5 M Alexa488-3kMW, or 2:5 M Alexa488-10kMW. These samples
were also transferred to the -slide 8 wells for examination by FCS. Again, experiments were
conducted with an excitation power of 10.9 W, expect for the experiments on the TopFluor
PC-labeled LUVs, which were excited with 2.6 W. Recorded autocorrelation curves were
again tted using Eq. 4.2.
Results
Fig. 4.7, A, C, and E, shows the mean number of Alexa488, Alexa488-3kMW, or Alexa488-
10kMW molecules in the excitation volume, N , vs the molar molecule concentration, C. In
the case of Alexa488-3kMW and Alexa488-10kMW, the mean number of molecules in the
excitation volume is an apparent number, Napp, due to the variable brightness of the dextran
molecules. Both uncorrected and background-corrected mean molecules numbers are shown
in Fig. 4.7. The background-corrected mean molecule numbers, Ncor, are calculated using
the equation
Ncor =
(Bexp  Bb)2
B2exp
Nmeas (4.30)
where Nmeas is the measured (uncorrected) mean molecule number, Bexp is the measured
photon count rate, and Bb is the uncorrelated background photon count rate as measured in
pure buer. (Note that Eq. 4.30 is same formula as Eq. 4.11, just with dierent symbols.)
After correcting for the uncorrelated background, we achieve a linear relationship between N
or Napp vs C as is also theoretically expected. From the slope of the line in Fig. 4.7 A, we
calculated the eective excitation volume to be 1.0 fL using the relation Ve = Nf= (NACf).
Fig. 4.7, B, D, and F, shows the diusion time of the uorescent molecules as a function
of molar concentration. The diusion times are essentially constant throughout the entire
concentration range, indicating the absence of intermolecular interactions. Typical diusion
times were  46 s,  110 s,  220 s for Alexa488, Alexa488-3kMW, and Alexa488-
10kMW, respectively, corresponding to hydrodynamic radii of  0:5 nm,  1:3 nm, and
 2:6 nm.
Fig. 4.8, A, C, E, and G, shows apparent average number of LUVs in the excitation
volume, Napp, as a function of the molar lipid concentrations of POPC/POPG (3:1) LUVs
labeled with 0:1 % TopFluor PC, or loaded 4 MAlexa488, 5 MAlexa488-3kMW, or 2.5 M
Alexa488-10kMW. Both uncorrected and background-corrected LUV numbers are included
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Figure 4.7: Free uorescent molecules in HEPES buer solution. (A, C, and E ) The mean number
of uorescent molecules in the excitation volume, N , as a function of molar concentration, C, for
Alexa 488 (A), Alexa488-3kMW (C ), or Alexa488-10kMW (E ). As Alexa488-3kMW and Alexa488-
10kMW are a type of uorescent molecules with variable brightness, their mean molecule numbers
are only apparent. Both uncorrected and background-corrected mean molecules numbers are included
in the plots. The straight lines are the best ts to the background-corrected data. (B, D, and F )
Diusion time, D, of the uorescent molecules as a function molar concentration, C, for the same
experiments. In all panels, the data are the average of three separate experiments. Error bars show
the standard deviations. The error bars are not shown when they are smaller than the symbols.
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Figure 4.8: POPC/POPG (3:1) LUVs dispersed in HEPES buer. (A, C, E, G ) Apparent mean
number of POPC/POPG (3:1) LUVs, Napp, as a function of lipid molar concentration, C, for LUVs
labeled with 0:1 % TopFluor PC (A), or entrapping 4 M Alexa488 (C ), 5 M Alexa488-3kMW
(E ), or 2.5 M Alexa488-10kMW (G ). Both uncorrected and background-corrected LUV numbers
are shown. The straight lines are the best ts to the background-corrected data. (B, D, F, H)
LUV diusion time, D, as a function of lipid molar concentration, C, for the same experiments.
In all panels, the data are the average of three separate experiments. Error bars show the standard
deviations. The error bars are not shown when they are smaller than the symbols.
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in the gure. For the background-corrected numbers, a linear relationship between Napp
and C is achieved. Diusion times of the LUVs as a function of lipid molar concentrations
are shown in Fig. 4.8, B, D, F, and H. Across the entire concentration range, no changes
in diusion times were observed, indicating that the vesicles were not interacting with each
other. Typical diusion times of LUVs were found to be  4800 s, corresponding to a
hydrodynamic radius of  56 nm, albeit small variations between individual batches were
observed.
4.7.3 Autocorrelation curves for varying fractions of entrapped molecules
Method
In the article, we described how we prepared a number of samples with variable percent-
ages of Alexa488, Alexa488-3kMW, or Alexa488-10kMW entrapped in POPC/POPG (3:1)
LUVs by mixing (i) a stock sample with 1 mM POPC/POPG (3:1) LUVs entrapping 4 M
Alexa488, 5 M Alexa488-3kMW or 2:5 M Alexa488-10kMW with (ii) a stock sample
with free Alexa488, Alexa488-3kMW, or Alexa488-10kMW in buer, respectively, with mo-
lar concentrations identical to those of samples in which 0:1 % Triton X-100 had induced
complete release from 1 mM POPC/POPG (3:1) LUVs entrapping 4 M Alexa488, 5 M
Alexa488-3kMW or 2:5 M Alexa488-10kMW, respectively.
Results
Representative examples of autocorrelation curves recorded from these samples are shown
in Fig. 4.9, A, C, and E, together with the best ts of Eq. 4.5 to these curves. Increasing
the ratio of unentrapped to entrapped uorescent molecules shifted the diusion times of
the autocorrelation curves towards smaller values mirroring the much higher diusion coe-
cient of unentrapped uorescent molecules as compared to entrapped uorescent molecules
which are restricted to diuse together with the LUVs. In addition, the amplitude of the
autocorrelation curves also decreased when the fraction of unentrapped uorescent molecules
increased. In Fig. 4.9, B, D, and F, the autocorrelation curves are all normalized to the
same amplitude to further allow visualization of the shift of diusion times as the fraction
of percentage of entrapped molecules is changed.
4.7.4 Dependence of brightness ratio on excitation intensity
Method
To test how the brightness ratio between entrapped and unentrapped uorescent molecules,
k, depends on the excitation power, we prepared a number of samples with 1 mM LUVs en-
trapping 4 M Alexa488, 5 M Alexa488-3kMW, or 2.5 M Alexa488-10kMW. Additionally,
we prepared a number samples with free Alexa488, Alexa488-3kMW, or Alexa488-10kMW in
buer solution. The concentrations of the samples with free molecules in buer corresponded
to those of samples in which 0:1 % Triton X-100 had induced complete leakage from 1 mM
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Figure 4.9: (A, C, and E ) Autocorrelation curves recorded in samples with variable percentages of
uorescent molecules entrapped in POPC/POPG (3:1) LUVs. (A) Free Alexa488 and POPC/POPG
(3:1) LUVs with 4 M Alexa488. (C ) Free Alexa488-3kMW and POPC/POPG (3:1) LUVs with
5 M Alexa488-3kMW. (E ) Free Alexa488-10kMW and POPC/POPG (3:1) LUVs with 2.5 M
Alexa488-10kMW. The black lines represent the best t of Eq. 4.5. (B, D, and F ) Autocorrelation
curves normalized to an amplitude of 1 to allow for more clear visualization of the shift in diusion
times associated with changes in the percentage of unentrapped uorescent molecules.
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Figure 4.10: The brightness ratio between entrapped and unentrapped uorescent molecules, k,
vs the excitation power, P , for Alexa488 (A), Alexa488-3kMW (B), or Alexa488-10kMW (C ). The
values of k in this gure are all normalized with respect to the value of k obtained at P = 0:74 W.
Consequently, this data point is by denition set to 1. The data in all panels are the average of three
separate experiments. The error bars show the standard deviations. Error bars are not shown if they
are smaller than the symbols. The black data points correspond to our standard choice of excitation
power for the leakage experiments in the article.
LUVs entrapping 4 M Alexa488, 5 M Alexa488-3kMW, or 2.5 M Alexa488-10kMW. All
samples were then transferred to the -slide 8 wells for examination by FCS.
All samples were subject to varying excitation powers, and the brightness ratio, k, was
calculated by the equation
k =
B0  Bb
B100  Bb (4.31)
where B0 is the photon count rate from the samples in which all uorescent molecules were
entrapped in LUVs, B100 is the photon count rate from the samples in which all uorescent
molecules were freely diusing in buer, and Bb is the uncorrelated background photon count
rate as determined from measurements in pure buer. Since the preparation procedure of the
samples with free molecules might lead to small uncertainties in concentrations, all values of
k were normalized by dividing them with the value of k obtained from the lowest excitation
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power of 0:74 W. In that way, k is by denition set to 1 when P = 0:74 W and any
uncertainties in k due to uncertainties in concentrations of free molecules are eliminated.
Results
Fig. 4.10 shows the determined brightness ratio, k, as a function of the excitation power.
Especially for Alexa488, k is found to be dependent on the excitation power. However, also
in the cases of Alexa488-3kMW and Alexa488-10kMW, high excitation powers might impact
k. The black data points in Fig. 4.10 represent our standard choice of excitation power for
the leakage experiments. Please note that Fig. 4.10 is primarily presented for illustrative
purposes. The values of k actually used for calculations in the article are calculated directly
from 1 mM LUV solutions with or without Triton X-100 or MPX to induce complete leakage
so as to avoid the normalization step described in the Methods section.
4.7.5 Kinetics of MPX-induced leakage
Method
To investigate MPX-induced leakage from POPC/POPG (3:1) LUVs, variable volumes of
MPX stock solutions were transferred to Protein LoBind tubes containing POPC/POPG
(3:1) LUVs entrapping 4 M Alexa488, 5 M Alexa488-3kMW, or 2.5 M Alexa488-10kMW.
The nal LUV concentrations of these samples were always 1 mM. Immediately after addition
of MPX, each sample was vigorously vortexed for a few seconds and subsequently incubated
at room temperature. After 10 min, 20 min, 1 h or 18 h incubation, the samples were
transferred to the -slide 8 wells for examination by FCS. Experiments were conducted with
an excitation power of 10.9 W. Leakage values were calculated using Eq. 4.10.
Results
Fig. 4.11 shows MPX-induced leakage after 10 min, 20 min, 1 h, or 18 h incubation
time for selected [P]/[L] ratios. The gure shows that values of leakage are essentially
always identical after 10 min, 20 min, and 1 h incubation. Thus, MPX-induced leakage from
POPC/POPG (3:1) LUVs is a transient process, in which a rapid burst of leakage within the
rst few minutes is followed by a dramatic slowing down or complete cessation of marker
eux. Therefore, values of leakage recorded after 1 h incubation essentially represent the
leakage that occurs within the rst few minutes after MPX addition to the LUVs. However,
the values of leakage recorded after 18 h incubation of MPX with LUVs reveal that leakage,
after the initial rapid burst of leakage, in some cases persists at a much slower rate. The
slower rate seems to be a function of the [P]/[L] ratio; the higher the [P]/[L] ratio, the higher
the rate of this secondary release process.
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Figure 4.11: MPX-induced leakage, L, after incubation of MPX with 1 mM POPC/POPG (3:1)
LUVs for 10 min, 20 min, 1 h, and  18 h. (A) Leakage from LUVs entrapping 4 M Alexa488.
(B) Leakage from LUVs entrapping 5 M Alexa488-3kMW. (C ) Leakage from LUVs entrapping 2.5
M Alexa488-10kMW. In all panels, the data are the average of three separate experiments. Error
bars represent standard deviations. Leakage is a biphasic process, in which a rapid burst of leakage
within the rst few minutes after MPX addition is followed by a dramatic slowing down or complete
cessation of leakage.
4.7.6 Investigation of leakage by equilibrium dialysis
Materials
Fast Micro-Equilibrium DIALYZER casettes with 500 L half-cells and cellulose acetate 300
kDa MWCO membranes for equilibrium dialysis were purchased from Harvard Apparatus
(Scandicat, Odder, Denmark).
Method
Variable volumes of MPX stock solutions were transferred to Protein LoBind tubes containing
POPC/POPG (3:1) LUVs entrapping 20 M Alexa488-3kMW. The nal LUV concentrations
were always 1 mM. After addition of MPX, samples were vigorously vortexed and subse-
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Figure 4.12: Equilibrium dialysis experiments to study MPX-induced leakage of Alexa488-3kMW.
(A) White bars are value of leakage as determined by Eq. 4.32. The sample "Alexa488-3kMW" is a
control sample to check equilibration of 60 nM Alexa488-3kMW across the dialysis membrane. For
this sample, an L-value of 100 % indicates complete equilibration. The black data bars are leakage
as determined by FCS; therefore, such black bars are not available for the "Alexa488-3kMW"-sample.
For [P]=[L] = 0, the black bar is by denition 0 %. Within the experimental uncertainty, leakage values
determined from dialyzed samples and from FCS on non-dialyzed samples are in good agreement.
(B) Apparent brightness values, Bf , of Alexa488-3kMW samples taken from the buer-containing
half-cells. The sample 'Control' is a sample with 30 nM Alexa488-3kMW that was not incubated in
the dialysis cassettes. Bf is found to be identical for all samples. Data are the average of two to ve
separate experiments. Error bars show the standard deviations.
quently incubated at room temperature for 30 min. The samples were then transferred
to the half-cells of equilibrium dialysis cassettes in which the other half cell was lled with
buer. A cassette in which the one half cell contained 60 nM free Alexa488-3kMW together
with 1 mM unlabeled POPC/POPG (3:1) LUVs and the other half-cell contained buer was
also prepared to check that Alexa488-3kMW equilibrated across the dialysis membrane. The
cassettes were incubated for  20 h before the contents of the cassettes were transferred
to the -slide 8 wells for examination by FCS. Experiments were conducted with excitation
power of 10.9 W.
From the photon count rates of the FCS measurements, the percentage of Alexa488-
3kMW that had leaked out of the vesicles, L, could be calculated by the formula
L =
2 (Bbuf  Bb)
(BLUV  Bbuf) k 1 + 2 (Bbuf  Bb) (4.32)
where Bbuf is the photon count rate of the sample from the buer-containing half-cell,
BLUV is the photon count rate of MPX/LUV-containing half-cell, Bb is the background
photon count rate, and k is the usual brightness ratio between entrapped and unentrapped
Alexa488-3kMW.
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Results
In the equilibrium dialysis experiments, we investigated MPX-induced leakage of Alexa488-
3kMW from POPC/POPG (3:1) LUVs at two dierent [P]/[L] ratios of 0.01 and 0.02. At
these [P]/[L] ratios, after the initial rapid burst of leakage, no additional leakage of Alexa488-
3kMW was observed during a  18 h incubation period (Fig. 4.11 B). Accordingly, the
role of the equilibrium dialysis experiments was simply to separate the Alexa488-3kMW-
molecules that were released during the initial rapid burst of leakage from the Alexa488-
3kMW-molecules that remained entrapped during this burst. In other words, the equilibrium
dialysis leakage data should be representative of the leakage that occurred during the initial
rapid burst of leakage. Consequently, leakage as determined from the dialyzed samples using
Eq. 4.32 should be directly comparable to leakage determined by FCS performed on non-
dialyzed samples. Fig. 4.12 A conrms that within the experimental uncertainties, this
notion is true, albeit we note that leakage as determined from the dialyzed samples at a
[P]/[L] ratio of 0.02 is associated with a rather high experimental uncertainty.
The Alexa488-3kMW molecules that had diused to the buer-containing half-cells dur-
ing equilibration must then be representable of the Alexa488-3kMW molecules that are re-
leased during the initial rapid burst of leakage. Therefore, by performing FCS on the samples
from the buer-containing half-cells, it is possible to check whether Bf of Alexa488-3kMW
is constant for dierent values of leakage. Fig. 4.12 B conrms that Bf of Alexa488-3kMW
in the buer containing half-cells is indeed constant for dierent values of leakage, meaning
that the probability of a given Alexa488-3kMW molecule being released during the initial
rapid burst of leakage is not dependent on the number of uorescent labels on the Alexa488-
3kMW molecules. Consequently, we conclude that our FCS-based protocol is fully applicable
to study release of Alexa488-3kMW from LUVs. Unfortunately, since Alexa488-10kMW only
equilibrates very slowly across the dialysis membranes, we were not capable of performing
the same type of experiments on leakage of Alexa488-10kMW. However, given the fact that
the value of Bf for Alexa488-3kMW was found to be completely unbiased during leakage,
we consider it unlikely that the Bf -value of Alexa488-10kMW will be strongly biased during
leakage.
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CHAPTER 5
Single-vesicle analysis of antimicro-
bial peptide-induced leakage
The following chapter contains a manuscript in preparation. The manuscript is entitled
"Single-vesicle analysis of leakage induced by cationic membrane-active peptides". The
manuscript is based on work carried out in collaboration with Nicky Ehrlich. Nicky Ehrlich
also wrote part of Section 5.3.4 for the manuscript.
5.1 Abstract
The mechanisms by which cationic membrane-active peptides interact with lipid bilayers have
for years been subject to signicant scientic attention. In particular, great eorts have been
put into studying the mechanisms by which cationic membrane-active peptides permeabilize
lipid bilayers. In this article, we combine two powerful techniques to study membrane per-
meabilization induced by the three -helical cationic membrane-active peptides mastoparan
X, melittin, and magainin 2. Specically, uorescence correlation spectroscopy to quantify
leakage from a bulk collection of large unilamellar lipid vesicles in aqueous solution was com-
bined with confocal imaging to visualize leakage from individual surface-immobilized large
unilamellar lipid vesicles. Our results show the all three peptides induce partial transient
permeabilization of POPC/POPG (3:1) bilayers by the formation of transmembrane pores.
Additionally, our results show that on the single-vesicle level this leakage process is heteroge-
nous in the sense that some vesicles are completely emptied and some vesicles are only partly
emptied.
5.2 Introduction
Cationic membrane-active polypeptides have been studied for years as candidates for becom-
ing a novel class of anti-infective therapeutics (6, 8). In particular, a great deal of eort
has been put into understanding the mechanisms by which cationic membrane-active pep-
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tides destabilize cellular membranes, as these destabilizing activities have been suggested to
play a central role for the antimicrobial and cytotoxic activities of cationic membrane-active
peptides (5, 10, 14, 28). To study these membrane-destabilizing activities, synthetic lipid
vesicles are often employed as minimal models of cellular membranes. In one of the most
popular assays with such synthetic lipid vesicles, size-homogenous unilamellar lipid vesicles
with a diameter of 100 nm (LUVs) are loaded with high self-quenching concentrations of
uorophores, such as calcein or carboxyuorescein (169, 170). These LUVs are then mixed
with peptides. If the peptides induce permeabilization of the vesicle membranes, the encap-
sulated uorophores will leak out of the vesicles, and the uorescence emission will increase
due to dequenching of the uorophores that escape the vesicle lumen.
One of the major limitations of the conventional quenching-based leakage assays is that
they only provide average information about leakage from an ensemble of vesicles. Therefore,
to study heterogeneities in leakage between individual LUVs, more sophisticated experimental
methods have been designed. These methods have especially been focussed on whether
peptide-induced leakage is a graded process, in which all of the vesicles release a similar
fraction of their contents, or an all-or-none process, in which part of the vesicles release
all of their contents and part of the vesicles release no contents. In one of these methods,
the self-quenching of the uorophores that remain inside the vesicles during the leakage
process is used to assess whether leakage occurs via a graded process or an all-or-none
process (171, 172). In another method, the dye/quencher pair ANTS/DPX is used to assess
whether leakage occurs via a graded process or an all-or-none process (49, 150, 151, 173). In
yet another method, the uorescence lifetime of calcein inside vesicles is analyzed to assess
the leakage mechanism (174, 175).
However, all of these methods to study heterogeneities in leakage between individual
LUVs are based on indirect analyses. To directly visualize peptide-induced leakage on the
single-vesicle level, giant unilamellar lipid vesicles (GUVs) with a diameter of 5 m or more
have been employed instead of LUVs (46{48). Due to the large size of the GUVs, uxes
of uorescent markers into or out of the GUVs are directly visible by optical microscopy.
By binning the degrees of llings of individual GUVs, it is then, for example, possible to
deduce whether a given peptide induces leakage by a graded process or an all-or-none process
(176, 177). However, an important limitation of the GUV experiments, as compared to the
LUV experiments, is that it is very dicult to control the experimental lipid concentration
and, thereby, also the experimental peptide-to-lipid ratio.
In this article, we study peptide-induced leakage from LUVs using two less conventional
techniques. The rst technique is uorescence correlation spectroscopy (FCS) (156, 157).
In FCS, uctuations in emission intensity from uorescent molecules diusing across a small
confocal volume are analyzed to obtain autocorrelation curves carrying information about
concentrations, diusion properties, and other things of uorescent molecules in solution.
We recently showed that FCS is applicable to quantitatively study peptide-induced leakage
of uorescent markers from LUVs in solution (Chapter 4), including leakage of uorescent
markers of dierent sizes. Thereby, FCS provide a high level of insight into the mechanisms
by which cationic membrane-active peptides induce leakage from LUVs. However, just like
for the conventional quenching based leakage assays, one major limitation of FCS is that
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the technique only provides average information about the leakage process; no information
about heterogeneity in leakage between LUVs is available by FCS.
Therefore, we also employed a second experimental technique to obtain information about
leakage on the single-vesicle level. In this technique, LUVs, labeled with a lipid-anchored
uorophore and loaded with a spectrally separated uorescent marker, are immobilized on
a cover glass slide, allowing individual LUVs to be visualized by confocal microscopy as
diraction-limited spots (178, 179). Thereby, the technique allows more direct observation
of peptide-induced leakage from individual LUVs than what hitherto has been possible. In
addition, the technique also allows us to study leakage of uorescent markers of dierent
sizes on the single-vesicle level; such studies remain so far as largely unexplored territory
for LUVs. In order to ensure that this more direct observation of leakage did not come at
the cost of poor control of the experimental peptide-to-lipid ratio, we designed a detailed
experimental protocol in which peptides were added to and subsequently removed from LUVs
before LUVs were immobilized.
By combining FCS with confocal imaging of surface-immobilized LUVs, we believe that
we have introduced a powerful experimental approach to study peptide-induced leakage from
LUVs. To demonstrate the potential of this approach, we considered the three archetypal
antimicrobial cationic membrane-active peptides mastoparan X, melittin, and magainin 2. All
these three peptides have in common that they are linear, small, and enriched in hydrophobic
and, of course, cationic amino acid residues. In addition, all three peptides are known to
fold into amphipathic -helical structures upon association to phospholipid bilayers (111,
117, 120{123). Moreover, all three peptides have been found to induce leakage from lipid
vesicles, and, for all three peptides, it has been extensively studied whether this leakage is
characterizable as an all-or-none process or a graded process (47, 48, 51, 52, 122, 128, 130{
133, 173, 180). For example, mastoparan X has previously been suggested to induce graded
leakage from egg PC/egg PG (7:3) LUVs (51) and from POPC/POPG GUVs of varying
POPG content (133), melittin has previously been suggested to induce all-or-none leakage
from POPC LUVs (134), and magainin 2 has previously been suggested to induce graded
leakage from egg PG LUVs (122) and all-or-none leakage from POPC/POPG (1:1) and
POPC/POPG (7:3) LUVs (173) and from DOPG/DOPC GUVs of varying DOPG content
(47). In this article, we study the interactions of these three peptides with POPC/POPG
(3:1) LUVs. Our experimental data conrms previous observations that these peptides are
indeed capable of permeabilizing lipid bilayers. In addition, our data also show that leakage
considered on the single-vesicle level is a heterogenous process in the sense that some vesicles
are completely emptied and some vesicles are only partly emptied. This heterogenous leakage
prole is found regardless of the size of the encapsulated uorescent marker.
5.3 Materials and methods
5.3.1 Materials
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)], sodium salt (POPG), 1,2-dioleoyl-sn-glycero-3-phosphoethanola-
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mine-N-(cap biotinyl), sodium salt (DOPE-Biotin), and 1-palmitoyl-2-[11-(dipyrrometheneb-
oron diuoride)undecanoyl]-sn-glycero-3-phosphocholine (TopFluor PC) were purchased from
Avanti Polar Lipids (Alabaster, AL, USA). Bovine serum albumin (BSA), biotin-labeled
bovine serum albumin (BSA-biotin), streptavidin from Streptomyces avidinii, N-(2-hydroxyet-
hyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES) and the corresponding sodium salt (HEP-
ES-Na), and NaCl were purchased from Sigma-Aldrich (Brndby, Denmark). 1,1'-dioctadecyl-
3,3,3',3'-tetramethylindodicarbocyanine perchlorate (DiD), Alexa Fluor 488 hydrazide, sodium
salt (Alexa488), Alexa Fluor 488 dextran, 3000 MW, anionic (Alexa488-3kMW), and Alexa
Fluor 488 dextran, 10000 MW, anionic, xable (Alexa488-10kMW) were purchased from
Life Technologies (Nrum, Denmark). Melittin was purchased from Peptide 2.0 (Chantilly,
VA, USA), and magainin 2 and mastoparan X were purchased from GL Biochem (Shang-
hai, China). Mastoparan X was further puried by semi-preparative HPLC (Waters semi-
preparative HPLC equipped with a Waters 600 pump & controller and a Waters 2489 UV/vis
detector, Waters, Milford, MA, USA). The purity of all three peptides was checked by ana-
lytical HPLC (Shimadzu LC-2010C analytical HPLC equipped with a UV/vis detector, Shi-
madzu, Kyoto, Japan, or Gilson analytical HPLC equipped with a Gilson 321 HPLC pump
and a Gilson 155 UV/vis detector, Gilson, Middleton, MI, USA) and the identity of the pep-
tides was conrmed by MALDI-TOF (Bruker Reex IV MALDI-TOF spectrometer, Bruker,
Billerica, MA, USA).
5.3.2 Sample preparation
LUV preparation and characterization
Lipid solutions were prepared in chloroform/methanol (9:1). The organic solvent was removed
under a gentle stream of nitrogen. The samples were subsequently kept in vacuum overnight
to remove the residual solvent. The lipid lms were hydrated in HEPES buer (10 mM
HEPES, 100 mM NaCl, pH 7.4) with vigorous vortexing every 5 min for a period of 30
min. To prepare dye-loaded vesicles, Alexa488, Alexa488-3kMW or Alexa488-10kMW were
added to the buer. (Concentrations of these uorescent molecules were determined from
the absorbance, recorded by a NanoDrop 2000c spectrophotometer (NanoDrop Products,
Wilmington, DE, USA), assuming that (i) the extinction coecient of Alexa488 at maximum
absorption at ca. 495 nm is 71000 cm 1M 1 and (ii) using the degree of labeling of Alexa488-
3kMW and Alexa488-10kMW that was stated by the manufacturer). The hydrated lipid
suspensions were then subject to 5 freeze-thaw cycles by alternately placing the sample vials
in an isopropanol/dry ice bath and a warm water bath. Next, the lipid suspensions were
extruded 21 times through a 100 nm polycarbonate lter (Whatman, Maidstone, UK) using
a mini-extruder (Avanti Polar Lipids) to form LUVs. The size of the LUVs was checked
by dynamic light scattering (ZetaPALS, Brookhaven Instruments, Holtsville, NY, USA).
Phosphorous concentrations of the LUV solutions were determined using the method of
Rouser et al. (144), albeit with slightly modied reagent concentrations. Phosphorous
concentrations of dye-loaded vesicles were determined after the vesicles had been run on
a size exclusion chromatography column (Sepharose CL-4B, GE Healthcare, VWR - Bie &
Berntsen, Herlev, Denmark) to separate the free dye from the vesicles.
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Peptide stock solutions
Peptide stock solutions were prepared in HEPES buer. To prevent loss of peptides due to
adsorption to tube walls and pipette tips, peptide stock solutions were generally handled in
Protein LoBind tubes (Eppendorf, VWR - Bie & Berntsen) and at high concentrations of
at least 100 M. To determine the concentration of peptide stock solutions, the extinction
coecients of peptides at 220 nm were calculated to be 40100 cm 1M 1 for mastoparan
X, 46700 cm 1M 1 for melittin, and 23900 cm 1M 1 for magainin 2 by correlating the
peptide concentrations determined by an Antek 8060 chemiluminescent nitrogen detector
(PAC, Houston, TX, USA) to the absorbance of the same peptide samples, determined by
a NanoDrop 2000c spectrophotometer. Given these extinction coecients, peptide concen-
trations of stock solutions were then always determined by recording the absorbance at 220
nm using the NanoDrop 2000c spectrophotometer.
5.3.3 FCS experiments
The details of the FCS measurements and analysis were the same as previously described
(Chapter 4).
Sample preparation
Varying volumes of 100 M peptide stock solutions were added to varying volumes of
POPC/POPG (3:1) LUV solutions in Protein LoBind tubes to a nal LUV concentration
of 1 mM. The LUVs were entrapping 4 M Alexa488, 5 M Alexa488-3kMW, or 2.5 M
Alexa488-10kMW, or labeled with 0:1 % TopFluor PC. Immediately upon addition of pep-
tide, the samples were vigorously vortexed for a few seconds and subsequently incubated for
1 h. The samples were then transferred to 8-well chambered cover glasses (-slide 8 wells,
ibidi, DFA Instruments, Glostrup, Denmark) for examination by FCS.
FCS measurements
FCS measurements were performed using a commercially available DCS-120 confocal scan-
ning FLIM system (Becker & Hickl, Berlin, Germany) connected to a Zeiss Axio Observer
Z1 inverted microscope equipped with a C-Apochromat 40x/1.2 W Corr UV-VIS-IR water
immersion objective (Carl Zeiss, Jena, Germany). The excitation source for the system was
a 473 nm picosecond diode laser (BDL-473-SMC, Becker & Hickl) operated at a pulse rep-
etition rate of 50 MHz. The incident excitation power at the objective rear aperture was
measured by a PM100D optical power meter (Thorlabs, Goteborg, Sweden). After passing
through a 485 nm longpass lter (HQ485LP, Becker & Hickl) and a confocal pinhole, the
uorescence emission was detected with a HPM-100-40 hybrid detector connected to a SPC-
150 module (Becker & Hickl). Lifetime-gating was used to partially suppress background
noise. SPCM software (Becker & Hickl) was used to calculate the experimental autocor-
relation curves. The curves were subsequently exported to be tted by MATLAB (The
MathWorks, Natick, MA, USA). All samples were measured by positioning the laser focus
 50 m above the top of the cover glass. The acquisition time for all FCS experiments
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was 300 s. By calibration with Alexa488, the eective excitation volume was determined to
be 1.0 fL and the structural S-parameter was determined to be 7.4. The S-parameter was
always xed to this value when tting all other experimental autocorrelation curves. Expect
for the experiments determining the S-parameter, all autocorrelation curves in this article
were analyzed using unweighted least squares tting. Autocorrelation curves dominated by
single bright events were discarded in the data analysis.
Data analysis
For a single type of diusing species in solution, the autocorrelation function, G(), is given
by:
G() =
1
N
g() =
1
N

1 +
T
1  T e
 =T

1 +

D
 1
1 +

S2D
  1
2
(5.1)
where  is the lag time, N is the average number of uorescent particles in the excitation
volume, T is the fraction of uorescent particles in the triplet state, T is the characteristic
triplet state lifetime, S is the ratio of the axial to radial dimensions of the excitation volume,
and D is the characteristic translational diusion time of the uorescent particles. For
samples in which peptides had been added to TopFluor PC-labeled LUVs, this equation was
used to t the recorded autocorrelation curves. In that case, N was the apparent average
number of LUVs in the excitation volume and D was the characteristic diusion time of the
LUVs.
For a leaky solution of LUVs, there are two diusing species: LUVs entrapping uorescent
molecules (index v) and free uorescent molecules (index f). In that case, the autocorrelation
function is given by
G() =
B2f Nfgf() +B
2
vNvgv()
B2tot
= Afgf() +Avgv() (5.2)
where Bf and Bv are the apparent brightness (photon count rate per molecule) of the
free uorescent molecules and the LUVs, respectively, Nf and Nv are the apparent average
number of the free uorescent molecules and LUVs in the excitation volume, respectively,
Af and Av are the amplitude of the free uorescent molecules and the LUVs, respectively,
and gf and gv are dened as given in Eq. 5.1.
During a leakage experiment, a certain fraction of the initially entrapped uorescent
molecules will leak out of the LUVs. This fraction, L, must be given by the equation
L =
Cf   Cf0
Cf100   Cf0 (5.3)
where Cf0 is the concentration of unentrapped uorescent molecules before peptide addition,
Cf is the concentration of unentrapped uorescent molecules after peptide addition, and Cf100
is the concentration of unentrapped uorescent molecules at complete leakage. Using Eqs.
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5.2 and 5.3, it is possible to derive a quadratic equation relating L to the output parameters
of the FCS experiments:
L =
Af (BfNf100L+ kBfNf100(1  L) +Bb)2  Af0 (kBfNf100 +Bb)2
Af100 (BfNf100 +Bb)
2  Af0 (kBfNf100 +Bb)2
: (5.4)
In this equation, Nf100 is the background-corrected average number of free uorescent
molecules in the excitation volume of a sample displaying 100 % leakage, Bb is the back-
ground photon count rate, Af is determined by tting Eq. 5.2 to a autocorrelation curve
acquired from a sample with unknown leakage, L, Af0 and Af100 are the values of Af as
determined from samples with 0 % leakage and 100 % leakage, respectively, and k is the
brightness ratio between entrapped and free uorescent molecules. Under our experimen-
tal conditions, we found that k = 0:85 for Alexa488, k = 0:96 for Alexa488-3kMW, and
k = 0:95 for Alexa488-10kMW. Eq. 5.4 was then solved for L using Maple (Maplesoft, Wa-
terloo, Ontario, Canada). For further details on how to derive and experimentally determine
the parameters of Eq. 5.4, see Chapter 4.
5.3.4 Confocal imaging experiments
Sample preparation
Varying volumes of 100 M peptide stock solutions were added to Protein LoBind tubes
containing solutions of POPC/POPG (3:1) LUVs functionalized with 0:1 % DOPE-biotin,
labeled with 0:1 % DiD, and loaded with either 200 M Alexa488 or 200 M Alexa488-
10kMW. The nal LUV concentrations of the samples were always 1 mM. Immediately upon
addition of peptide, the samples were vigorously vortexed for a few seconds. After 1 h incuba-
tion, a large excess of unlabeled POPG LUVs was added to a nal POPG LUV concentration
of 6.7 mM and a nal POPC/POPG (3:1) LUV concentration of 0.83 M. Immediately
after addition of the POPG LUVs, the samples were vortexed for a few seconds and then
incubated overnight. The next day, the samples were transferred to 8-well chambered cover
glasses (ibidi). These 8-well chambered cover glasses had been prepared by incubation with
1 g/l BSA-biotin/BSA (1:10) for 10 minutes and then incubation with 0.025 g/l streptavidin
for 10 minutes. After each incubation step, the chambers were washed thoroughly with PBS
buer and nally with HEPES buer. The biotinylated POPC/POPG (3:1) LUVs were then
immobilized on the streptavidin functionalized surfaces by incubating the samples for 7-10
minutes followed by washing with HEPES buer. The surface density of LUVs was varied
by the amount of added sample.
Setup
Immobilized LUVs were imaged with a commercially available inverted confocal microscope
(Leica TCS SP5 AOBS, Leica Microsystems, Wetzlar, Germany) using a water immersion
objective (HCX PL APO CS 63.0x/1.20, Leica). The microscope stage was placed in an
incubator box (Life Imaging Services, Basel, Switzerland), in which the temperature remained
constant at 22 C. Micrographs from the membrane signal (DiD) and lumen signal (Alexa488
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or Alexa488-10kMW) were acquired sequentially to avoid cross excitation. First, the lumen
dye was excited using the 488 nm line of an argon laser, and the emission between 495
and 555 nm was collected with a PMT. A 633 nm diode laser was then used to excite the
membrane dye, and the emission between 640 nm and 711 nm was collected. Imaging was
repeated 15 times and a pinhole size of 1 AU was used. Additionally, for each image sequence,
a bright eld image for each laser was obtained for later correcting the uorescence signal
for laser uctuations between dierent images, samples, and days. Images had a resolution
of 1024 x 1024 pixel, with a physical pixel area of 72,9 x 72,9 nm2 and a bit depth of 8.
Specimens were scanned bidirectional with a speed of 100 Hz, corresponding to an exposure
time in each sub-image of 9.8 s for each pixel.
Data analysis
A custom made software routine in Igor Pro 6 (Wavemetrics, Lake Oswego, OR, USA) was
used for single-vesicle analysis. Using the micrographs acquired from the membrane dye
detector channel, the software routine localized single LUVs in the micrographs and tted
their uorescence intensity distribution via a 3D Gaussian t; thresholding, minimum vesicle
area and ellipticity were used as tools for faithfully localizing LUVs, and only LUVs that
had no overexposed pixels and for which the Gaussian t matched the criteria of having an
uncertainty below 10 % and a width of 3:5  0:5 pixels were included in the data analysis.
These strict criteria assured us to have intact single LUVs with sucient uorescent signal
for single-vesicle analysis. The lumen dye and membrane dye emission intensity of each
individual localized LUV were then determined by integrating the pixel intensities of a 7 7
pixel area. For each experiment, between 200 to 1000 LUVs were typically localized and
included in the data analysis.
The average background intensity and the detection threshold of the apparatus were
for every image series determined by plotting a cumulative probability density histogram of
single pixel intensities from image areas where no vesicles had been detected. Based on this
cumulative probability density histogram, we then conducted a Monte Carlo simulation to
determine the background intensity distribution of the 7 7 pixel areas; from this intensity
distribution, the average background intensity and the detection threshold of the apparatus
were determined.
To calculate the average fraction of markers released from LUVs in a sample of peptide-
treated immobilized LUVs, L, we used the equation
L = 1  I   Ib
I0   Ib (5.5)
where I is the average lumen dye emission intensity per LUV of the given sample of peptide-
treated immobilized LUVs, I0 is the average lumen dye emission intensity per LUV of un-
treated LUVs, and Ib is the background intensity.
To calculate the fraction of LUVs that upon treatment by peptide had been completely
emptied below the detection threshold of the apparatus, we used the equation
E = 1  F
F0
(5.6)
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where E is the fraction of LUVs that had been emptied upon treatment by peptide, F is
the fraction of non-empty LUVs of the peptide-treated sample, and F0 is the fraction of
non-empty LUVs of a sample of untreated LUVs.
5.4 Results and discussion
5.4.1 FCS experiments
First, we used FCS to study peptide-induced leakage from an ensemble of LUVs in solution.
Fig. 5.1 shows leakage vs the peptide-to-lipid ratio as determined by FCS after 1 h incubation
of peptides together with 1 mM POPC/POPG (3:1) LUV loaded with Alexa488, Alexa488-
3kMW, or Alexa488-10kMW. These data demonstrate that leakage induced by mastoparan
X (Fig. 5.1 A) and melittin (Fig. 5.1 B) is dependent on the size of the entrapped marker;
both peptides induces much more eective release of Alexa488, with a molar mass of 570
Da, than of Alexa488-3kMW and Alexa488-10kMW, with nominal molar masses of 3 kDa
and 10 kDa, respectively. In contrast, leakage induced by magainin 2 (Fig. 5.1 C ) did not
display the same dependency on the marker size.
Leakage was also checked for shorter incubation times. These data (not shown) demon-
strate that leakage induced by mastoparan X, melittin, and magainin 2 is a partial transient
process in which a rapid burst of leakage, over the course of a few minutes, is followed by
dramatic slow down or complete cessation of leakage. In that way, the leakage values that
we record after 1 h incubation is, by and large, representative of the rapid burst of leakage
that occurs within the rst few minutes after addition of peptide. It should be noted that
such transient partial leakage is a commonly reported phenomenon for leakage induced by
membrane-active peptides (45); however, the specic molecular details underlying partial
transient leakage are still not completely understood
We also used FCS to evaluate the mechanism by which mastoparan X, melittin and
magainin 2 induce leakage from POPC/POPG (3:1) LUVs. Fig. 5.2 shows the eect of the
peptides on TopFluor PC-labeled POPC/POPG (3:1) LUVs as determined by FCS after 1
h incubation of peptides together with 1 mM LUV. For mastoparan X (Fig. 5.2, A and B)
and melittin (Fig. 5.2, C and D) the apparent average number of LUVs in the excitation
volume and diusion times of the LUVs were largely constant for all peptide-to-lipid ratios.
This strongly implies that leakage induced by mastoparan X and melittin is due to formation
of transmembrane pores. For magainin 2 (Fig. 5.2, E and F ), the apparent number of
LUVs gradually decreased as a function of the peptide-to-lipid ratio, and, concurrently, the
LUV diusion times gradually increased as a function of the peptide-to-lipid ratio. These
observations imply that magainin 2 induce aggregation or fusion of the POPC/POPG (3:1)
LUVs. However, we do not believe that this aggregation/fusion process play a major role in
the magainin 2-induced leakage. Thus, we note that magainin 2 induced almost complete
leakage of all markers already at a peptide-to-lipid ratio of 0.01 (Fig. 5.1 C ). At this peptide-
to-lipid ratio, magainin 2 did not induce signicant changes in the apparent average number
of LUVs in the excitation volume and in the LUV diusion times (Fig. 5.2, E and F ),
indicating the aggregation/fusion process to only play a minor role in magainin 2-induced
88 Single-vesicle analysis of antimicrobial peptide-induced leakage
0 0.02 0.04 0.06
0
20
40
60
80
100
Peptide−to−lipid ratio
Le
ak
ag
e 
(%
)
 
 
Melittin
570 Da
3000 MW
10000 MW
0 0.01 0.02 0.03 0.04
0
20
40
60
80
100
Peptide−to−lipid ratio
Le
ak
ag
e 
(%
)
 
 
Magainin 2
570 Da
3000 MW
10000 MW
0 0.02 0.04 0.06
0
20
40
60
80
100
Peptide−to−lipid ratio
Le
ak
ag
e 
(%
)
 
 
Mastoparan X
570 Da
3000 MW
10000 MW
A
CB
Figure 5.1: Peptide-induced leakage from 1 mM POPC/POPG (3:1) LUVs containing Alexa488
(molar mass of 570 Da), Alexa488-3kMW (nominal molar mass of 3 kDa), or Alexa488-10kMW
(nominal molar mass of 10 kDa) as determined by FCS after 1 h incubation of peptides together with
LUVs. In all panels, the data are the average of three separate experiments. The error bars show
the standard deviations. The error bars are not shown when they are smaller than the symbols. The
leakage values at the lowest and highest peptide-to-lipid ratios correspond to no leakage and complete
leakage, respectively, and, therefore, they are, by denition, always set to 0 % and 100 %, respectively.
Trendlines are added to guide the eye. Leakage induced by mastoparan X (A) and melittin (B) is
dependent on the size of the entrapped marker. Contrary, leakage induced by magainin 2 (C ) is less
dependent on size of the entrapped marker.
leakage. Therefore, we conclude that magainin 2, just like mastoparan X and melittin,
induce leakage from POPC/POPG (3:1) LUVs by formation of transmembrane pores, and
not by any other molecular processes, such as membrane fusion. Holding the conclusion
that mastoparan X, melittin, and magainin 2 form transmembrane pores together with the
observations in Fig. 5.1 that leakage from POPC/POPG (3:1) LUVs induced by magainin
2 is less dependent on the marker size than leakage induced by mastoparan X and melittin,
we deduce that magainin 2 must form larger and/or more stable transient pores during
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partial transient leakage from POPC/POPG (3:1) LUVs than melittin and mastoparan X.
The questions is then whether these dierences in pores size and/or stability will also give
rise to dierences in the leakage proles on the single-vesicle level.
5.4.2 Confocal imaging experiments
In the confocal imaging experiments, we considered POPC/POPG (3:1) LUVs functionalized
with DOPE-biotin, labeled with DiD, and loaded with either Alexa488 or Alexa488-10kMW.
1 mM of these LUVs were incubated together with peptides for 1 h in solution. After this
incubation time, a large excess of POPG LUVs was added to the solutions. As mastoparan
X, melittin and magainin 2, just like cationic membrane-active peptides in general, all exhibit
high anity for partitioning onto such anionic POPG LUVs (110, 112, 128, 129, 181), they
will dissociate from the POPC/POPG (3:1) LUVs and instead partition onto the POPG LUVs.
To ensure maximal transfer of peptide from the POPC/POPG (3:1) LUVs to the POPG
LUVs, the samples were incubated overnight. The next day, the LUVs were immobilized to
cover glasses for visualization by confocal imaging. Fig. 5.3 A shows a schematic drawing
of a surface-immobilized LUV. Fig. 5.3, B-E, shows a few representative confocal images of
the surface-immobilized LUVs.
The POPG-induced removal of peptides from the POPC/POPG (3:1) LUVs served two
purposed. First, the POPG-induced removal of peptides from the POPC/POPG (3:1) LUVs
completely halted the leakage process (see Fig. 5.8 in the Supporting material), thereby
ensuring that leakage observed from the immobilized LUVs was representative of peptide-
induced leakage that had occurred from LUVs in solution during the 1 h incubation period
before POPG had been added. Second, the fact that peptides had been removed from the
POPC/POPG (3:1) LUVs ensured that all LUVs were immobilized under identical experi-
mental conditions, i.e., removal of peptides from the POPC/POPG (3:1) LUVs ensured that
peptides partitioned onto the POPC/POPG (3:1) LUVs could not inuence the immobiliza-
tion process. Since FCS control experiments in addition had shown that adding DOPE-biotin
and DiD to the POPC/POPG (3:1) LUVs did not perturb the leakage process (see Fig. 5.7
in the Supporting material), the confocal imaging data should then be directly comparable
to the FCS data. To conrm that this notion is true, we used Eq. 5.5 to calculate the
average percentage of released uorescent markers from collections of surface-immobilized
LUVs and compared it to the leakage percentages determined by FCS. Fig. 5.4 shows the
calculated average leakage percentages of the surface-immobilized LUVs as a function of
the peptide-to-lipid ratio. For the Alexa488-containing LUVs, very good agreement be-
tween leakage calculated from the surface-immobilized LUVs and FCS was achieved. For the
Alexa488-10kMW-containing LUVs, reasonably good agreement between leakage calculated
from the surface-immobilized LUVs and FCS was achieved, albeit leakage determined from
the surface-immobilized LUVs was generally slightly lower than in FCS. The small devia-
tions in leakage of Alexa488-10kMW observed between the surface-immobilized LUVs and
FCS might be due to dierences in experimental conditions between the two techniques.
For instance, the molar concentration of 200 M Alexa488-10kMW inside the immobilized
LUVs corresponds to a relatively high mass concentration; we can not rule out that such
high mass concentrations impact the kinetics of the leakage process, for example, because
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Figure 5.2: Eect of peptides on TopFluor PC-labeled POPC/POPG (3:1) LUVs as determined by
FCS after 1 h of incubation of peptides together with 1 mM LUVs. In all panels, the data are the
average of three separate experiments. The error bars show the standard deviations. The error bars
are not shown when they are smaller than the symbols. For mastoparan X (A and B) and melittin (C
and D), the apparent average number of LUVs in the excitation volume and the diusion times of
the LUVs were largely constant for all peptide-to-lipid ratios. In contrast, for magainin 2 (E and F ),
the apparent number of LUVs gradually decreased and the LUV diusion times gradually increased
as a function of the peptide-to-lipid ratio. By comparison with Fig. 5.1, we conclude that leakage
induced by all three peptides must be due to formation of transmembrane pores.
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Figure 5.3: (A) Schematic drawing of a surface-immobilized POPC/POPG (3:1) LUV. The LUVs
were functionalized with DOPE-biotin, labeled with the membrane dye DiD, and loaded with Alexa488
or Alexa488-10kMW. The LUVs were immobilized to cover glass slides by biotin/streptavidin cou-
pling only after treatment with peptide. They could then be visualized as diraction-limited spots
by confocal microscopy. (B) and (C ) Representative confocal images of immobilized DiD-labeled
Alexa488-loaded LUVs that had not been treated with peptide (i.e., corresponding to a peptide-
to-lipid ratio of 0) before surface-immobilization. A high degree of colocalization between the DiD
detector channel (B) and the Alexa488 detector channel (C ) was observed, demonstrating that al-
most all LUVs contained Alexa488. (D) and (E ) Representative confocal images of immobilized
DiD-labeled Alexa488-loaded LUVs that had been treated with mastoparan X (peptide-to-lipid ratio
of 0.018) before surface-immobilization. Now, the LUVs were completely void of Alexa488 signal,
demonstrating that mastoparan X induced release of Alexa488 from the LUVs. Sizes of the confocal
images shown in (B-E ) are 8:7 8:7 m. In order to allow the reader to clearly visualize individual
LUVs in the images, the contrast of the confocal images in (B-E ) was enhanced.
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Figure 5.4: Average leakage percentage from the surface-immobilized POPC/POPG (3:1) LUVs
as a function of the peptide-to-lipid ratio. In all panels, the data are the average of two separate
experiments. The error bars show the standard deviations. The error bars are not shown when
they are smaller than the symbols. By denition, the leakage values determined at peptide-to-lipid
ratios of 0 are set 0 %. The trendlines are taken from the FCS leakage data in Fig. 5.1 to allow
for direct comparison to FCS data. (A) Peptide-induced leakage of Alexa488 from the LUVs. Very
good agreement between the leakage percentages calculated from the immobilized LUVs and the
FCS experiments is observed. (B) Peptide-induced leakage of Alexa488-10kMW from the LUVs.
Reasonably good agreement between the leakage percentages calculated from the immobilized LUVs
and the FCS experiments is observed, albeit the leakage determined from the immobilized LUVs is
generally slightly lower than leakage determined by FCS.
of intermolecular interactions between the dextran molecules.
From the surface-immobilized LUVs, we can then obtain insight into peptide-induced
leakage on the single-vesicle level by considering the intensity distributions of the immobi-
lized vesicles. Fig. 5.5 shows a few representative examples of such single-vesicle intensity
distributions. Specically, Fig. 5.5 A shows the Alexa488 single-vesicle intensity distributions
of two samples of unperturbed (peptide-to-lipid ratio 0) and mastoparan X-treated (peptide-
to-lipid ratio 0.014) LUVs, respectively. For the mastoparan X-treated LUVs, a large fraction
of LUVs were completely emptied of Alexa488 below the detection limit of the apparatus. In
contrast, such an empty fraction of LUVs was not observed in the untreated sample. Fig. 5.5
B shows the DiD single-vesicle intensity distributions of the same two samples. Interestingly,
the DiD single-vesicle intensity distributions were identical for the untreated LUVs and for
the mastoparan X-treated LUVs. This observation implies that the LUVs remained intact
upon treatment of mastoparan X, and thereby that mastoparan X-induced leakage must be
due to the formation of transmembrane pores. In fact, for peptides at all peptide-to-lipid
ratios, we always found that the DiD single-vesicle intensity distributions appeared largely
identical. This observation corroborates the conclusion that leakage studied in this article is
due formation of transmembrane pores.
To systematize the observations from the single-vesicle intensity distributions, we used
Eq. 5.6 to calculate the percentage of LUVs that had been completely emptied of lu-
men dye during leakage induced by mastoparan X, melittin, or magainin 2. Fig. 5.6 A
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Figure 5.5: Representative examples of single-vesicle intensity distribution of surface-immobilized
DiD-labeled Alexa488-containing POPC/POPG (3:1) LUVs. Two dierent LUV batches were con-
sidered: untreated LUVs (peptide-to-lipid ratio of 0) and mastoparan X-treated LUVs (peptide-to-lipid
ratio of 0.014). (A) Alexa488 single-vesicle intensity distributions. The vertical dashed line show the
detection threshold of the apparatus. A large fraction of the LUVs were completely emptied of
Alexa488 upon treatment by mastoparan X. (B) DiD single-vesicle intensity distributions. The DiD
intensity distributions did not change upon treatment by mastoparan X, indicating that the LUVs
remained intact.
shows a plot of the percentage of emptied LUVs vs the average percentage leakage from
Alexa488-containing LUVs. The plot shows that the three peptides do not induce leakage
from Alexa488-containing POPC/POPG (3:1) LUVs by an ideal all-or-none process. If that
would have been the case, then the data points in the plot would have been positioned along
the diagonal line. Rather, the peptides induce leakage of Alexa488 from POPC/POPG (3:1)
LUVs by a strongly heterogenous process in which a fraction of the LUVs are completely
emptied and another fraction of the LUVs are only partly emptied. The same type of het-
erogenous peptide-induced leakage is also observed from LUVs containing Alexa488-10kMW
(Fig. 5.6 B). Thus, this heterogenous leakage process occurs regardless of the size of the
lumen dye. Interestingly, even though magainin 2 by FCS was found to form larger pores than
mastoparan X and melittin, our data demonstrates that on the single-vesicle level, magainin
2-induced leakage is similar to leakage induced by mastoparan X and melittin in the sense
that all three peptides entail these heterogenous leakage proles. One could perhaps have
expected that the larger and/or more stable magainin 2 pores would lead to leakage by an
all-or-none-type process since the larger and/or more stable pores would allow for complete
emptying of individual LUV. However, the data in Fig. 5.6 show that this notion is not true,
at least for magainin 2-induced leakage from POPC/POPG (3:1) LUVs.
The question is then what molecular processes that might provide an explanation for
the heterogenous leakage process that was observed on the single-vesicle level. In order to
come up with a possible explanation, we consider a model in which cationic membrane-active
peptides will initially bind to the outer leaet of the LUVs to create an asymmetric tension
in the bilayers, promoting the formation of transmembrane pores (75). Upon equilibration of
the peptides across the membranes, the internal tension in the membranes is reduced and,
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Figure 5.6: The percentage of emptied LUVs vs the average percentage of leakage as determined
from confocal imaging of peptide-treated surface-immobilized POPC/POPG (3:1) LUVs containing
Alexa488 (A) or Alexa488-10kMW (B). Each data point corresponds to an individual experiment
at a specic peptide-to-lipid ratio. The solid lines represent ideal all-or-none leakage. The data
demonstrates that all three peptides induce a heterogenous type of leakage. This heterogenous
leakage persists regardless of the size of the lumen dye.
therefore, the transmembrane pores shrink in size or completely closes. Assuming that this
model is valid, we conjecture that the heterogenous leakage proles that we observed on
the single-vesicle level imply that the pores that are transiently opened as a result of the
asymmetric tension have a distribution of sizes and/or lifetimes. To be more specic, we
conjecture that the transiently opened pores might sometimes be suciently large and/or
long-lived to induce complete leakage of the LUV contents. In other cases, the transiently
opened pores will be of a size that restricts the leakage of LUV contents, or they will be so
short-lived that the LUVs are only partially emptied before the pores once again close. Thus,
in other words, we conjecture that the transient transmembrane pores are not characterizable
by one single well-dened radius and one single well-dened lifetime. To corroborate the
notion of the transmembrane pores having a distribution of sizes and/or lifetimes, we note
that heterogenous leakage was also identied for the two membrane-active peptides CpreTM
and NpreTM in a study using GUVs (176).
However, it should be noted that the above scheme only represents a hypothesis. That
is, there might also be other explanations for the heterogenous single-vesicle leakage proles.
For example, heterogeneity in leakage on the single-vesicle level could also be a result of
heterogeneity in the properties of individual LUVs. For instance, there is no guarantee
that the POPC/POPG ratio is completely identical for all LUVs. Indeed, variations in lipid
composition would most likely also result in heterogenous single-vesicle leakage proles. Also,
even though LUVs are often assumed to be completely monodisperse, reality is that there
will be some polydispersity in samples of LUVs. Dierences in sizes between individual LUVs
would probably also lead to heterogenous single-vesicle leakage proles, for example, because
of dierences in lumen volumes between individual LUVs and because of dierences in the
membrane curvature between individual LUVs (160). Thus, further eorts are required to
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fully understand how to interpret the data in Fig. 5.6 to corroborate or dismiss the hypothesis
that transient pores formed by mastoparan X, melittin, and magainin 2 have a distribution
of sizes and/or lifetimes.
5.5 Concluding remarks
In this article, we used two techniques to study partial transient leakage of uorescent mark-
ers of dierent sizes from POPC/POPG (3:1) LUVs induced by the three -helical cationic
membrane-active peptides mastoparan X, melittin, and magainin 2. FCS was used to study
peptide-induced leakage on the bulk level. From the FCS experiments we noticed that
magainin 2 forms larger and/or more stable pores than mastoparan X and melittin. Confo-
cal imaging of surface-immobilized LUVs was used to study peptide-induced leakage on the
single-vesicle level. The confocal imaging experiments were designed so that peptide-induced
leakage as observed from the surface-immobilized LUVs was directly representable of peptide-
induced leakage from LUVs in solution as observed by FCS. Thereby, the surface-immobilized
vesicles provided a more direct and exible way to observe peptide-induced leakage from in-
dividual LUVs than what hitherto has been possible. The data from the surface-immobilized
LUVs show that leakage induced by mastoparan X, melittin, and magainin 2 follows a het-
erogenous process in which some LUVs are completely emptied and some LUVs are only
partly emptied, and that this type of leakage is always identied, regardless of the size of the
entrapped marker.
5.6 Supporting material
5.6.1 Perturbation induced by DOPE-biotin and DiD
Method
Varying volumes of 100 M peptide stock solutions were added to varying volumes of
POPC/POPG/DOPE-biotin/DiD (74.9:24.9:0.1:0.1) LUV solutions in Protein LoBind tubes
to a nal LUV concentration of 1 mM. The LUVs were entrapping 4 M Alexa488 or 2.5-5
M Alexa488-10kMW. Immediately upon addition of peptide, the samples were vigorously
vortexed for a few seconds and subsequently incubated for 1 h. The samples were then
transferred to the 8-well chambered cover glasses for examination by FCS. The FCS setup
was as described in the main document, albeit with the small dierence that an additional
520-550 nm bandpass lter (HQ535/30, Becker & Hickl) was inserted before the pinhole to
lter away emission from DiD. From the acquired autocorrelation data, peptide-induced leak-
age from the POPC/POPG/DOPE-biotin/DiD (74.9:24.9:0.1:0.1) LUVs was then calculated
using Eq. 5.4 as described in the main document.
Results
Fig. 5.7 shows leakage vs peptide-to-lipid ratio as determined by FCS after 1 h incubation
of peptides together with 1 mM POPC/POPG/DOPE-biotin/DiD (74.9:24.9:0.1:0.1) LUVs
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Figure 5.7: Peptide-induced leakage from 1 mM POPC/POPG/DOPE-biotin/DiD
(74.9:24.9:0.1:0.1) LUVs containing Alexa488 (A) or Alexa488-10kMW (B) as determined by
FCS after 1 h incubation of peptides together with LUVs. In both panels, the data are the average
of three separate experiments. The error bars show the standard deviations. The error bars are
not shown when they are smaller than the symbols. The leakage values at the lowest and highest
peptide-to-lipid ratios correspond to no leakage and complete leakage, respectively, and, therefore,
they are, by denition, always set to 0 % and 100 %, respectively. Trendlines are those of the FCS
experiments in Fig 5.1. The data demonstrate that addition of 0:1 % DOPE-biotion and 0:1 % DiD
to POPC/POPG (3:1) LUVs induce no perturbations in the leakage process.
loaded with Alexa488 or Alexa488-10kMW. The data demonstrate that addition of 0:1 %
DOPE-biotion and 0:1 % DiD to the POPC/POPG (3:1) LUVs does not induce signicant
changes in leakage as compared to unfunctionalized and unlabeled POPC/POPG (3:1) LUVs.
5.6.2 Eect of POPG addition
Method
Varying volumes of 100 M peptide stock solutions were added to varying volumes of
POPC/POPG/DOPE-biotin/DiD (74.9:24.9:0.1:0.1) LUV solutions in Protein LoBind tubes
to a nal LUV concentration of 1 mM. The LUVs were entrapping 4 M Alexa488 or 2.5-5
M Alexa488-10kMW. Immediately upon addition of peptide, the samples were vigorously
vortexed for a few seconds and subsequently incubated for 1 h. After 1 h incubation, a large
excess of POPG LUVs was added to a nal POPG LUV concentration of 6.7 mM and a nal
POPC/POPG (3:1) LUV concentration of 0.83 M. Immediately after addition of the POPG
LUVs, the samples were vortexed for a few seconds and then incubated overnight. The next
day, the samples were transferred to 8-well chambered cover glasses for examination by FCS.
The FCS setup was as described in the main document, albeit with the small dierence that
an additional 520-550 nm bandpass lter (HQ535/30, Becker & Hickl) was inserted before
the pinhole to lter away emission from DiD. From the acquired autocorrelation data, leak-
age from the POPC/POPG/DOPE-biotin/DiD (74.9:24.9:0.1:0.1) LUVs was then calculated
using Eq. 5.4 as described in the main document.
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Figure 5.8: Peptide-induced leakage from 1 mM POPC/POPG/DOPE-biotin/DiD
(74.9:24.9:0.1:0.1) LUVs containing Alexa488 (A) or Alexa488-10kMW (B) as determined by
FCS conducted on samples in which peptides and LUVs are incubated for 1 h before peptides are
removed from the LUVs by addition of a large excess of POPG followed by overnight incubation.
In both panels, the data are the average of three separate experiments. The error bars show
the standard deviations. The error bars are not shown when they are smaller than the symbols.
The leakage values at the lowest and highest peptide-to-lipid ratios correspond to no leakage and
complete leakage, respectively, and, therefore, they are, by denition, always set to 0 % and 100 %,
respectively. Trendlines are those of the FCS experiments in Fig. 5.1. The data demonstrate leakage
is completely halted upon addition of POPG LUVs.
Results
Fig. 5.7 shows leakage vs peptide-to-lipid ratio as determined by FCS conducted on samples
in which peptides had been incubated for 1 h together with 1 mM POPC/POPG/DOPE-
biotin/DiD (74.9:24.9:0.1:0.1) LUV loaded with Alexa488 or Alexa488-10kMW before a
large excess of POPG had been added for overnight incubation. The data shows that upon
addition of POPG, no further leakage occurs from the POPC/POPG/DOPE-biotin/DiD
(74.9:24.9:0.1:0.1) LUVs.
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CHAPTER 6
Conclusions and future perspectives
6.1 Conclusions
A number of specic conclusions were presented at the end of Chapters 3-5. However, for
completeness, the three following sections will briey again summarize the conclusions of
this thesis. Specically, each the three following sections will summarize the conclusions
obtained from the three experimental techniques that were employed in this thesis.
6.1.1 Analytical HPLC
Analytical HPLC was used in Chapter 3 to study adsorption of mastoparan X, melittin, and
magainin 2 to solid surfaces of glass and plastic. Using this technique, we found that each
of the three peptides readily adsorb to both glass and plastic surfaces. Especially alarming
is the nding that at typical experimental concentrations of 1-2 M, 90 % or more of the
peptides might be adsorbed to the surfaces of disposable glass and plastic containers. Thus,
surface adsorption of antimicrobial peptides is clearly an eect that has to be taken into
account when designing experiments on antimicrobial peptides.
6.1.2 FCS
FCS was considered in Chapters 4 and 5 as a technique for quantifying antimicrobial peptide-
induced leakage of uorescent markers from LUVs in solution. Specically, in Chapter 4,
the mathematical theory required for this purpose was derived. In addition, Chapter 4 also
considered a number of experimental pitfalls that might compromise the correctness of the
leakage values determined by FCS. It was shown that if all of these pitfalls were avoided,
then FCS can be used to accurately quantify leakage of uorescent markers from LUVs in
solution, including leakage of uorescent markers of dierent sizes. In Chapter 4, mastoparan
X was then used to demonstrate that FCS is indeed applicable to study antimicrobial peptide-
induced leakage from LUVs in solution.
In Chapter 5, FCS was used to compare partial transient leakage induced by mastoparan
X, melittin, and magainin 2 from POPC/POPG (3:1) LUVs. Thus, it was found that leakage
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induced from POPC/POPG (3:1) LUVs by all three peptides is due to formation of trans-
membrane pores. Furthermore, it was found that magainin 2 on average induced larger pores
and/or more stable pores than did mastoparan X and melittin.
6.1.3 Confocal imaging of immobilized LUVs
Confocal imaging was used in Chapter 5 to study antimicrobial peptide-induced leakage of
uorescent markers from surface-immobilized LUVs. To that end, an experimental protocol
was developed that allowed the leakage data from the surface-immobilized LUVs to be
directly correlated to leakage data determined by FCS on LUVs in solution. Thereby, the
surface-immobilized LUVs could be used to gain a higher level of insight into antimicrobial
peptide-induced leakage from LUVs on the single-vesicle level than what so far has been
achieved by other techniques. For example, the surface-immobilized vesicles could be used
for single-vesicle studies of leakage of uorescent markers of dierent sizes; such studies on
LUVs have hitherto remained as unexplored territory.
The surface-immobilized LUVs were then used to study partial transient leakage induced
by mastoparan X, melittin, and magainin 2. The obtained leakage data revealed that on the
single-vesicle level, all three peptides induced leakage through a strongly heterogenous process
in which some LUVs are completely emptied and some LUVs are only partly emptied. This
heterogenous leakage prole is observed regardless of the size of the uorescent encapsulant.
This observations lead to the hypothesis that transmembrane pores formed by mastoparan
X, melittin, and magainin 2 might have a distribution of pores and/or lifetimes. However,
further work is need to corroborate or dismiss that hypothesis.
6.2 Future perspectives
In the following, it is briey discussed how the work presented in this thesis might in the future
be used to elucidate the mechanisms of antimicrobial peptide-lipid membrane interactions.
6.2.1 Analytical HPLC
As mentioned in Section 2.5, a major goal for research on antimicrobial peptide-lipid mem-
brane interactions is to quantitatively relate the physicochemical properties of the peptides
to their mode of membrane interactions. However, for such quantitative relations to be
established, it is a prerequisite that the experimental peptide-to-lipid ratio is well-known.
The information given in Chapter 3 provides knowledge on how to control this experimental
peptide-to-lipid ratio, and thereby also provides a basis for conducting quantitative inves-
tigations relating physicochemical properties of the peptides to their mode of membrane
interactions.
However, for completeness, it should be noted that in order for the physicochemical
properties of the peptides to be quantitatively related to the mode of membrane interactions
of the peptides, it is also important to have information about the concentrations of the
peptides in the lipid membranes. In order to deduce these membrane-bound concentrations,
it is necessary to know the partition coecient for the partitioning of the peptides from water
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into the lipid membranes. However, information about partition coecients is not as such
available by any of the techniques presented in this thesis. Instead other techniques could
be used for the purpose of determining the partition coecients, for example, techniques
based on intrinsic tryptophan uorescence (182), isothermal titration calorimetry (64), or
equilibrium dialysis combined with analytical HPLC (183).
6.2.2 FCS
A great advantage of FCS is that the technique can be used as a medium-throughout tech-
nique for quantifying peptide-induced leakage from LUVs of uorescent probes of dierent
sizes. Thereby, the technique is applicable for performing quantitative systematic studies
to investigate the inuence of peptide amino acid residue sequence and lipid composition
on the characteristic size of transmembrane pores. Additionally, in cases where leakage is
independent on the marker size (168), FCS is applicable to reveal whether leakage occurs
due to formation of transmembrane pores or due to membrane solubilization. Thus, FCS
is highly applicable for conducting systematic quantitative studies that aim at relating the
physicochemical properties of antimicrobial peptides to their mode of membrane interactions.
Another advantage of FCS is that the technique only requires a very low concentration
of encapsulated uorescent markers. Consequently, the experimental conditions in the FCS
experiments are much more freely varied than they are in the conventional quenching-based
leakage assay, in which very high concentrations of uorescent markers are encapsulated. In
particular, in FCS experiments, it is possible to vary freely the buer conditions on both the
inside and the outside of LUVs. Thereby, FCS would be suitable for studying the impact
of osmotic pressure dierences between the inside and outside of the vesicle lumen on the
leakage process. Another interesting possibility of the FCS experiments would be to evaluate
the impact of transmembrane potentials on the leakage process (184). Information about
how these parameters inuence pore size and leakage mechanism would help to shed light
on the mechanisms underlying antimicrobial peptide-lipid membrane interactions.
6.2.3 Confocal imaging of immobilized LUVs
Leakage induced by mastoparan X, melittin, and magainin 2 from POPC/POPG (3:1) LUVs
was on the single-vesicle level a heterogenous process for all three peptides. However, it
would in future be very interesting to investigate how the leakage process on the single-
vesicle level depends on the peptide amino acid residue sequence and the lipid composition
of the LUVs; that is, it would be interesting to investigate whether leakage is always a
heterogenous process on the single-vesicle level, independent on the peptide sequence and
lipid composition, or whether leakage sometimes might be characterized as an ideal all-or-
none-type process. Such studies could provide insight into the nature of the transmembrane
pores formed by antimicrobial peptides and possibly also a quantitative link between the
physicochemical properties of antimicrobial peptides and their behavior in dierent lipid
membranes.
Finally, it should be noted that confocal imaging of surface-immobilized LUVs, when
compared to the conventional quenching-based leakage assays, requires relatively low concen-
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trations of uorescent markers. Thereby, it might be possible to use the surface-immobilized
LUVs to conduct systematic studies on the eect of osmotic pressure dierences and trans-
membrane potentials on the leakage process on the single-vesicle level, just like FCS is
applicable to study the eect of osmotic pressure dierences and transmembrane potentials
on the leakage process on the bulk level. Systematic studies on the inuence of osmotic pres-
sure dierences and transmembrane potentials on the leakage process on the single-vesicle
level might provide new and interesting insights into the mechanisms by which antimicrobial
peptides interact with phospholipid membranes.
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